Production and characterization of genetically modified magnetized cells for future targeted treatment of cardiovascular diseases by Voronina, Natalia (gnd: 1155939417)
 
 
 
 
 
Dissertation 
 
To obtain  
the academic degree  
Doctor rerum humanarum (Dr. rer. hum.) 
at the Medical Faculty, University of Rostock 
 
 
 
Production and Characterization of Genetically 
Modified Magnetized Cells for Future Targeted 
Treatment of Cardiovascular Diseases 
 
 
 
 
Submitted by 
Natalia Voronina 
born on 04.11.1989 in Novgorod, Russia 
 
Rostock, 2016 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Reviewers: 
1. Reviewer: 
Prof. Dr. Alexander Pfeifer,  
Institut für Pharmakologie und Toxikologie, Universitätsklinikum Bonn 
2. Reviewer: 
Prof. Dr. Robert David,  
Referenz-und Translationszentrum für Kardiale Stammzelltherapie, 
Unversitätsmedizin Rostock  
3. Reviewer: 
Prof. Dr. Michael O. Glocker, 
Proteomzentrum, Unversitätsmedizin Rostock 
 
 
Date of submission: 14. Oktober 2016 
Date of defence: 5. Juli 2017 
 
 
CONTENTS 
ORIGINAL PUBLICATIONS DESCRIBING DATA USED IN THIS DISSERTATION ............... I 
ABBREVIATIONS ........................................................................................................................................... II 
ZUSAMMENFASSUNG ................................................................................................................................. IV 
ABSTRACT ................................................................................................................................................... VI 
INTRODUCTION ........................................................................................................................................ 1 
1.1 TREATMENT APPROACHES FOR CARDIOVASCULAR DISORDERS ..................... 1 
1.1.1 CARDIOVASCULAR DISORDERS. BRIEF OVERVIEW ............................................... 1 
1.1.2 EXISTING TREATMENT APPROACHES OF CVD ........................................................ 1 
1.1.3 OVERVIEW OF STRATEGIES FOR REPAIRING DAMAGED HEART USING 
GENE AND CELL THERAPY ................................................................................................................. 2 
1.2 GENE THERAPY FOR CVD......................................................................................................... 3 
1.2.1 Gene therapy. Introduction to concept and approaches. ....................................... 3 
1.2.2 GENE THERAPY FOR CARDIAC PATIENTS ................................................................. 5 
1.2.3 PROMISING MOLECULAR TARGETS FOR GENE THERAPY OF CVD .................. 7 
1.2.4 CURRENT DIFFICULTIES AND POSSIBLE SOLUTIONS ........................................... 8 
1.3 CELL THERAPY FOR CVD .......................................................................................................... 8 
1.3.1 STEM AND PROGENITOR CELL APPLICATION FOR CARDIAC 
REGENERATION ................................................................................................................................... 10 
1.3.2 CURRENT STATE AND CHALLENGES OF ADULT STEM CELL 
TRANSPLANTATION FOR CVD TREATMENT ........................................................................... 13 
1.3.3 THERAPEUTIC VALUE OF CELL ENGINEERING PRIOR TO 
TRANSPLANTATION .......................................................................................................................... 14 
1.4 DELIVERY VECTORS FOR GENETIC MATERIAL ......................................................... 15 
1.4.1 VIRAL VS NON-VIRAL ....................................................................................................... 16 
1.4.2 MAGNETIC NANOPARTICLES AS A TOOL FOR ADVANCED GENETIC 
MANIPULATION ................................................................................................................................... 17 
1.4.3 PROPERTIES OF PEI/MNP DELIVERY VECTOR ..................................................... 18 
1.4.4 KNOWN AND UNKNOWN CHARACTERISTICS OF THE VECTOR .................... 19 
1.5 AIM OF THE THESIS ................................................................................................................. 21 
2 MATERIALS AND METHODS ............................................................................................... 22 
2.1 CELL ISOLATION AND CULTURE ....................................................................................... 22 
2.1.1 FIBROBLAST-LIKE CELL LINE (COS7) ....................................................................... 22 
2.1.2 ENDOTHELIAL CELLS (HUVEC) ................................................................................... 22 
2.1.3 HEMATOPOIETIC CD133+ STEM CELLS ................................................................... 23 
2.2 PREPARATION AND CHARACTERIZATION OF TRANSFECTION COMPLEXES 
……………………………………………………………………………………………………………………………..23 
 
 
2.2.1 BIOTINYLATED POLYETHYLENEIMINE ................................................................... 23 
2.2.2 STREPTAVIDINE-COATED SUPERPARAMAGNETIC NANOPARTICLES ....... 24 
2.2.3 DELIVERED NUCLEIC ACIDS ......................................................................................... 25 
2.2.4 FLUORESCENT LABELING OF TRANSFECTION COMPLEXES FOR 
MICROSCOPY ......................................................................................................................................... 25 
2.3 TRANSFECTION .......................................................................................................................... 25 
2.4 ANALYSIS OF TRANSFECTION RESULTS ....................................................................... 26 
2.4.1 VIABILITY ASSESSMENT ................................................................................................. 26 
2.4.2 TRANSFECTION EFFICIENCY EVALUATION ........................................................... 29 
2.4.3 SURFACE MARKER EXPRESSION OF CD133+ CELLS ........................................... 29 
2.4.4 MONITORING OF FUNCTIONAL PROPERTIES OF MODIFIED HUVEC AND 
CD133+ 30 
2.4.5 INTRACELLULAR LOCALIZATION OF TRANSFECTION COMPLEXES............ 31 
2.4.6 INVESTIGATION OF VECTOR UPTAKE MECHANISM ........................................... 32 
2.4.7 INTERCELLULAR COMMUNICATION OF MODIFIED CELLS THROUGH GAP-
JUNCTIONS AS ASSESSED BY FRAP .............................................................................................. 33 
2.5 TARGETING EXPERIMENTS ................................................................................................. 34 
2.5.1 MAGNETIC TARGETING OF TRANSFECTION VECTOR ....................................... 34 
2.5.2 MAGNETIC TARGETING OF MODIFIED CELLS IN STATIC AND DYNAMIC 
CONDITIONS .......................................................................................................................................... 35 
2.5.3 IRON CONTENT MEASUREMENT OF TRANSFECTED CELLS ........................... 36 
2.6 MAGNETIC RESONANCE IMAGING .................................................................................... 36 
2.6.1 PHANTOM PREPARATION ............................................................................................. 36 
2.6.2 MR IMAGING ........................................................................................................................ 37 
2.7 STATISTICAL ANALYSIS......................................................................................................... 37 
3 RESULTS .............................................................................................................................................. 38 
3.1 STANDARDIZATION OF VECTOR PRODUCTION AND ITS EXTENDED 
CHARACTERIZATION ........................................................................................................................... 38 
3.2 SELECTION OF OPTIMAL TARGETING STRATEGY ................................................... 42 
3.2.1 ENDOTHELIAL CELLS CAN BE SAFELY AND EFFICIENTLY MODIFIED 
USING NA/PEI/MNP ........................................................................................................................... 44 
3.2.2 MAGNETIC TARGETING OF PEI/MNP VECTOR IS LIMITED ............................. 48 
3.2.3 MAGNETICALLY ENGINEERED CELLS REPRESENT AN OPTIMAL 
TARGETING APPROACH ................................................................................................................... 50 
3.2.4 DEFINING IRON LOADING OF CELLS SUFFICIENT FOR THEIR MAGNETIC 
GUIDANCE .............................................................................................................................................. 53 
3.3 DETAILED EXAMINATION OF MAGNETICALLY ENGINEERED ENDOTHELIAL 
CELLS ............................................................................................................................................................ 54 
 
 
3.3.1 TIME DEPENDENT ANALYSIS OF MAGNETICALLY RESPONSIVE AND NON-
RESPONSIVE TRANSFECTED HUVEC .......................................................................................... 54 
3.3.2 ANTI-MIR DELIVERY WITH PEI/MNP RESULTS IN EFFICIENT 
KNOCKDOWN OF ENDOGENOUS MIR ......................................................................................... 57 
3.3.3 CELLS TRANSFECTED WITH MIR/PEI/MNP MAINTAIN THEIR KEY 
FUNCTIONAL PROPERTIES ............................................................................................................. 58 
3.3.4 VECTOR INTERNALIZATION STUDIES ...................................................................... 59 
3.3.5 IMPACT OF TRANSFECTION ON GJIC ......................................................................... 61 
3.3.6 DETECTION LIMITS OF MRI VISUALIZATION FOR MIR/PEI/MNP-
MODIFIED CELLS ................................................................................................................................. 63 
3.4 APPLICATION OF THE DEVELOPED ENGINEERING APPROACH FOR A 
PRODUCTION OF MODIFIED HEMATOPOIETIC STEM CELLS .......................................... 64 
3.4.1 CD133+ CELLS WELL TOLERATE TRANSFECTION WITH MIR/PEI/MNP 
RESULTING IN EFFICIENT MIR UPTAKE ................................................................................... 64 
3.4.2 MAGNETICALLY MODIFIED CD133+ ARE EFFICIENTLY GUIDED IN VITRO
 68 
3.4.3 TRANSFECTION WITH MIR/PEI/MNP HAS NO NEGATIVE INFLUENCE ON 
CD133+ SURFACE MARKER EXPRESSION AND DIFFERENTIATION .............................. 70 
3.4.4 PEI/MNP VECTOR IS EFFICIENT IN SUPPORTIVE CYTOKINE-
SUPPLEMENTED MEDIUM OPTIMAL FOR CD133+ CELLS ................................................. 71 
3.5 SUMMARY ..................................................................................................................................... 74 
4 DISCUSSION ...................................................................................................................................... 75 
4.1 PEI/MNP EFFICIENTLY DELIVERS FUNCTIONAL MIR AND DNA TO 
ENDOTHELIAL CELLS AND ENSURES THEIR LOADING WITH IRON ............................ 75 
4.2 SELECTION OF OPTIMAL TARGETING APPROACH – MIR/PEI/MNP-
MODIFIED CELLS .................................................................................................................................... 78 
4.2.1 MAGNETICALLY ENGINEERED CELLS REPRESENT A SUPERIOR 
TARGETING APPROACH COMPARED TO DIRECT PEI/MNP TARGETING .................... 78 
4.2.2 MIR DELIVERY USING PEI/MNP IS BENEFICIAL AND OPTIMAL VS DNA ... 79 
4.3 DETAILED CHARACTERIZATION OF MIR/PEI/MNP-MODIFIED CELLS ......... 81 
4.3.1 MNP PRESENCE RESTORE FUNCTIONAL CAPACITY OF HUVEC INITIALLY 
COMPROMISED BY PEI ...................................................................................................................... 81 
4.3.2 APPLICATION OF STATIC MAGNETIC FIELD IS SAFE FOR MIR/PEI/MNP-
MODIFIED CELLS ................................................................................................................................. 83 
4.3.3 TARGETING PERSPECTIVES OF MIR/PEI/MNP-CELLS IN VIVO ..................... 84 
4.3.4 MODIFIED CELLS MAINTAIN GJIC CRITICAL IN CELL ENGINEERING .......... 85 
4.3.5 MIR/PEI/MNP-TRANSFECTED CELLS CAN BE SUFFICIENTLY VISUALIZED 
USING MRI .............................................................................................................................................. 85 
4.3.6 THERAPEUTIC VALUE OF MODIFIED HUVEC ........................................................ 86 
 
 
4.4 APPLICATION OF THE DEVELOPED STRATEGY TO HIGHLY CLINICALLY 
RELEVANT CD133+ HEMATOPOIETIC STEM CELLS ............................................................. 87 
4.4.1 PEI/MNP IS SUITABLE FOR MIR DELIVERY TO CD133+ AND THEIR 
MAGNETIZATION ................................................................................................................................ 87 
4.4.2 TARGETING POTENTIAL OF MIR/PEI/MNP-CD133+ IN VITRO IN STATIC 
CONDITIONS .......................................................................................................................................... 89 
4.4.3 OPTIMAL CULTURE CONDITIONS ENSURE HIGH CD133+ SURVIVAL 
WITHOUT AFFECTING TRANSFECTION EFFICIENCY OF MIR/PEI/MNP ..................... 89 
4.5 PERSPECTIVES ........................................................................................................................... 90 
REFERENCES ................................................................................................................................................. 94 
FINANCIAL SUPPORT .............................................................................................................................108 
PUBLICATION LIST ..................................................................................................................................109 
ABSTRACT PRESENTATIONS AND CONFERENCES ..................................................................111 
ACKNOWLEDGEMENT ............................................................................................................................112 
 
 
 
ORIGINAL PUBLICATIONS DESCRIBING DATA USED IN THIS DISSERTATION 
 
 
I 
 
ORIGINAL PUBLICATIONS DESCRIBING DATA USED IN THIS 
DISSERTATION 
Voronina N, Wiekhorst F, Kühn J-P, Rimmbach C, Steinhoff G & David R. “Non-Viral 
Magnetic Engineering of Endothelial Cells with microRNA and Plasmid-DNA-An 
Optimized Targeting Approach.” Nanomedicine : nanotechnology, biology, and medicine 
12.8 (2016): 2353–2364. Web. 15 Sept. 2016. (impact factor 5.67) 
Müller P#, Voronina N#, Hausburg F#, Lux C, Steinhoff G & David R (#, authorship 
equally shared) “Magnet-bead based microRNA delivery system to modify CD133+ stem 
cells”: Magnet-Bead Based MicroRNA Delivery System to Modify CD133 + Stem Cells. 
Stem Cells Int. 2016, 1–16 (2016). (impact factor 3.687) 
Voronina N, Lemcke H, Wiekhorst F, Kühn J-P, Steinhoff G & David R. “Manufacturing 
and in vitro characterization of magnetized miR-modified endothelial cells for 
regenerative medicine.” Invited original publication: under revision in JoVE (impact 
factor 1.325) 
Patent pending DE 102016216657.3: “Eukaryotische adulte Zellen umfassend ein 
Transfektionssystem und deren Herstellung und Verwendung”. Invention is equally 
shared between Voronina N, Hausburg F, Müller P, Steinhoff G & David R. 
Additional co-autorships and conference presentations are listed on p. 109-111.
ABBREVIATIONS 
 
 
II 
 
ABBREVIATIONS 
- AAV – adeno-associated virus 
- ACE – angiotensin-converting-enzyme 
- AC6 - adenylyl cyclase 6 
- ADA-SCID – Adenosine Deaminase Severe Combined Immunodeficiency 
- BM-MNCs - bone marrow mononuclear cells 
- CABG - coronary artery bypass grafting 
- CAD - coronary artery disease 
- CMV - cytomegalovirus 
- CRISPR – clustered regularly interspaced short palindromic repeat 
- CSCs - cardiac stem and progenitor cells 
- CVD – cardiovascular diseases 
- Cx – connexin 
- DMEM - Dulbecco's Modified Eagle's Medium 
- DNA – deoxyribonucleic acid 
- EdU - 5-ethynyl-2’-deoxyuridine 
- EGFP – enhanced green fluorescent protein 
- EPCs - endothelial progenitor cells 
- ER – endoplasmic reticulum 
- ESCs – embryonic stem cells 
- FGF - fibroblast growth factor 
- FRAP –fluorescence recovery after photobleaching 
- GJ – gap junction 
- GJIC - gap junctional intercellular communication 
- HF – heart failure 
- HIFα - hypoxia-specific transcription factor 
- HSCs - hematopoietic stem cells 
- HUVECs – human umbilical vein endothelial cells 
- iPSCs - induced pluripotent stem cells 
- LV – left ventricle 
- LVEF - LV ejection fraction 
- MI – myocardial infarction 
- miR – microRNA 
ABBREVIATIONS 
 
 
III 
 
- MNPs - magnetic nanoparticles 
- MSCs - mesenchymal stem cells 
- MTT - 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
- PAD – peripheral arterial disease 
- PDGF - platelet-derived growth factor 
- PEI – polyethyleneimine 
- qRT-PCR – quantitative real-time polymerase chain reaction 
- RISC - RNA-induced silencing complex 
- SDF-1 – stromal derived factor-1 
- SEM – standard error of mean 
- SERCA2a - sarcoplasmic reticulum calcium ATPase 
- shR – small hairpin RNA 
- siR – small interfering RNA 
- SKM - skeletal myoblasts 
- TALENs – transcription activator-like effector nucleases 
- VEGF - vascular endothelial growth factor 
- WHO – World Health Organization 
- ZFNs – zinc-finger nucleases 
ZUSAMMENFASSUNG 
 
 
IV 
 
ZUSAMMENFASSUNG 
CVD zählen nach wie vor zu den bedeutendsten und kostenintensivsten Erkrankungen, 
während das Ergebnis chirurgischer und pharmakologischer Interventionen hier 
limitiert und häufig palliativer Natur ist. Gleichzeitig bietet sich mit der Gentherapie ein 
viel versprechendes Instrument für die zukünftige kausale CVD-Behandlung an. Ihre 
breite klinische Anwendung ist jedoch durch das Fehlen von geeigneten gezielten 
Genvektor-Systemen noch sehr beschränkt. 
Darüber hinaus wird die Entwicklung von multifunktionalen Gen-Vektoren, welche für 
die klinische Translation geeignet sind, eine Optimierung der Stammzelltypen 
ermöglichen, die derzeit bereits in klinischen Studien mit CVD-Behandlung angewendet 
werden.  
Um dieses Ziel zu erreichen wurden im Rahmen dieser Arbeit nicht-virale Vektoren 
verwendet, bestehend aus Polyethyleneimin und magnetischen Nanopartikel 
n(PEI/MNP), die in unserer Gruppe entwickelt worden waren. 
Zunächst wurde PEI/MNP an primären Endothelzellen (HUVECS) als in-vitro-Modell für 
die Angiogenese getestet, welche ein bedeutendes Therapieziel bei CVD darstellt. 
Optimale Transfektionsbedingungen wurden für MicroRNA (MiR) und Plasmid DNA 
definiert - dies führte zu ~ 95-98 % Aufnahme von markierter MiR sowie zu ~40-55 % 
Markergen-exprimierender Zellen nach Plasmid-Transfektion, was jeweils mittels 
Durchflusszytometrie ermittelt wurde. 
Wenn funktionelle Anti-MiR transfiziert wurde, konnte ein vollständiger Knock-down 
der endogenen Ziel-miR erzielt werden und darüber hinaus eine entsprechende 
Hochregulation des Zielgens, was sich aus qRT-PCR-Analysen ergab. Dies gelang ohne 
Beeinträchtigung der Zellviabilität, wie die Beobachtung über 96h zeigte.  
Darüber hinaus wurden zwei Targting-Modalitäten in vitro verglichen: 1) Direktes 
Vektor-Targeting, welches in lokaler Vektor-Aufnahme der Zellen in der Region des 
Magneten resultierte und 2) Modifikation von Zellen und deren anschließendes 
Targeting. Dabei dienten FACS, konfokale Mikroskopie, MACS© und Magnetpartikel-
Spektroskopie als Analysetechnologien. 
Ansatz 2, das magnetische Targeting miR-transfizierter Zellen erwies sich als sehr 
effizient: ~70 to 80% der Zellen, welche mit mindestens 0,16 pg Eisen pro Zelle geladen 
waren, konnten sowohl unter statischen als auch unter dynamischen Bedingungen in 
vitro magnetisch gezielt lokal gesteuert werden. Dagegen war Ansatz 1, also das direkte 
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Vektor-Targeting nur teilweise erfolgreich. Daher wurde im Folgenden der Fokus auf die 
zell-basierte Strategie gelegt, also die Verwendung miR/PEI/MNP-modifizierter, 
magnetisierbarer Zellen. 
Hierbei konnte ein signifikant vorteilhafter Einfluss von MNP auf die Toxizität von PEI 
gezeigt werden, was normale Tubuli-Ausbildung der HUVECs widerspiegelte, die bei 
Verwendung von PEI alleine um ~50-80% zurückging. Zudem ergaben FRAP-Analysen 
die Ausbildung interzellulärer Zytoplasmaverbindungen („gap-junctions“), über welche 
möglicherweise miRs ausgetauscht werden können. Hier böten sich die modifizierten 
Zellen als gezielte miR-Vektoren an. Mikroskopische Analysen der miR/PEI/MNP 
Internalisierung ergaben für die miR keinen Unterschied zwischen An- und Abwesenheit 
von MNP bei der Transfektion. Daneben wurden die transfizierten Zellen hinsichtlich 
ihres Potentials zur MRT basierten Detektion untersucht, wobei bereits 104 Zellen bei 
einer Beladung mit ~0.37 pg Eisen pro Zelle nachweisbar waren. 
Im Folgenden wurde diese optimierte Modifikationsstrategie auf einen für die 
Behandlung von CVD hoch relevanten Zelltyp übertragen - CD133-positive 
hämatopoetische Stammzellen. Auch hier wurde hoch effiziente Aufnahme von miR 
mittels PEI/MNP-Vektor erzielt (~80%), während die Zell-Viabilität erhalten blieb, wie 
durchfluß-zytometrisch nachgewiesen wurde. Darüber hinaus wurde stabile Expression 
charakteristischer Oberflächenmarker sowie das hämatopoetische Differenzierungs-
potentials der Zellen in vitro belegt. Zudem konnten die Zellen in vitro effizient 
magnetisch zum Zielort gelenkt werden. 
Zusammenfassend weisen die im Rahmend der Arbeit erzielten Daten eindeutig darauf 
hin, das transiente genetische Modifikation von Zellen mit miR/PEI/MNP einen 
attraktiven Ansatz darstellt und die Magnetisierung der Zellen sich für das Targeting 
sowie für MRT basiertes Monitoring der Zellen eignet. Der entwickelte Ansatz scheint 
besonders vielversprechend zur Optimierung von Zelltherapeutika im Bereich der 
kardiovaskulären Medizin. 
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ABSTRACT 
CVD remain one of the most damaging and costly disease groups, whereas the outcome 
of surgical and pharmacological interventions is limited and often palliative. At the same 
time, gene therapy is a promising tool for CVD treatment. Its wide clinical application is, 
however, limited by the lack of suitable targeted gene delivery systems. Moreover, the 
development of multifunctional gene delivery vectors suitable for clinical translation can 
be used for modification of stem cells, currently applied in clinical trials of CVD 
treatment. This could improve their properties and allow overcoming current 
limitations of the concept. 
To accomplish this objective, a non-viral vector was used composed by 
polyethyleneimine and magnetic nanoparticles (PEI/MNP) previously designed in our 
group. 
First, PEI/MNP was tested with primary endothelial cells (HUVEC) as in vitro model for 
angiogenesis, which is a key target of CVD. Optimal transfection conditions were defined 
for microRNA and plasmid DNA, which resulted in ~95-98% uptake of tagged miR and 
~40-55% of cells expressing an introduced marker gene, respectively (measured by 
flow cytometry). In addition, when functional anti-miR was transfected, a complete 
knock-down of its endogenous target miR was observed along with respective target 
gene upregulation as measured by qRT-PCR. This was achieved without affecting cell 
viability as 96h-observation has shown.  
Further, two magnetic targeting modalities were compared in vitro: 1) direct vector 
guidance resulting in localized uptake above the magnet 2) modification of cells and 
their subsequent magnetic targeting. Flow cytometry, confocal microscopy, MACS© cell 
separation and magnetic particle spectroscopy served as analyzing tools for this 
purpose.  
Modality 2), magnetic guidance of miR-transfected cells was proven to be very efficient: 
~70 to 80% of cells, loaded with no less than 0,16 pg of iron per cell, were magnetically 
responsive under both, static and dynamic conditions in vitro. In contrast, the approach 
1) based on direct vector guidance was restricted, presumably by the mechanism of PEI 
action during transfection. Hence, the focus of further investigation was on the cell-
based strategy, i.e. miR/PEI/MNP-modified magnetized cells. 
Furthermore, significant positive impact of MNP on the initial toxicity of PEI has been 
demonstrated (retained tube formation capacity of HUVECs vs ~50-80% decrease in 
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case of PEI only). In addition, FRAP technique demonstrated that miR/PEI/MNP-
modified endothelial cells do maintain intercellular gap-junctional communication and 
potentially can exchange miR, thereby serving as its carrier to injured tissues. 
Microscopic investigation of the miR/PEI/MNP internalization mechanism revealed no 
difference introduced by MNP presence as compared to PEI only. Further, transfected 
cells were tested in vitro in terms of their MRI detection potential. As a result, as few as 
104 cells could be detected when loaded with at least ~0.37 pg iron/cell.  
Next, this optimized modification strategy was successfully transferred to a cell type 
highly relevant for the treatment of cardiovascular diseases (CVDs), namely, CD133-
positive hematopoietic stem cells. In particular, efficient uptake of miR delivered by 
PEI/MNP was achieved (~80%) while retaining cell survival as measured by flow 
cytometry. Moreover, the capacity of CD133+ cells to maintain surface marker 
expression and in vitro hematopoietic differentiation capacity was shown. Importantly, 
these miR-modified cells were proven to be efficiently guided in vitro with a magnet. 
Taken together, the obtained results indicate that transient genetic modification of cells 
with miR/PEI/MNP is feasible and results in their magnetization sufficient for targeting 
and MRI detection. This approach is particularly promising as a tool for improvement of 
cell therapeutics applied in the cardiovascular field. 
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INTRODUCTION 
1.1 TREATMENT APPROACHES FOR CARDIOVASCULAR DISORDERS 
1.1.1 CARDIOVASCULAR DISORDERS. BRIEF OVERVIEW  
According to the statistics of the World Health Organization (WHO), cardiovascular 
diseases (CVD) are the major cause of mortality worldwide: in the United States alone, 
approximately 1 million of myocardial infarctions occur yearly and many of these 
patients develop heart failure which is currently diagnosed in 5 million patients1. It also 
represents a serious financial burden since the cost of the treatment is significantly 
higher than for any other disease group2,3. CVD include various disorders affecting heart 
and vessels: coronary heart disease, cerebrovascular disease, peripheral arterial disease, 
rheumatic heart disease, congenital heart disease, deep vein thrombosis and pulmonary 
embolism. Among these, the most frequent cases of tissue ischemia are associated with 
coronary heart disease, stroke and peripheral arterial disease (PAD), accounting for 
more than half of all CVD2.  
Until recently, the heart was thought to be a terminally differentiated tissue incapable of 
regeneration. However, the latest findings have proven that at the age of 20 the renewal 
rate for cardiomyocytes reaches 1%, whereas at 70 it decreases down to 0,4%1.  At the 
same time, even without diagnosed heart disease cardiac overload or simple aging are 
associated with significant loss of cardiomyocytes – up to 20 million yearly (to compare, 
the left ventricle (LV) contains 2-4 billion cardiomyocytes). Furthermore, such an acute 
event as myocardial infarction (MI) cause loss of over a billion of cells, approximately 
25% of the total heart mass3. Since cardiomyocytes are endogenously regenerated in a 
very limited degree, compensation of this cell loss is achieved by formation of fibrotic 
scar tissue1.  
1.1.2 EXISTING TREATMENT APPROACHES OF CVD 
Currently, there are no efficient pharmaceutical or surgical strategies for complete 
prevention of such damage and full regeneration of the damaged tissue3,4. In addition to 
common treatment strategies, several groups of medicaments are applied for CVD 
prevention or as additives during treatment. For example, medications for the 
management of hypertension or dyslipidemia can reduce the risk of CVD approximately 
by 30% when applied separately and by 50% when used simultaneously5.  
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In heart failure (HF), pharmacological treatment is principally palliative: ß-blockers, 
angiotensin-converting-enzyme (ACE) inhibitors, mineralcorticoid-receptor antagonists 
are mainly able to control metabolic symptoms. Together with cardiac 
resynchronization and LV assist devices, they are helpful in improving quality of life, 
however, not able to change the course of the disease4. Heart transplantation is known 
to provide the best therapeutic outcome4 - yet, the current number of patients on the 
waiting list greatly exceeds the amount of available hearts according to recent annual 
Eurotransplant reports6.  
In case of MI, such options as angioplasty or thrombolysis are considered as a standard 
of care and intended to reverse the ischemia. In addition to these, certain medications 
are applied after MI to decrease the workload of the heart, eg diuretics and 
vasodilators3. Furthermore, ACE inhibitors, angiotensin receptor blockers and renin 
inhibitors are usually used to prevent renal dysfunction, which often accompany CVD3. 
Notably, even the most successful developments in surgery are restricted to an 
improvement of blood supply through large vessels. At the same time, one of the key 
mechanisms for inoperable heart conditions is microangiopathy, in which the lack of 
microcirculation is causing ischemia. 
Taken together, currently applied pharmaceutic and surgical interventions help to 
reduce the rate of disease progression and mortality for patients with CVD2. However, 
they do not treat the underlying cause of disorders, creating thereby a necessity to 
design other treatments. Gene or cell therapy and their combination are the major 
promising strategies thereof1,3. 
1.1.3 OVERVIEW OF STRATEGIES FOR REPAIRING DAMAGED HEART USING GENE 
AND CELL THERAPY 
Depending on the type of cardiovascular disorder and concomitant dysfunctions, several 
points can be targeted using gene and cell therapy: enhancement of regenerating 
capacity of damaged tissue; activation of cytoprotective mechanisms; suppression of 
disease-related apoptosis; improvement of angiogenesis; providing endogenous or 
exogenous precursor cells; replacing damaged myocardium with functional cells1,3. In 
cases where regeneration is a main target, it can be induced by overriding a cell cycle 
checkpoints using signaling factors. Cytoprotective mechanisms can be activated by 
stimulation of single or multiple cytokines or growth factors. Similarly, for the 
suppression of disease-triggered apoptosis, either inhibition or enhanced delivery of 
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cytokines or regulatory proteins can be exploited. Induction of angiogenesis, naturally 
occurring after ischemia serves to increase the supply of nutrients and oxygen to 
damaged tissues and to reduce thereby negative outcome of hypoxia3. Several of these 
mechanisms can be introduced by the delivery of precursor cells since they have been 
shown to secrete protective and antiapoptotic paracrine factors and to participate in the 
formation of new vessels7. Along with such indirect pathways, transplanted cells can 
participate in the regeneration of the injured organ directly, by differentiation into 
functional tissue4. 
1.2 GENE THERAPY FOR CVD 
1.2.1 GENE THERAPY. INTRODUCTION TO CONCEPT AND APPROACHES. 
In gene therapy, the prevention and treatment of diseases are accomplished by the 
delivery of functional genetic material into human cells, tissues and organs resulting in 
the correction of genetic defects or in new therapeutic functions3. Initially, gene therapy 
was designed as the replacement of a mutated gene for the treatment of monogenic 
diseases. Currently existing gene therapy strategies can be divided into 3 groups: gene 
transfer, gene silencing and gene editing (summarized in Figure 1)8,9.  Gene transfer is 
aiming to restore or supplement specific therapeutic factors most often by utilizing 
complementary DNA or mRNA9. Gene silencing is achieved either by the introduction of 
dominant negative molecules or by RNA interference, which is accomplished by the 
delivery of small interfering RNA (siR), microRNA (miR) or small hairpin RNA (shR)9. 
Gene editing is based on the induction of DNA double-strand breaks at specific genomic 
loci, which subsequently stimulate the endogenous DNA-repair mechanisms to mediate 
genome editing in situ10. To date, such site-specific genome editing is being realized by 
delivery of 4 major classes of nucleases: meganucleases, zinc-finger nucleases (ZFNs), 
transcription activator-like effector nucleases (TALENs) or CRISPR (clustered regularly 
interspaced short palindromic repeat) associated nuclease Cas9 (reviewed in 10).  
Currently, after the successful marketing of the first gene therapeutic drug Glibera© in 
2012 for the treatment of a rare form of familial dyslipidaemia11, the second medication 
is very close to approval – stem cell gene therapy product Strimvelis© for the treatment 
of Adenosine Deaminase Severe Combined Immunodeficiency (ADA-SCID)12. At the same 
time, multiple phase I and II clinical trials have provided a strong evidence of gene 
therapy being safe for the treatment of other conditions: severe inherited diseases of the 
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blood, immune and nervous systems, including primary immunodeficiencies, 
leukodystrophies, thalassaemia and sickle cell disease, haemophilia B, inherited 
neurological disorders, retinal dystrophy and cancers (reviewed in 11,13). Application of 
gene therapy for the treatment of CVD comprises 7.8% of total number of clinical trials, 
however, several of them progressed to phase II and III14. 
Figure 1. Schematic illustration of gene therapy strategies. (A) Gene transfer. Gene replacement 
therapy is based on correction of the mutated gene (orange dot on black helix) which led to disease via 
abrogated protein synthesis (a cross over circles representing target protein). 
Gene addition treatment is ensured by supplementing therapeutic genes which interfere with specific 
aspects of disease (caused by various factors). 
B) Gene silencing strategy is based on small noncoding RNA (blue combs) which are capable of inhibiting 
the aberrant disease-causing mRNA. 
(C) Gene editing relies on the targeted change of a disease-promoting sequence (orange dot) into a 
disease-preventing sequence (blue dot) by using chimeric nucleases (circle and pie). (adapted from Wang 
et al, 20148) 
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1.2.2 GENE THERAPY FOR CARDIAC PATIENTS 
For CVDs, more than 150 clinical trials involving gene therapy are completed or running 
according to the GeneMed Database15. Thus far, the targets include such growth factors 
as vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF), stromal 
derived factor-1 (SDF-1), hypoxia-specific transcription factor HIFα, sarcoplasmic 
reticulum calcium ATPase (SERCA2a) and adenylyl cyclase 6 (AC6)3,16,17. 
The majority of these studies involve overexpression of growth factors (e.g. VEGF, FGF, 
G-CSF, platelet-derived growth factor (PDGF), HGF, etc) which are primarily known by 
the ability to stimulate vasculogenesis and angiogenesis18. Often, they possess other 
beneficial properties: VEGF (through binding to VEGFR2 receptor) has been proven to 
increase cell survival, permeability and recruitment of local cardiac stem cells to 
ischemic areas; FGF influences cell proliferation, migration, and production of proteases 
in endothelial cells and cardiomyocytes, etc17,19. In clinical trials, growth factors are 
mainly aimed to treat angina and coronary artery disease (CAD), the most common form 
of heart disease, which along with other causes can lead to HF. Several studies using 
VEGF reported no major adverse events and inconsistent positive outcomes, including 
improvements in myocardial perfusion (phase II KAT201, GENESIS-I and VIF-CAD); in 
regional wall motion (EUROINJECT-ONE); in functional class and exercise tolerance 
(VIF-CAD where VEGF and FGF were applied together); in angina severity and frequency 
(VIVA)3,16–18. Another target, hHGF, was tested in the “Phase I intracoronary 
administration of Ad-Hhgf” study, resulting in improved activity tolerance; FGF – in the 
FIRST trial, where a trend towards symptomatic improvement was recorded. In 
addition, the AGENT III/IV study using FGF overexpression (after successful AGENT I & 
II in terms of safety and improved myocardial perfusion) was aiming to treat angina 
pectoris, however, no difference between placebo and treatment was reported17. 
Preclinical and clinical trials using HIFα were initiated as it is a regulator of cellular 
responses to hypoxia and is able to influence angiogenesis, cell survival, migration and 
stem cell behavior17.  To date, it was tested for safety (NCT00117650 & “Multicentre 
Phase I and Safety Study”) with no resulting concerns reported16,17. SDF-1, was 
introduced to clinical trials due to its capacity to maintain cardiac repair: one phase I 
study was carried out with patients suffering from ischemic HF and as a result its safety, 
improvement of 6-minute walk test, quality of life, and NYHA class were reported16.  
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Another promising therapeutic agent, introduced in 2007 into phase I and II clinical 
trials 
 (CUPID & CUPID-2b), is sarcoplasmic reticulum calcium ATPase (SERCA2a) to treat 
advanced HF. The loss of SERCA2a activity and corresponding impairment in calcium 
homeostasis is one of the components of the disease3. During the phase I/II trials, a 
single injection of the vector has been shown to significantly improve cardiac function, 
symptoms and reduce hospitalization of patients, but recent results of a phase IIb study 
did not confirm the initially reported therapeutic outcome17,20. 
One phase I/II clinical trial (NCT00787059) involving virally-mediated transfer of AC6, 
which is a regulator of calcium cycling in cardiomyocytes and SERCA2a activity, has 
started in 2008 and results have not been published yet. This study is aiming to test the 
safety of therapy in patients with congestive HF and its efficiency in improving LV 
contractility21. 
 
Arrhythmias represent another prevalent class of CVDs, which is being evaluated for 
therapeutic benefit of gene therapy. In this case, however, clinical trials have not yet 
started despite multiple successful pre-clinical investigations(reviewed in 9). 
 
In clinical studies for CVDs, most often viruses (adeno-associated viruses (AAV) 1, 6 & 9 
& adenoviruses with cardiac-specific cytomegalovirus (CMV) promoter) and sometimes 
naked plasmid are employed as delivery vectors3,17,18. Notably, main risks of gene 
therapeutics are related to these vehicles: immune reaction of host to viral particles and 
insertional mutagenesis, inadequate duration or expression and off-target activity16. 
In addition, certain trauma can be caused by the administration procedure since local 
intracardiac routes are most efficient in terms of gene delivery and avoiding off-target 
expression. In particular, myocardial injection can physically damage healthy tissue, 
cause inflammation and scarring or in some cases ventricular perforation; aortic cross-
clamp LV cavity infusion can cause similar myocardial injury; pericardial delivery bears 
minimal risk of pericardial effusion and pneumothorax16,17. At the same time, 
development and wider accessibility of such image-guided injection strategies as 
NOGA® based on electromechanical mapping of the heart helps to maximally prevent 
negative events associated with the administration route22. 
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1.2.3 PROMISING MOLECULAR TARGETS FOR GENE THERAPY OF CVD 
In addition to results of clinical trials, pre-clinical studies suggest that, among others, the 
following targets bear significant translational potential: S100A1; G protein α subunit; 
ribonucleotide reductase23; ADCY1; βARKct-carboxy terminal peptide from GRK2; b-
Adrenergic receptor; KCNH2-G628S; Cardiac sodium channel 4a (SCN4a); connexins 40, 
42 and 43; Kir2.19,16,17.  
In particular, G protein α subunit was reported to control heart rate and remodeling, 
whereas S100A1, in addition to reversed LV remodeling, also normalizes metabolism of 
calcium and improves contractility16,17. In addition to SERCA itself, which is already 
being tested in clinical studies, related proteins also regulate myocardial contractility 
and cardiac function16. Application of βARKct-carboxy terminal peptide from GRK2 leads 
to improvements in β-adreno-receptor signaling and in contractile dysfunction, to heart 
failure rescue16. In addition, for HF treatment, β-adrenergic receptors are proposed as 
targets: they are downregulated in many patients with HF and their upregulation in rats 
and rabbits significantly improved LV function21. Cardiac inherited myopathies can be 
influenced by enzymes or sarcomeric proteins (myosin, ribonucleotide reductase)23. The 
following targets were proven efficient in vivo for arrhythmia correction: KCNH2-G628S 
for prolonging refractory period and eliminating arrhythmia inducibility; SCN4a as 
reducing arrhythmia inducibility and decreasing electrogram fragmentation; connexins 
40, 42 and 43 as improving conduction and reducing arrhythmia susceptibility; Kir2.1 
was shown to improve pacemaking16.  
 
Importantly, many of the therapeutic targets for CVD are regulated by miR as pre-
clinical studies have demonstrated21. In particular, miR25 and miR22 are known to 
regulate SERCA2a; miR 499 was proven to be a promoter of ventricular hypertrophy, 
along with miR 23a and 208; miR 1, 9, 98, 133 & 378 were shown to inhibit 
hypertrophy; circulating miR4235p can be used as a predictor of HF, whereas miR 34, 
192 and 194 – of development of HF in patients with MI. Several miR are participating in 
regulation of fibrosis: miR-24, 299, 30c, 101a or b, 214. AntimiR21 expressed in cardiac 
fibroblasts suppresses fibrosis together with miR2921. Among others, such miRs as miR-
2124, 92a, 34a, 126, 210, 503, 16, 130a and miR-23∼27∼24 cluster were defined as 
angiogenesis regulators by having multiple targets (PNUTS, VEGFR2, FGFR1, ITGA5, 
eNOS, MKK4, Spred-1, etc)24–32. Importantly, various miR are known to modulate the 
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fate of stem cells applied for transplantation, e.g. for HSCs miR-125 family and miR-
29a33. 
To date, according to clinicaltrials.gov the safety of miR / antago-miR administration 
was shown in patients with hepatitis, whereas the majority of trials is testing miRs as 
potential biomarkers and predictors of various diseases (including cancers, metabolic 
disorders, sepsis, CVD, etc.)34. 
1.2.4 CURRENT DIFFICULTIES AND POSSIBLE SOLUTIONS 
Main obstacles for wide clinical application of gene therapy are shaped by its nature. 
Any kind of gene therapy implies a transfer of various therapeutic constructs in order to 
directly or indirectly influence protein structure or expression. By definition, this 
requires appropriate delivery strategies, which becomes a critical component of success. 
As discussed above, currently obtained pre-clinical data defined several molecular 
targets, which have been successfully used in animal models16,17. However, clinical trials 
have not demonstrated as successful or consistent outcome as in vivo studies have. This 
mismatch can be partly explained by the difficulty of modelling human disorders in 
animals and possible inaccurate prediction of human responses in respective clinical 
settings35. At the same time, targeting of therapeutic molecules to the cells of interest in 
sufficient quantities remains a highly challenging.  Therefore, current directions in 
which gene therapy is being developed are: selection of proper genetic targets, 
development of optimized delivery methods and adjustment of administration routes. 
1.3 CELL THERAPY FOR CVD 
Another major direction within alternative treatment modalities for CVD is cell-based 
therapy. In general, effects of applied cells are expected to influence the entire course of 
disease: from vasculature dysfunction to damaged myocardial tissue, which together 
may lead to improved heart function. 
In order to define a proper cells source and population for cardiac regeneration, 
multiple cell types have been tested in preclinical trials: embryonic stem cells 
(ESCs), induced pluripotent stem cells (iPSCs), neonatal cardiomyocytes, skeletal 
myoblasts (SKMs), endothelial progenitor cells (EPCs), cardiac stem and progenitor cells 
(CSCs), bone marrow mononuclear cells (BM-MNCs), hematopoietic stem cells (HSCs) 
and mesenchymal stem cells (MSCs)1. By now, all these have progressed to clinical 
studies for CVDs treatment, except neonatal cardiomyocytes and iPSCs1,36 (summarized 
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in Figure 2).   Initially, clinical cell transplantations started with skeletal myoblasts due 
to the ability of quiescent satellite cells located under the basal membrane to proliferate 
and thereby regenerate skeletal muscle. Although preclinical tests for MI were 
successful resulting in improved LV function, clinical trials including MAGIC (phase I) 
and MARVEL (Phase II/III) did not show functional improvement in the treatment group 
as compared to placebo. Importantly, elevated incidence of arrhythmias in myoblast-
treated patients was registered, which is thought to be caused by lack of connexins 43 
(Cx43) and, therefore, electromechanical integration 1,37,38. Taken together, the lack of 
significant clinical improvement and pro-arrhythmicity discredited skeletal myoblasts 
as a promising therapeutic product1.  
Figure 2. Overview of cell therapeutics applied in clinical trials for cardiac regeneration. To note: 
products from embryonic stem cells have been already transplanted to a first patient with heart failure; 
lineage-specified MSCs were tested during the C-CURE trial which promoted future CHART trials. (adapted 
from Fuster, 201439) 
Currently, the main focus of regenerative therapy for CVD is persisting on different types 
of stem and progenitor cells. 
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1.3.1 STEM AND PROGENITOR CELL APPLICATION FOR CARDIAC REGENERATION 
Stem cells carry the capacity for self-renewal as well as directed differentiation38. 3 main 
categories of stem cells are exploited for cardiac regenerative medicine: adult stem cells; 
embryonic (ESCs) and induced pluripotent stem cells (iPSCs) where either differentiated 
derivatives are being explored for transplantation or cells are differentiated in situ after 
transplantation36,38,40. As potential therapeutic agents, all these cell types carry certain 
advantages and disadvantages38,40. 
In particular, ESCs and iPSCs share several similar risks: teratome formation due to 
possible co-transplantation of remaining pluripotent cells together with the final 
therapeutic product or impaired in situ differentiation; cancerogenic potential defined 
by upregulation of miRNAs commonly found in cancers and possible development of 
tumorogenic mutations during prolonged culture; possibility of genetic and epigenetic 
abnormalities40. In addition, the use of ESCs has led to serious ethical debates and is 
risky in terms of immune system reaction to the allogenic cells40.To date, one clinical 
trial for CVD treatment has been initiated involving pluripotent cells: ESC-derived 
cardiac progenitors with a reported purity of 99% were transplanted into an infarct area 
of a patient with severe heart failure. As a result, at 3 months follow-up an improvement 
of symptoms from NYHA class III to I and increase in LV ejection fraction (LVEF) of 10% 
were reported followed by no complications such as arrhythmias or tumor formation36. 
However, as promising as these results are, much better developed protocols, more data 
and long-term proofs of safety are required to bring early progenitors to wide clinical 
practice38,41. 
On the contrary, the clinical development of adult stem and progenitor cells for the 
treatment of cardiac patients is much more advanced: these are the only cells which 
have undergone most of the clinical translation path up to now. The main risks related to 
their transplantation are rare, usually manageable and similar for all cell products: 
immunogenicity and possible occurrence of arrhythmias (the latter particularly for 
MSCs)1,38. The class of adult stem cells consists of different populations of stem and 
progenitor cells, isolated from various sources, including bone-marrow, circulating 
blood or solid resident tissues.  
Autologous bone marrow represents the most widely applied source of cells for cardiac 
regeneration. Unselected BM-MNCs (or peripheral blood MNCs) have been extensively 
studied in pre-clinical and clinical settings. MNCs are beneficial since they are easy to 
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harvest in large numbers, can be transplanted without in vitro expansion and contain 
different fractions of stem and progenitor cells42. In patients with MI, several primary 
trials including BOOST, REPAIR-AMI and FINCELL have reported early improvements, 
i.e. increase in LVEF of 5-6% in the cell-treatment group4. In contrast, such trials as 
ASTAMI, HEBE, TIME and Late-TIME have reported that BM-MNC have no effect on 
myocardial function as compared to placebo4. In patients with HF, among others 2 large 
trials were carried out TOPCARE-CHD (I/II) and FOCUS-CCTRN (II). TOPCARE-CHD 
compared the influence of circulating progenitor cells and BM-MNC and as a result, in 
the BM-MNC group a 2.9% increase of LVEF was observed, whereas control and 
circulating progenitor cells did not cause any improvement. The FOCUS-CCTRN trial 
demonstrated positive impact of BM-MNC in patients with symptomatic HF and 
LVEF≤45% (LVEF increase of 2.7% vs control group)4,22. 
In case further III trials with large patient cohorts (e.g. ongoing BAMI study) prove the 
positive outcome of BM-MNC therapy, it can be considered as an adjuvant to standard-
of-care treatment4. At the same time, the concept can be improved, in particular by 
removing its intrinsic variability due to heterogeneity of BM-MNC cell population22. In 
order to achieve this, uniform progenitor or stem cell fractions were isolated from BM-
MNC and tested in pre-clinical and clinical trials. 
Hematopoietic stem cells (HSCs) represent a subset of bone marrow, which composes 
less than 0.1% of BM-MNC. They are usually identified by the expression of CD34, CD45 
and/or CD133 antigens and were shown to induce angiogenesis and prevent LV 
remodeling in ischemic conditions in vivo43. Completed clinical trials for patients with MI 
or HF (I, II, III phase) have reported inconsistent outcomes: CD133+ cell intramyocardial 
injection to patients with MI in some cases resulted in improved LVEF (~5%) and 
myocardial perfusion; in some studies no difference towards the control group was 
reported22,44. 
Endothelial progenitor cells (EPCs), a subset of BM-MNC, are closely related to HSCs: 
they express the CD34 marker, the endothelial marker protein (VEGF-R2/KDR) and 
CXCR-4 receptors (after several weeks in culture, EPCs start to express VE-cadherin and 
von Willebrand factor)42. Preclinical studies have demonstrated that EPCs home to the 
site of tissue injury and participate directly by forming new vessels and indirectly by 
secreting proangiogenic cytokines and growth factors; CD34+ cells delivered after MI 
significantly improved cardiac function in small and large animals1,42. Several clinical 
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trials were initiated on this basis including ACT34-CMI (Ib/II), REGENT (II) and RENEW 
(III), where the safety of EPC therapy was proven and evidence of efficiency was shown4. 
In particular, the ACT34-CMI trial showed that the intramyocardial injection of low-dose 
circulating CD34+ EPC had significantly reduced the rate of angina in patients and 
improved tolerance of exercise4. In the REGENT trial, patients with reduced LV function 
were treated either with unselected BM-MNC or with CD34+/CXCR4+ cells. As a result, a 
similar improvement of LVEF of 3% was observed in both cell-treated groups and 
remained unchanged in the control group22. The RENEW study has reported an 
improvement in exercise tolerance as a result of CD34+ EPC transplantation to patients 
with chronic myocardial ischaemia1. 
From bone marrow stroma, (along with such sources as adipose tissue, lung, liver, 
peripheral and umbilical cord blood, etc), MSCs can be isolated  which are currently 
defined by following criteria: ability to adhere to plastic under normal culture conditions 
and display a fibroblast-like morphology; ability to differentiate to osteoblasts, 
chondrocytes and adipocytes in vitro; expression of surface markers CD73, CD90 and 
CD105 in the absence of CD11b, CD14, CD19, CD34, CD45, Cd79a and HLA-DR (Human 
leukocyte antigen)1. The regenerative potential of MSCs is still under investigation; to 
date, their capacity for multilineage differentiation is demonstrated (controversial 
reports in terms of transdifferentiation to cardiomyocytes), as well as ability to control 
stem cell niches (in HCS & bone marrow), secrete angiogenic paracrine factors (VEGF, 
bFGF and PDGF) and immunomodulatory properties1,42. Large-animal studies have 
reported that MSCs decrease infarct size and improve ventricular function1. 
Interestingly, POSEIDON trial compared autologous and allogenic BM-MSC and reported 
no difference between these groups in terms of immunosensitization, although no 
significant improvement of LVEF was observed, either4. In addition, several trials 
including STEMI (II) and STEM-104-M-CHF (II) showed the safety of allogenic MSC 
transplantation1. In such trials as Prochymal® (II), improvement of LV and end systolic 
volume was demonstrated for patients with AMI after allogenic MSC transplantation; in 
PROMETHEUS (I/II) improvement of global LV function occurred after autologous MSC 
transplantation; in phase I trial PRECISE, adipose tissue-derived stem cell 
transplantation was safe and improved total LV mass by 20g in patients with ischemic 
cardiomyopathy1,45,46. 
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In post-natal hearts, different subtypes of tissue-resident cardiac stem and progenitor 
cells have been identified with shared properties of clonality, multipotency and self-
renewal 1,22. Therapeutic effects of these populations are being explored (incl. Sca-1+, Isl-
1+, SSEA-1+, side-population cells and telocytes), however, to date c-kit+ cells and 
cardiosphere-derived cells (CDC) demonstrated highest translational potential1,44.  
C-kit+ cells lack hematopoietic lineage markers and are able to differentiate in 
cardiomyocytes, endothelial and smooth muscle cells1. Preclinical studies in mice and 
pigs have reported that after transplantation these cells can successfully engraft and 
improve cardiac function after MI. In phase I clinical trial SCIPIO autologous c-kit+ cells 
were isolated from patients undergoing coronary artery bypass grafting (CABG) and 
infused back 113 days after; as a result, ~12.3% improvement of LV function vs baseline 
value was recorded4.  
CDCs are obtained by the expansion of heart biopsy samples using spheroid culture 
technique, which results in the formation of heterogenous cell aggregates expressing 
such stem cell markers as c-kit, Sca-1 and CD34. Preclinical studies in pigs have 
confirmed the ability of CDC to improve cardiac function and reduce the infarct size after 
MI1. Furthermore, CADUCEUS phase I clinical study have tested therapeutic benefits of 
CDCs in patients with AMI. The general safety and feasibility of isolated and expanded 
SCFR+ were reported. At the same time, no effect of this transplantation on LVEF was 
recorded, although decreased scar size and positive influence on LV volumes were 
observed in the cell-treatment group4. In order to further prove the efficiency of CSCs, 
the phase I/II study ALLSTAR is currently recruiting patients with MI and further phase 
III trials will be necessary1.  
1.3.2 CURRENT STATE AND CHALLENGES OF ADULT STEM CELL TRANSPLANTATION 
FOR CVD TREATMENT  
Together, preclinical and clinical trials have led to serious positive outcomes within the 
field of adult stem and progenitor cell transplantation for CVD therapy. First, as 
discussed in detail above, the therapeutic regeneration using cell products has been 
demonstrated (RENEW, Prochymal, SCIPIO, FINCELL, etc). In addition, different 
advanced delivery strategies were developed (e.g. 3D MyoStar®Injection Catheter 
combined with NOGA®electromechanical mapping system; 2D fluoroscopic guidance 
systems Helix™ infusion catheter and the MyoCath™). Notably, the possibility of safe 
allogenic cell therapy without immunosensitization has been proven for MSCs and CSCs 
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(POSEIDON, STEMI, Prochymal, ALLSTAR), which enables the generation of “off the 
shelf” products. Moreover, since such cell types as BM-MNC, HSC, EPC, MSC and CSC have 
been proven safe for transplantation, with a certain evidence of clinical efficacy, further 
phase II and III trials can be initiated. In addition, an optimal match between cell product 
and patient’s cohort can be established: BM derived progenitor cells were positively 
influencing patients with most extensive MI-induced damage including low baseline of 
LVEF (REPAIR-AMI, FINCELL, REGENT). For other patients emerging cell types such as 
CSCs may be suitable which will be defined in planned and ongoing clinical trials41. 
 
At the same time, analysis of carried trials reveals current problems and challenges, 
which cell therapy for CVD is facing. In particular, in the majority of conducted trials, the 
criteria of patient selection are inconsistent, which might in part explain some 
controversies in the reported results. In addition, the intrinsic biological variability of 
such applied cell products as unselected MNCs can be another factor resulting in the 
inconsistent outcomes of clinical trials, which is less pronounced in more uniform cell 
fractions (e.g. positive functional outcomes in BOOST, REPAIR-AMI and FINCELL vs no 
outcome in ASTAMI, HEBE, TIME and Late-TIME). 
Other limitations of currently available cell therapeutics are the following: available 
numbers of fractioned BM-derived cells are low, replicative capacity of adult stem cells 
in situ is limited compared to ESCs and iPSCs, and cells are restricted to a certain lineage. 
Moreover, the regenerative capacity of cells declines with age and progenitors mobilized 
in the body may also lack  capability with age41,47,48. 
Delivery of sufficient cell numbers to the site of interest also remains a challenging issue:  
currently reported rates of cell retention drop below 5-10% as soon as several minutes 
to hours post application, regardless of administration routes49–51. After delivery, the 
regenerative potential of cells is often compromised by poor engraftment and survival in 
the ischemic tissue52,53.  These factors may explain, at least in part, why the therapeutic 
benefit of adult  stem cell application is so limited (~4-5% functional improvement 
except primary studies of CSCs)54. 
1.3.3 THERAPEUTIC VALUE OF CELL ENGINEERING PRIOR TO TRANSPLANTATION 
Main directions, which are currently trying to address the challenges of cell therapy of 
CVD, are following: selection of particular cell types, development of pluripotent cells for 
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cardiac regeneration and improvement of administration strategies as discussed above 
(1.2.2 & 1.3.1.); cell preconditioning for functional and survival improvement55–57; 
control over adhesion molecules and growth factors58; enhancement of homing and 
engraftment, including development of supportive biomaterials59,60. At the same time, 
genetic cell engineering can be a complex answer to these objectives. In particular, by 
genetic modification or delivery of non-peptidic molecules, either innate cell properties 
can be improved or additional therapeutics agents can be incorporated. Moreover, using 
magnetic particles or surface modification with targeting moieties (enzymatic 
modification, chemical conjugation or non-covalent interactions) external targeting or 
increased homing can be achieved, respectively. Importantly, during adjustment and 
improvement, the balance between obtained therapeutic enhancement and minimized 
loss of stem cells’ intrinsic functions must be maintained61.  
Among the mentioned engineering approaches, genetic modification of cells is the most 
promising, mainly because of its multimodality and ability to cover several challenges 
for stem cell therapy simultaneously62. Introduction of reporter genes can be applied to 
isolate highly purified cell populations by flow cytometry or to track transplanted cells 
(e.g. as a result of expression of fluorescent or luminescent proteins)63,64. Forced 
expression of certain factors with high cardiogenic potential can be achieved in 
transplanted cells65. Introduction of factors, which are responsible for such innate cell 
properties as mobilization, adhesion, migration or integration, can enhance their 
retention and activity in the desired area58,66,67. A similar outcome can be achieved by 
enhancing intrinsic cell properties, i.e. their survival in an ischemic environment or their 
paracrine potential58,62,68. Furthermore, a broad spectrum of therapeutic agents can be 
incorporated in order to specifically complement and promote regenerative properties 
of delivered cells69,70. 
Genetic cell engineering can be done based on different strategies to manipulate cell 
properties are described above: gene correction, gene silencing and gene editing (Figure 
1 & section 1.2.1). There are various methods that enable delivery of genetic material. 
1.4 DELIVERY VECTORS FOR GENETIC MATERIAL 
Delivery strategies aim to protect the delivered therapeutics from degradation by serum 
nucleases, to selectively accumulate in the tissue of interest, to ensure cellular 
internalization followed by appropriate intracellular trafficking and functionality, e.g. 
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intranuclear transport for pDNA or uptake into RNA-induced silencing complex (RISC) 
for miR. Broadly, delivery systems can be divided in two main groups by their origin: 
viral and non-viral71,72. 
1.4.1 VIRAL VS NON-VIRAL 
To date, in terms of efficiency viral vectors greatly exceed non-viral systems, which has 
led to their wider application in clinical trials (~67%)14. The most successful vectors 
which have entered clinical trials belong to adenoviruses, retroviruses (incl. 
lentiviruses), vaccina virus, adeno-associated viruses (AAV), poxviruses and herpes 
simplex virus, whereas development and application of such types as human foamy 
virus, Eppstein-Barr virus, cytomegalovirus, etc. is less advanced14,72. Among non-viral 
delivery systems, the application of naked/plasmid DNA and lipofection are mainly 
present in clinical studies14. 
Viral vectors enable highly efficient sustainable delivery of genetic material and their 
application allows both, long-term (years) and short-term (weeks to months) expression 
for integrating and non-integrating viruses, respectively. To compare the efficiency of 
viral and non-viral delivery for pDNA: in MSCs, viral delivery easily provides more than 
90% gene expression, whereas non-viral usually does not exceed 50-60%; similarly, in 
CD34+ HSCs transduction ensures efficient expression of transgene by 80-90% of cells 
whereas non-viral strategy is considered successful already if more than 30-50% of cells 
start to overexpress the protein of interest73–77. 
However, viruses as delivery vehicles carry serious risks: their pronounced 
immunogenicity causes inflammatory response leading to severe complications 
including degeneration of the transducted tissue; limitations in size of the carried 
genetic material; risk of insertion possibly causing oncogene activation or tumor-
suppressor gene inactivation72.  
Therefore, the use of non-viral systems is currently of great interest due to these safety 
concerns, difficulties and high costs of viral vector production. It is particularly 
reasonable in such cases as expression of growth factors controlling angiogenesis or 
delivery of vaccines, where transient genetic correction is required. For such situations 
virus-free systems pose more attractive options as they are non-pathogenic, non-
immunogenic and not limited by the size of delivered genetic material. Notably, 
significant progress has been achieved in enhancing their efficiency – yet not reaching 
the level of viral vectors - and producing more advanced vectors71,78.  
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1.4.2 MAGNETIC NANOPARTICLES AS A TOOL FOR ADVANCED GENETIC 
MANIPULATION 
As the development of non-viral vectors progresses, many advanced strategies are being 
explored: including the design of stimuli-responsive vectors; targeted delivery; co-
delivery of several molecules; production of biodegradable vectors and noninvasive 
monitoring of delivered systems79. Advanced strategies mostly require the production of 
hybrid vectors to consolidate their benefits and improve the quality and functionality of 
the final product. Often nanoparticles, particularly of inorganic origin, become the basis 
of these hybrid vectors79. 
Responsiveness of gene delivery systems to physicochemical stimuli allows for  
controlled release of cargo at certain time points and at targeted sites80. Recently 
numerous magnetically-, ultrasound-, light- and redox-triggered systems based on 
inorganic nanoparticles were reported by different research groups81–84.  
Targeted delivery of the vectors improves specificity of therapy, reduces off-target 
effects and toxicity. External guidance of magnetic nanoparticle-based vectors by a 
magnetic field is one of the options80,85. Cell surface modification with targeting moieties 
represents another possible approach and nowadays, various targeting ligands are being 
successfully applied. These include peptides (e.g., RGD peptide, TAT peptide), folate and 
other small molecules, glycoproteins (e.g. lactoferrin, transferrin), antibodies, aptamers 
(peptide- and nucleic acid-based), etc.80,86,87.  
Such advanced concepts as combinations of two or more therapeutic molecules with 
synergy effects, are widely used for cancer treatment due to its complicated drug 
resistance mechanisms. In this case, simultaneous delivery of chemotherapeutic agents 
and molecules for genetic manipulation to the tumors are shown to result in efficient 
cancer treatment in vivo88. In addition, co-delivery of nucleic acids can be used, e.g. 
siRNA and DNA. It is particularly valuable for the treatment of such disorders, where 
knockdown of expression and a transient increase in the amount of different proteins 
are required in parallel (e.g., immunodeficient states, certain types of cancer, cystic 
fibrosis)89. 
Biodegradability is a beneficial property of some modern gene delivery systems. It can 
reduce toxicity and side effects of the vector, thus facilitating the approval of the vector 
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for clinical use. Inorganic nanoparticles are known to be poorly metabolized in vivo, 
therefore their further development towards biodegradable vectors would be an 
important step forward86. 
Another important feature - for any gene delivery system - is the possibility to 
noninvasively monitor its post application fate and biodistribution. Magnetic 
nanoparticles and quantum dots can fulfill this requirement due to their magnetic and 
fluorescent properties, respectively90,91. 
Only few nanoparticle-based vectors combine several beneficial properties, and 
magnetic nanoparticles are among those79. They share common characteristics of 
inorganic nanoparticles, such as easy preparation, wide availability, storage stability and 
high functionality. Moreover, they possess several advantageous properties depending 
on the nature of magnetic response: magnetic guidance or cell sorting can be achieved in 
a permanent magnetic field; temperature increase can be produced in an oscillating 
magnetic field (a combination of both is also applicable)92,93. In addition, several studies 
have shown a positive impact of magnetic nanoparticles on transfection efficiency93,94. 
Importantly, magnetic nanoparticle-based vectors can be non-invasively visualized 
using conventional MRI or such developing techniques as magnetic particle imaging81,95. 
1.4.3 PROPERTIES OF PEI/MNP DELIVERY VECTOR  
In our group, a non-viral vector based on streptavidine-coated superparamagnetic 
nanoparticles (MNP), bound to biotin-coated polyethyleneimine (PEI) by biotin-
streptavidine interaction, was designed96 as a potential tool for magnetically guided 
nucleic acid (NA) delivery for induction of angiogenesis in the clinic (vector structure is 
schematically represented in Figure 3). 
In this case, PEI as a highly protonated polyamine ensures nucleic acid condensation and 
thus protection from degrading factors, vector internalization in cells and endosomal 
escape97. The nucleic acid (NA) is condensed due to electrostatic interactions between 
its negatively charged phosphates and positively charged protonated amino groups of 
PEI. The resulting positive charge of complexes ensures their unspecific interaction with 
the cell surface14. Next, cationic particles are endocytosed: for PEI clathrin- and 
caveolae-mediated uptake has been demonstrated, however, PEI modification can shift 
the balance between these two processes98,99. The details of the next step in transfection 
– endosomal escape – are still debated, but the most commonly accepted mechanism is 
the so-called “proton sponge effect”. Briefly, the low pH of the endosomal environment 
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leads to PEI protonation, which resists to further acidification leading, in turn, to influx 
of ions and water into endosomes and resulting in osmotic swelling and endosomal 
disruption14. Once in the cytoplasm or nuclei, the release of bound NA is thought to 
mainly occur as exchange of polycations for surrounding protein components14. Notably, 
the role of free uncondensed PEI in different stages of transfection and its resulting 
efficiency has been extensively demonstrated100,101. In the PEI/MNP vector, MNPs are 
meant to reduce PEI toxicity, which has already been demonstrated by our group in 
terms of enhanced survival of hMSCs94. Moreover, the presence of a magnetic 
component allows for exploration of targeted delivery and, therefore, minimized 
dosages and off-target effects as well as detection with MRI or the advanced imaging 
modality magnetic particle imaging (MPI) 81,92,95.  
Figure 3. Structure of transfection complexes. A superparamagnetic nanosized core (MNP) is attached 
to polyethyleneimine (PEI), which condenses nucleic acid (miR is shown as an example here). Binding of 
the two structural vector components is ensured by biotin – streptavidine interaction resulting from 
respective PEI and MNP coating. 
1.4.4 KNOWN AND UNKNOWN CHARACTERISTICS OF THE VECTOR  
Previous studies of our group have demonstrated that, according to size and zeta 
potential measurements, NA/PEI/MNP complexes are stable in terms of aggregation and 
are small enough not to cause embolism after injection94,97,102. However, the magnetic 
component of the vector has not been described before in terms of morphology or 
INTRODUCTION 
 
 
20 
 
magnetic properties. At the same time, proper vector characterization and standardized 
production is an important step towards the clinic. 
Using the PEI/MNP vector, both, pDNA (EGFP, Luciferase reporter constructs) and miR 
(tagged non-functional miR, therapeutic miR-335), can be efficiently delivered into 
fibroblasts and hMSCs94,96,97. Interestingly, highly increased transfection efficiency of 
plasmid was demonstrated in the presence of MNP compared to PEI only94,96. Since the 
PEI/MNP vector has been proven efficient for transfection of proliferating cells, it would 
be of high interest to define if the vector is likewise successful for the modification of 
non-proliferating clinically relevant cells. 
In case of pDNA, the positive influence of MNP on cell survival was also shown in hMSCs. 
In order to explain this observation, superresolution imaging of internalized 
DNA/PEI/MNP complexes was performed. It revealed that MNP are preventing PEI from 
binding to nuclear DNA, which, in turn, might be the reason for improved cell survival94. 
On the other hand, the investigation of another crucial component of transfection, 
endocytosis, might prove another explanation. In addition, the knowledge about 
transfection regulators on cellular uptake level could be useful for clinical translation. 
A preliminary attempt to achieve targeted gene expression in the murine heart was 
made96. As a result, localized thoracic vector uptake (left lung and endothelium of the 
heart) has been demonstrated after i.v. vector administration and epicardial magnet 
application. However, such direct vector targeting in vivo was proven to be incomplete: 
gene expression was observed also in off-target tissues, which are known to accumulate 
PEI – liver, spleen and kidneys. Detailed investigation of two possible targeting 
approaches – direct vector targeting and magnetic engineering of cells – could define the 
optimal one. 
Moreover, the superparamagnetic part of the vector offers a highly beneficial potential 
for non-invasive MRI tracking. Testing this opportunity is of great importance.  
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1.5 AIM OF THE THESIS 
Based on the background described above, the aim of the present study was to 
investigate the potential of a non-viral PEI/MNP based vector for magnetic targeting and 
non-invasive monitoring in vitro. In particular, the following questions were addressed: 
 
 Can vector production be highly standardized? 
 
 Is a direct vector guidance approach well suited for the current vector design, 
since its previous in vivo performance was not entirely successful? 
 
 Can NA/PEI/MNP-modified cells be magnetically guided in static and dynamic 
conditions? And if yes, which amount of iron loading is sufficient for cell 
targeting? Does the application of static magnetic field negatively affect the 
modified cells? 
 
 Does magnetic engineering of cells with NA/PEI/MNP influence their initial 
functional capacities? Does transfection affect their ability to maintain 
intercellular communication, which is crucial for cellular therapeutics intended 
for transplantation? 
 
 How does the presence of MNP interfere with the toxicity known for PEI? Can this 
be associated with the impact of iron oxide particles on the intracellular 
processing? 
 
 Will magnetically-responsive cells – modified at conditions optimal for 
transfection and targeting – be detectable using MRI? What are the limits of 
detection? 
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2 MATERIALS AND METHODS 
2.1 CELL ISOLATION AND CULTURE 
2.1.1 FIBROBLAST-LIKE CELL LINE (COS7) 
The African green monkey kidney fibroblast-like cell line (COS7) was obtained from 
American Type Culture Collection (VA, USA) and cultured in Dulbecco`s Modified Eagle 
Medium (DMEM, Pan Biotech GmbH, Aidenbach, Germany), supplemented with 10% 
fetal bovine serum (FBS, Pan Biotech), non-essential amino-acids (Merck Millipore, 
Billerica, MA, USA), 100 U/ml Penicillin and 100 µg/ml Streptomycin (both Gibco, 
Thermo Fisher Scientific, Waltham, MA, USA). Cell cultures were maintained according 
to the manufacturer’s protocol. 
2.1.2 ENDOTHELIAL CELLS (HUVEC) 
Human umbilical cords for cell isolation were obtained directly post partum from 
informed healthy women, who gave written consent to the use of this material for 
research according to the Declaration of Helsinki. The ethical committee of the 
University of Rostock has approved the presented study (reg. No. A 2011 06, prolonged 
23 September, 2013). 
Human umbilical vein endothelial cells (HUVEC) were isolated from cords by 
collagenase digestion from the interior of the cord vein following a previously developed 
protocol103 - a modification of the procedure described by Jaffe et al104. Obtained cells 
were either stored long-term in liquid nitrogen or cultured in the endothelial growth 
medium (EGM-2, Lonza, Basel, Switzerland), supplemented with 100U/ml penicillin and 
100 µg/ml streptomycin at 37C in a humidified atmosphere containing 5% CO2. For all 
experiments HUVEC were pooled (5 patients) and their passage did not exceed 4. 
Characterization of obtained cells was carried out by staining for an endothelial marker 
CD31 (platelet endothelial cell adhesion molecule, PECAM-1). For this purpose, cells 
were grown on Gelatine-coated (Sigma Aldrich, St Louis, MO, USA) coverslips, fixed with 
4% PFA (Merck) for 10 minutes and immunofluorescently stained using PECAM-1 as a 
primary antibody (Santa Cruz Biotechnology Inc, Dallas, Texas, USA) and Alexa Fluor 
Alexa Fluor ® 647 (Thermo Scientific) as a secondary antibody. In addition, tube 
formation assay was performed: 3.5x104 HUVECs were seeded in 24 well-plates (Greiner 
Bio-One, Kremsmünster, Austria), coated with 140 μl Matrigel Basement Membrane 
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Matrix (BD Biosciences, Heidelberg, Germany) and formation of tubes was observed 
after 24h. 
2.1.3 HEMATOPOIETIC CD133+ STEM CELLS 
Bone marrow (BM) was obtained from informed donors, who gave their written consent 
to use of their samples for research according to the Declaration of Helsinki. The study 
was approved by the ethical committee of the University of Rostock in 2010 and 
renewed in 2015 (registration number A 2010 23). Sternal BM aspirates were taken 
from cardiac patients undergoing coronary artery bypass grafting at the Department of 
Cardiac Surgery (University Hospital Rostock, Germany). To prevent coagulation in 
samples, heparin sodium (250 i.E./ml BM) (Rathiopharm GmbH, Ulm, Germany) was 
used.  
First, mononuclear cells (MNCs) were isolated by layering patient derived BM on Pancoll 
human separation solution (Pan Biotech) and subsequent density gradient 
centrifugation. Next, CD133+ cells were magnetically enriched using the MACS CD133 
MicroBead Kit (Miltenyi Biotec GmbH, Teterow, Germany) following the manufacturer´s 
instructions. Quality control was carried out with all batches of CD133+ immediately 
after isolation and only cell fractions with viability and purity higher than 80% were 
used for further experiments (for the description of the assessment methods see the 
respective sections below). Obtained cells were treated immediately with transfection 
complexes and further cultured in humidified atmosphere at 37 °C and 5% CO2 in DMEM 
supplemented with 1% penicillin/streptomycin and 2% fetal bovine serum. The only 
exception was made in the set of experiments carried out to further optimize culture 
conditions for CD133+ cells. In this case, StemSpan™ H3000 culture medium (Stemcell 
Technologies Inc, Canada) supplemented with StemSpan™ CC100 (Stemcell 
Technologies Inc) was used for incubation (see Fig. 8). 
2.2 PREPARATION AND CHARACTERIZATION OF TRANSFECTION COMPLEXES 
Biotin-Streptavidine interaction was used to create a stable binding of vector 
components. 
2.2.1 BIOTINYLATED POLYETHYLENEIMINE 
Biotinylated polyethyleneimine (PEI) was obtained as a product of 25 kDa branched 
Polyethyleneimine (Sigma) reaction with EZ-Link Sulfo-NHS-LC-Biotin (Biotin, Thermo 
Scientific) as described in the manufacturers’ protocol and previous reports 96. Several 
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changes, however, were introduced to a previously developed protocol and 
characterization strategy in order to standardize the biotinylation procedure. Briefly, 
polyethyleneimine and biotin were diluted in the amine-free water (Gibco) and 
appropriate amount of Biotin solution was dropwise added to Polyethyleneimine. 
Obtained mixture was incubated for 16h under stirring at RT and unreacted Biotin was 
removed by size-exclusion chromatography with PD-10 Desalting columns (GE 
Healthcare, Little Chalfont, United Kingdom) as described elsewhere 105. After 
purification, biotinylated polyethyleneimine (PEI) was characterized by primary amine 
group concentration (Ninhydrin assay, Ninhydrin was purchased from Sigma). For this 
purpose, the standard curve generated for Glycine during each repeated measurement 
and subsequent definition of PEI concentration was performed. Further, the degree of 
biotinylation was defined in a so-called HABA assay (Pierce Biotin Quantitation Kit, 
Thermo Scientific) following previously reported protocols 105,106 and manufacturers’ 
recommendations. 
2.2.2 STREPTAVIDINE-COATED SUPERPARAMAGNETIC NANOPARTICLES 
The second component of the vector construct - MNP – was prepared as reported before 
94 by filtration of Streptavidin MagneSphere® Paramagnetic Particles (Promega, 
Madison, Wisconsin, USA) through 0,45µm Millix-HV PVDF syringe driven filter (Merck) 
in order to exclude bigger toxic aggregates. 
Obtained nanoparticles were characterized using a commercial dc-magnetometer 
(MPMS-XL, Quantum Design, San Diego, CA, USA). The magnetization curve M(H) 
(magnetic moment normalized to iron content) of the MNPs as a function of the external 
magnetic field (up to 5 T) was determined at room temperature T=295 K. For the 
measurement, 30 µL of the suspension were placed into a polycarbonate capsule. 
Core morphology of MNPs was characterized by transmission electron microscopy 
(TEM). For this purpose, 16µl of nanoparticle suspension was diluted with 40µl of 
distilled water, sonicated and vortexed. A small drop of the obtained solution (approx. 3 
µl) was placed onto a 300 mesh formavar-carbon coated copper grid. The liquid was 
dried completely by placing the grid onto a glass slide on a heating plate. Subsequently, 
the specimen was analyzed in a Zeiss Libra 120 transmission electron microscope at 120 
KV and digital images were recorded with a 2x2k Proscan camera (TRS, Moorenweis, 
Germany) using iTEM camera control and imaging software (Olympus Soft Imaging 
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Solutions, Münster, Germany). In addition, elemental composition of the specimen was 
verified using an X-ray detector (Sapphire / EDAX-Ametek, Weiterstadt, Germany). 
2.2.3 DELIVERED NUCLEIC ACIDS 
The delivery capacity of PEI/MNP vector was tested with both, pDNA and miR, and for 
this purpose several test NA were selected.  
Commercially available fluorescent Cy™3 labeled Pre-miR™ Negative Control #1 (Cy3-
miR) (Thermo Scientific) was used to define optimal miR delivery and targeting 
conditions. Pre-miR™ miRNA Precursor Molecules - Negative Control #1 (Thermo 
Scientific) served for flow cytometry gating controls, colony forming unit (CFU) assays, 
surface marker expression analysis and intracellular visualization of transfection 
complexes. For the real-time PCRs, a synthetic inhibitor against hsa-miR-92a-3p was 
used:  Anti-miR™ miRNA Inhibitor (Thermo Scientific) (mature miR sequence as 
provided by manufacturer: UAUUGCACUUGUCCCGGCCUGU).    
To investigate the delivery and magnetic guidance of plasmid, pEGFP-N3 and pcDNA3.1-
Luc plasmids were transformed in E. coli DH5α-strain and amplified (long-term storage 
of bacteria at -80 C). Their following isolation and purification were performed using 
Plasmid DNA Purification Kit (Macherey-Nagel, Düren, Germany) in accordance with 
manufacturer’s instructions.  
2.2.4 FLUORESCENT LABELING OF TRANSFECTION COMPLEXES FOR MICROSCOPY 
The previously developed protocol for 3-colour labeling of NA/PEI/MNP was applied 94, 
using different set of dyes. Briefly, PEI was labeled with NHS-Esther Atto 488 (ATTO-
TEC GmbH, Siegen, Germany), purified by size-exclusion chromatography (PD-10 
Desalting columns) and characterized by Ninhydrin assay for amine group 
concentration (see above); miR and DNA were labeled with Cy®5 using respective Label 
IT® kit (Mirus Bio, WI, USA) and their concentration was measured 
spectrophotometrically by NanoDrop ND-1000 (Thermo Scientific); MNP were labeled 
every time freshly during NA/PEI/MNP complex formation with Biotin Atto 565 or 488 
(ATTO-TEC) in 1:1000 w/w dye to MNP ratio. 
2.3 TRANSFECTION 
In all experiments, COS7 were seeded in a multiwell plate (Greiner) suitable for the 
assay 24 h before transfection. HUVEC were cultured for 48 hours prior to transfection 
(TPP, Trasadingen, Switzerland, unless indicated otherwise) until 70-80% confluence. In 
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case of CD133+, cells were treated directly after their isolation and seeding in 24 well-
plates (Greiner). Seeding formats and applied cell amounts are specified in the Table 1. 
NA/PEI or NA/PEI/MNP complexes were prepared fresh before adding to the cell 
culture medium as previously described 94,97. Briefly, to form NA/PEI complexes PEI and 
NA were pre-diluted in appropriate amounts of 5% Glucose solution (MP Biomedicals, 
Germany), mixed together, vortexed and incubated for 30 minutes. In order to prepare 
the NA/PEI/MNP formulation MNP were first incubated in an ultrasonic bath for 20 min 
and afterwards added to pre-prepared NA/PEI complexes. To form different complex 
compositions, various amounts of nucleic acid (µg or pmol per cm2 of cell growth surface 
for pDNA and miR, respectively), molar ratios of PEI nitrogen and NA phosphate (NP 
ratio, NP) and amounts of iron (µg iron per ml of prepared NA/PEI) were used.  
Obtained complexes were further added to the cell culture medium and incubated for 
different time-periods: in all experiments with HUVEC the transfection medium was 
replaced with fresh culture medium 6 hours after; treated CD133+ were always 
incubated with complexes for at least 18h and either directly used for measurements or 
fresh medium was supplied. 
2.4 ANALYSIS OF TRANSFECTION RESULTS 
2.4.1 VIABILITY ASSESSMENT 
Trypan blue exclusion assay (concentration 0.4%; Sigma) was applied both, during 
manual cell counting and when T20 automated cell counter (Bio-Rad, Hercules, CA, USA) 
was used in the experiments with MACS© separation of transfected cells (see the 2.5 
section for more information). 
In case of COS7 transfection with Luc pDNA, the viability assessment was performed by 
MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide] assay94. For 
this purpose, 24h after transfection the working solution 5 mg/ml of MTT in phosphate 
buffered saline (PBS, Pan Biotech) was added to each well for further incubation for 4 h 
at 37°C, 5% CO2. After the removal of reaction medium, crystals of purple formazan 
formed in cells were dissolved in 100 µl of DMSO. Absorbance was measured by Bio-Rad 
Model 680 microplate reader (Bio Rad Laboratories GmbH, Munich, Germany) at a 550 
nm using 655 nm wavelength as a reference. Cell viability was calculated and 
normalized to control, where cells were treated with 5% Glucose equal in volume to the  
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Table 1. Description of experimental formats 
transfection mixture. In all other cases, cell viability was evaluated using flow cytometry 
(FACS). To perform the measurement, cells were collected at the appropriate time point,  
stained with Near-IR LIVE/DEAD® Fixable Dead Cell Stain Kit (Molecular Probes) and  
Cell 
type 
Experiment 
type 
Seeding format: Cell 
number/well 
Applied magnet Evaluation strategy 
 
Cos 7 
Transfection 
optimization 
48 well-plate: 1.5*104 
- 
Flow cytometry for cell 
viability & transfection 
efficiency 
96 well-plate: 7.5*103 
MTT assay for viability 
Luciferase assay for 
efficiency 
 
 
 
 
 
 
 
 
HUVEC 
Transfection 
assessment 
24 well-plate: 2.5*104 
 
12 well-plate: 5*104 
- 
Flow cytometry 
Proliferation & tube 
formation assays 
Real-time PCR 
Intracellular 
iron 
quantification 
24 well-plate: 2.5*104 
Bdrive = 25 mT, frequency 
f0 = 25 kHz 
Magnetic Particle 
Spectroscopy 
NA/PEI/MNP 
targeting on 
seeded cells 
pDNA/ 6 well-plate: 
1*105 
Magnetic plate (OZ 
Biosciences, Marseille, 
France). Field strength 
and gradient: 70-250 mT 
and 50-130 T/m, 
respectively 81. 
 
 
 
 
 
Microscopy (confocal 
LSM) 
miRNA/ Gelatine-
coated Lab-Tek 4-well 
chamber slide or 
6 well-plate with 4 
Gelatine-coated 
coverlips: 2 placed 
over magnet, 2 – 
without.: 2.5*104 and 
10*104, respectively 
Cell targeting 
24h after 
transfection 
24 well-plate 
(transfection): 2.5*104 
 
12 well-plate 
(targeting after 
detachment): 5*104 
Ring Neodym Magnet 
(magnets4you GmbH 
Lohr a. Main, Germany), ø 
10 mm; remanescence is 
~1.3T, coercivity ≥ 955 
kA/m. 
 
Microscopy 
(conventional light) 
MACS cell separation 
system (Miltenyi). Field 
strength is 0.4-1T, 
gradient is up to 104 T/m 
107 
Flow cytometry for 
negative and positive 
fractions after MACS 
sorting 
MRI 
visualization 
of transfected 
cells 
6-well plate 
(transfection): 1*105 
7.1T (animal MRI system) 
 
Intercellular 
communicati
on evaluation 
Gelatine-coated Lab-
Tek 4-well chamber 
slide: 2.5*104 
- 
 
Microscopy (FRAP) 
 
 
 
 
CD133+ 
Transfection 
optimization 
24 well-plate: 5*104 - 
Flow cytometry 
Cell targeting 
24h after 
transfection 
24 well-plate 
(transfection): 2.5*104 
12 well-plate 
(targeting): all 
collected 
Magnetic plate (OZ 
Biosciences, Marseille, 
France). 
 
 
Microscopy (LSM) 
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fixed with 4% PFA in accordance with standard procedures97. These cells were 
subsequently analyzed using BD FACS LSRII™ flow cytometer (BD Biosciences) with BD 
FACSDiva Software 6 (BD Biosciences, 2007) using untreated cells as negative control, 
whereas cells transfected with scrambled NA were used to form adequate gating 
strategy (a sample gating strategy applied for Cy3-miR or EGFP transfected HUVECs is 
illustrated in Figure 4).  
Figure 4. Representative flow cytometry data obtained for HUVEC, which illustrates the gating 
strategy used for analysis of transfection results. 
Scrambled miR (A) or pDNA (C) were applied for transfection to form an adequate gating strategy. First, a 
dot plot of side scatter (SSC-A) and forward scatter (FSC-A) served to define cell populations and 
discriminate them from debris. Next, the amount of life and dead cells was defined by plotting cell 
population within coordinates SSC-A versus APC-Cy7-A. Further, the amount of Cy3-positive or EGFP-
positive cells was analyzed (B & D, respectively) by plotting the signal from the excitation of cells with 
561-nm laser for Cy3 detection (PE-A, log) or 488-nm laser for EGFP detection (GFP-A), against SSC-A 
scatter.  
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2.4.2 TRANSFECTION EFFICIENCY EVALUATION 
Transfection efficiency for Luciferase plasmid was examined as reported previously 
using the Bright-Glo Luciferase Assay System (Promega)94. Relative light units were 
normalized against protein concentration determined by the BCA Protein Assay Kit 
(Thermo Scientific). 
Efficiency of delivery of EGFP plasmid or Cy3-miR were assessed by flow cytometry. 
Probes for the measurement were prepared and examined as described above (2.4.1).  
 
Real-time PCR was performed to quantify the level of miR silencing (92a, normally 
expressed in HUVEC) after transfection with inhibiting miR (anti-92a) delivered by 
miR/PEI or miR/PEI/MNP complexes. In addition, the expression of a target gene (ITGA 
V as a direct target for miR 92a 32) was assessed. To perform these measurements, cells 
were transfected as described above and incubated for 48 h. After that, either total RNA 
was isolated with the NucleoSpin® RNA Kit (Macherey-Nagel, Düren, Germany) or miR - 
with mirVana™ miRNA Isolation Kit (Thermo Scientific). Reverse transcription was 
performed using the TaqMan® MicroRNA Reverse Transcription Kit (Thermo Scientific) 
and High Capacity cDNA Reverse Transcription Kit (Thermo Scientific). Further, human 
mature miR-92a and ITGA V transcripts were quantified by the StepOnePlus Real-Time 
PCR System (Applied Biosystems™) using the corresponding TaqMan Assays (Thermo 
Scientific). 
To calculate the relative expression ratio (R) the ΔΔCT method was used (see equations 
1, 2 below). Therefor RNU6B (Assay ID 001093) and Human 18s Endogenous Control 
(Thermo Scientific) were used as endogenous normalization controls for miR and 
protein coding genes, respectively. Untransfected cells were used as a reference. The 
obtained data are representative of 3 independent biological experiments (n = 3), each 
of which was measured in qPCR-triplicates. 
Applied equations:  
∆𝐶𝑇 = 𝐶𝑇 𝑡𝑎𝑟𝑔𝑒𝑡 − 𝐶𝑇 𝑒𝑛𝑑𝑜𝑔𝑒𝑛𝑜𝑢𝑠 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 (1) 
𝑅 = 2−(∆𝐶𝑇 𝑠𝑎𝑚𝑝𝑙𝑒− ∆𝐶𝑇 𝑟𝑒𝑓𝑒𝑟𝑒𝑛𝑐𝑒) (2) 
2.4.3 SURFACE MARKER EXPRESSION OF CD133+ CELLS 
The expression of surface markers is a crucial parameter for the characterization of 
stem cells and stability of marker expression after cell modification indicates 
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preservation of cell type and function. For the CD133+ cell characterization, the 
following antibodies were used: anti-CD34-FITC (clone: AC136), anti-CD133/2-PE 
(clone: 293C3), isotype control mouse IgG 2b-PE (Miltenyi), anti-CD45-APC-H7 (clone: 
2D1) and 7-AAD (BD Biosciences). To reduce unspecific binding, FcR blocking reagent 
(Miltenyi) was added. After incubation for 10 min at 4 °C samples were measured with 
LSR-II flow cytometer (BD Biosciences) and data analysis was performed on FACSDiva 
software (BD Bioscience). For evaluation Boolean gating strategy was arranged based on 
the ISHAGE guidelines for CD34+ cells analysis108 in the following order: cell population, 
viable CD45+ cells, viable CD45+/CD34+ cells, viable CD45+/CD34+/CD133+ cells (Figure 
5).   
Calculation of surface marker expression was based on following equation: 
Surface marker pattern[%] =
Viable CD45 +/CD34 +/CD133 + cells
Viable CD45 + cells
× 100 
The procedure was carried out with freshly isolated CD133+ to control the quality of 
cells obtained from BM and also 18h after transfection.  
Figure 5: Application of Boolean gating strategy for the flow cytometry of CD133+ cells  
(A) A dot plot of side scatter (SSC-A) and forward scatter (FSC-A) was built to exclude debris from the 
intact cell population. (B) CD45+ cell population is defined in coordinates SSC-A/APC-H7 and subsequently 
viable (C) cells (7-AAD neg.) are detected in this population. Next, (D) CD34+ cells (FITC pos.) are 
distinguished from viable CD45+ population and, further, (E) CD133+ cells (PE pos.) – out of viable 
CD45+/CD34+ population; (F) PE – isotype control. 
2.4.4 MONITORING OF FUNCTIONAL PROPERTIES OF MODIFIED HUVEC AND CD133+ 
The proliferative capacity of HUVEC was examined in DNA synthesis-based proliferation 
assay using the Click-iT Plus EdU Imaging Kit (Thermo Scientific). The assay was carried 
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out 24h after transfection following the manufacturer’s instructions. The result - 5 
random fields in each well - was recorded with LSM 780 ELYRA PS.1 (Carl Zeiss) and 
evaluated using ImageJ (NIH). In particular, EdU stained and total nuclei (Hoechst-
stained) numbers were defined and the rate of proliferating cells was calculated. To 
evaluate the influence of miR/PEI or miR/PEI/MNP complexes, the rate of proliferating 
transfected cells was divided by the rate of EdU-positive cells in untreated control and 
expressed in %. 
To assess functional capacities of HUVEC, a tube formation assay was performed 
following standard protocols32. Briefly, cells were transfected with miR/PEI or 
miR/PEI/MNP as previously described and incubated for 48 h. After that, 3.5x104 of 
modified HUVECs were seeded in 24 well-plates (Greiner), coated with 140 μl Matrigel© 
as described before (2.1.2). Images of 10 random fields in each well were recorded on 
the LSM 780 ELYRA PS.1 system (Carl Zeiss) and analyzed using ImageJ software, 
upgraded with an AngiogenesisAnalyzer (NIH). Parameters such as total length of 
branches, number of branches and number of junctions were used to compare different 
transfection conditions. Final plotted values were calculated as % of respective 
parameters vs untreated control. 
In order to monitor the hematopoietic differentiation capacity of miR-modified CD133+ 
cells, CFU assays were performed. After transfection, 1x103 cells were mixed with 
MethoCult H4434 Classic (STEMCELL Technologies, Germany) and seeded in a 35 mm 
dish.  Formed colonies were identified (CFU-erythroid (CFU-E) (A), Burst-forming unit-
erythroid (BFU-E) (B), CFU-granulocyte, erythroid, macrophage, megakaryocyte (CFU-
GEMM) (C) and CFU-granulocyte, macrophage (CFU-GM)) and counted for the 
assessment after 14 d of incubation at 37 °C and 5% CO2. As recommended by the 
manufacturer, all samples for each repetition were prepared in duplicates. 
2.4.5 INTRACELLULAR LOCALIZATION OF TRANSFECTION COMPLEXES 
Qualitative analysis of cells transfected with Cy3-labeled miR was carried out using 
confocal LSM. This allowed to define whether miR was internalized during transfection 
or attached to the cell surface, whereas for pDNA this point was adressed by the 
presence or absence of protein expression.  
CD133+ cells, transfected with miR/PEI/MNP were prepared 18 h post-treatment by 
washing with 2 % FBS in PBS and fixation with 4 % FA for 20 min. Afterwards, cells 
were spun down to a coverslip and washed with PBS. Prepared coverslip was mounted 
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with Fluoroshield™ containing DAPI (Sigma-Aldrich) on microscope slides. Obtained 
samples were visualized on the ELYRA PS.1 LSM 780 system in the tile-scan mode in 
order to acquire larger areas of 1062.33 µm x 1062.33 µm (40x oil immersion objective, 
514 nm excitation laser, differential interference contrast). To identify the intra- or 
extracellular localization of Cy3 signal, z-stacks of approx. 7 µm depth were recorded. 
In case of HUVECs, cells transfected with Cy3-labeled miR were repeatedly washed with 
PBS 24 h post-treatment, fixed by 4% PFA and their nuclei were counterstained with 
DAPI. Visualization of prepared samples was similar to CD133+ cells. 
 
Detailed information on intracellular localization of transfection complexes was 
obtained after cell transfection with 3-colour labelled NA/PEI/MNP (for both, miR and 
pDNA). In particular, cells were transfected at previously optimized conditions with 
labeled complexes, where each component carried a fluorescent tag (see 2.2.4. section 
for detailed description). 24h after transfection cells were washed twice with 2% BSA in 
PBS in order to remove non-internalized MNPs and complexes 109 and fixed by 
incubation with 4% PFA solution for 15 min. Nuclei were counterstained by 1.25 nM 
DAPI (Molecular probes) in PBS and washed thoroughly to remove the excess of the dye. 
Coverslips prepared this way were mounted with FluorSave™ Reagent (Calbiochem, 
Darmstadt, Germany) on microscopic slides. Similar strategy was applied in case of 
CD133+, except several changes, mainly introduced due to the suspension character of 
cell culture. In particular, cells fixed with 4% PFA cells were spun down on to a 
coverslip. After washing, the coverslip was mounted with Fluoroshield™ with DAPI 
(Sigma-Aldrich, Germany) on microscopic slides.  
All SIM observations were carried out on the ELYRA PS.1 LSM 780 system with ZEN 
Software (Carl Zeiss). Using a 63x alpha Plan-Apochromat or 100x alpha 1.46 Plan 
Apochromat® (Carl Zeiss) objective with oil immersion, Z-stacks were recorded in SIM 
mode with a 16bit depth at 3 or 5 angles, with averaging 4; 23 µm grid was applied for 
405 laser line, 34 µm – 488, 42 µm – 561, 51 µm – 633. These SI raw datasets were 
computationally reconstructed by ZEN software. Presented final images were obtained 
as a result of alignment of Maximum projections created separately for each channel. 
2.4.6 INVESTIGATION OF VECTOR UPTAKE MECHANISM 
A specific inhibitor of dynamin, Dynasore110 (Abcam, Cambridge, UK), was applied to 
verify the character of pathways involved in the internalization of transfection 
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complexes. In this setup, cells were pre-treated with Dynasore (6.8mg/ml111) for 1h, 
transfected with Cy3-miR/PEI or Cy3-miR/PEI/MNP as described above and incubated 
for 4h. The obtained probes were subsequently investigated by flow cytometry for 
viability and amount of Cy3-positive HUVEC (see above). Untransfected cells treated 
with Dynasore served to define the appropriate gating strategy, whereas HUVEC 
transfected, but untreated with the inhibitor, were used for comparison. The efficiency 
of uptake blockage was calculated in each experiment using the following equation:  
𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 𝑜𝑓 𝑏𝑙𝑜𝑐𝑘𝑖𝑛𝑔 = 100% −  
𝑁𝑟 𝑜𝑓 𝐶𝑦3 + 𝐷𝑦𝑛𝑎𝑠𝑜𝑟𝑒 𝑡𝑟𝑒𝑎𝑡𝑒𝑑
𝑁𝑟 𝑜𝑓 𝐶𝑦3 + 𝐷𝑦𝑛𝑎𝑠𝑜𝑟𝑒 𝑢𝑛𝑡𝑟𝑒𝑎𝑡𝑒𝑑
∗ 100% 
Further, vector uptake studies were carried out at different time-points (30 minutes, 1h 
and 4h) after transfection with miR. In these experiments, Atto-565 labelled PEI was 
used to investigate its colocalization either with early endosomes (EEA1 marker), 
lysosomes (LAMP1 marker) or endoplasmic reticulum (Calnexin). For early endosome 
staining, cells were fixed with 4% PFA, permeabilized with 0.1% Triton ™ X-100 (Sigma 
Aldrich), blocked in 1% BSA (Cell Signalling Technology, Danvers, MA) for 1 hour at RT 
and incubated with primary anti-EEA1 antibody (Abcam), diluted 1:200 in suitable 
buffer (0.1% Tween + 1%BSA in PBS). Alexa Fluor ® 647 was used as a secondary 
antibody (1:300 in 1%BSA in PBS). Lysosomes were stained after cell fixation with 4% 
PFA for 10 minutes, permeabilization with 0.5% Saponin in PBS (Sigma Aldrich) and 
blocking of non-specific protein-protein interactions with 5% BSA in PBS for 1 hour. 
Primary anti-LAMP1 antibody was diluted in buffer (0.01% Saponin + 1%BSA in PBS), 
incubated on cells for 1h and Alexa Fluor ® 647 was used as a secondary antibody as 
described before. For staining of endoplasmic reticulum, cells were fixed with 4% PFA 
for 10 minutes, washed with 0.01% Tween in PBS, permeabilized with 0.2% Triton ™ X-
100 for 5 minutes and incubated with 5% BSA in PBS to block unspecific antibody 
binding. After that antibody against Calnexin (Abcam) diluted 1:300 was added for 90 
min and subsequently stained with secondary antibody Alexa Fluor ® 647.  Prepared 
coverslips were further mounted on microscopic slides with Fluoroshield™ with DAPI 
(Sigma-Aldrich, Germany). 
2.4.7 INTERCELLULAR COMMUNICATION OF MODIFIED CELLS THROUGH GAP-
JUNCTIONS AS ASSESSED BY FRAP 
Fluorescence recovery after photo-bleaching (FRAP) experiments were carried out to 
assess the ability of transfected endothelial cells to maintain gap-junctional intercellular 
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communication (GJIC). For this purpose, HUVEC were treated with 2.5 pmol/cm2 miR NP 
25 combined MNP 5 µg/ml & 25 µg/ml 24h prior to microscopy as described above. 
Directly before measurement these cells were loaded with gap-junction permeable 
fluorescent dye CellTrace Calcein red-orange AM (Thermo Scientific) as described 
elsewhere 112. Prepared samples were placed in the CO2 cage incubator of ELYRA PS.1 
LSM 780 (Carl Zeiss) and visualized over time using 40x objective (oil immersion), LSM 
mode. Intracellular calcein was photobleached with 561 nm excitation light in the 
defined regions (selected cell within a cluster of cells). Subsequent fluorescence 
recovery due to communication with neighboring cells was recorded during the 
following 15 min by obtaining z-stacks (10-15 images per each) every 60 seconds. In 
each measurement, unbleached HUVEC were used as a reference for unspecific 
photobleaching during scanning process. In addition, wild-type HeLa cells, known to 
establish no GJIC 113, served as controls. All FRAP measurements were performed with 
5-10 cells per experiment and repeated at least 3 times. 
2.5 TARGETING EXPERIMENTS 
2.5.1 MAGNETIC TARGETING OF TRANSFECTION VECTOR 
In order to assess the possibility of the vector to be magnetically guided in HUVEC, LSM 
was performed. For this purpose, cells were placed on the magnet (Table 1) right after 
adding transfection complexes. In case of plasmid targeting, 24 hours after transfection 
with EGFP cells were fixed, stained with DAPI and visualized (10x & 20x objectives, air 
immersion, 405 and 488 nm excitation lasers) using using tile-scan acquisition mode to 
record images of bigger areas (1699 µm x 1699 µm). Afterwards the nuclei and EGFP-
positive cells were counted using ImageJ software and transfection efficiency in % was 
calculated.  
When miR guided uptake was assessed, higher resolution was applied (40x objective, oil 
immersion, 514 nm excitation laser, differential interference contrast) in order to detect 
also diffused or weak signal of miR-Cy3 in the cytoplasm. Subsequently, the total amount 
of cells per field and amount of Cy3-positive cells were examined. To quantitatively 
assess miR/PEI/MNP targeting, cells were seeded on Gelatine coated coverslips placed 
in a 6-well-plate (4 coverslips per well). After 2 days in culture, these cells were 
transfected with miR/PEI or miR/PEI/MNP complexes using previously optimized 
conditions and including different amounts of iron (half of the original dose of 
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complexes). Right after transfection, the 6-well-plates were located on the magnet in 
such manner that 2 coverslips per each well were placed above the magnetic plate and 
the other two remained without magnetic influence. After incubation, the cells on 
coverslips influenced by the magnetic field were analyzed independently from cells 
which remained out of the magnet range. In both cases, flow cytometry was used for 
quantification of Cy3+ HUVEC (for the FACS protocol see above).  
2.5.2 MAGNETIC TARGETING OF MODIFIED CELLS IN STATIC AND DYNAMIC 
CONDITIONS 
To examine the targeting potential of transfected cells (HUVEC & CD133+) in static 
conditions, they were treated with various complex formulations defined during the 
optimization step, incubated for 24h (HUVEC) or 18h (CD133+), collected and seeded 
again with the magnet attached locally under the culture well-plate (Table 1. 24h 
thereafter (total of 48h or 42h after transfection) the images of areas with and without 
magnetic field were acquired using LSM (differential interference contrast) or 
conventional light microscopy. In case of CD133+, cell numbers in the area with and 
without magnet were counted using ImageJ software. Magnetic targeting ratios were 
calculated by dividing obtained cell numbers of both areas.  
During the examination of the targeting potential of modified endothelial cells, the 
properties of magnetically responsive and non-responsive cell fractions were analyzed 
independently. For this purpose, MACS© separation was applied to divide modified cells 
24h after transfection. Each of the obtained fractions were further split in 4 parts: 1) for 
cell counting on the T20 automated cell counter (Bio-Rad, Hercules, CA, USA) and 
viability evaluation with Trypan blue exclusion assay (concentration 0.4%; Sigma-
Aldrich); 2) for immediate preparation of FACS probes; 3&4) for culture and further 
flow cytometry analysis 24 and 72 hours after magnetic separation (48 and 96 hours 
after transfection, respectively). Untreated cells and cells transfected with NA/PEI 
complexes served as controls in all described experiments. 
In order to more extensively verify the possibility of miR/PEI/MNP-modified cells to be 
guided, we have simulated dynamic conditions in vitro. For this purpose, transfected 
cells (Cy3-miR/PEI/MNP and Cy3-miR/PEI as control) were placed in suspension in the 
wells of a 12 well-plate rotating on a shaker (150 RPM)114. After 12h of incubation, the 
cells were fixed with 4% PFA and stained with DAPI as previously described. Obtained 
probes were visualized using LSM. 
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2.5.3 IRON CONTENT MEASUREMENT OF TRANSFECTED CELLS 
Magnetic Particle Spectroscopy (MPS) was applied in order to quantify the loading of 
HUVEC with superparamagnetic iron oxide MNP. MPS is a sensitive magnetic detection 
method that allows for the specific quantification of the magnetic nanoparticle iron 
content without being affected by cells or suspension medium115. After incubation with 
transfection complexes for 24h cells were washed twice with 2% BSA in PBS, collected 
and the measurements were carried out employing a commercial MPS device (Bruker 
Biospin, Germany) operating at a magnetic field Bdrive = 25 mT and a frequency f0 = 25 
kHz. For iron quantification of the samples the third harmonic A3 of the MPS-spectrum 
was normalized to the corresponding A3,ref of a MNP reference sample of known iron 
amount of 2.1 µg  as described before116. Untreated cells and cells transfected with 
NA/PEI complexes served as controls in all described experiments. 
A similar MPS measurement strategy was applied for transfected CD133+ cells to 
quantify their iron loading. Briefly, 18 h post-treatment cells were collected, washed 
with 2% FBS in PBS, resuspended in PBS, fixed with 4% PFA and transferred into 0.1 ml 
PCR tubes for the measurement. The third harmonic A3 of the MPS-spectrum was 
normalized to the corresponding A3,ref of a MNP reference sample of known iron amount 
(3.2 µg for MNPs only reference and 2.5 µg for the CD133 MicroBeads reference). The 
ratio of the fifth to third harmonic A5/A3 was used as a characteristic finger print to 
identify the magnetic nanoparticle type (MNPs or CD133 MicroBeads) in the sample. 
2.6 MAGNETIC RESONANCE IMAGING 
The possibility to non-invasively track modified cells was tested on HUVEC in vitro using 
magnetic resonance imaging (MRI).  
2.6.1 PHANTOM PREPARATION 
Agar gel phantoms were constructed using previously described protocols 117. Briefly, 
various numbers of transfected cells were embedded in different layers of 2% agarose in 
order to define the detection limits. Air bubbles, which could be a source of false-
positive signals, were removed in each layer by placing the 50ml tube with sample in the 
ultrasound bath and its following centrifugation at 500g for 1 minute. The compositions 
of NA/PEI/MNP complexes used for transfection were defined as a result of previously 
conducted targeting experiments. Phantoms containing 5.5*105 HUVEC treated with 
non-magnetic NA/PEI complexes served as controls.  
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2.6.2 MR IMAGING 
All examinations of obtained phantoms were carried out on a high-field 7.1 Tesla animal 
MRI system (ClinScan, Bruker Corp., Billerica, MA, USA) after placing the phantom 
centrally in the used coil parallel to the z-axis of the magnetic field. The following 
sequence parameters were applied for a gradient-echo sequence acquisition: TR: 66 ms; 
TE1/TE2/TE3/TE4/TE5/TE6: 1.44/2.88/4.51/6.11/7.60/9.01 ms; flip angle: 3°; matrix: 
128×128 interpolated to 256x256; field of view: 42 mm; 100%; averages: 1, echo train 
length: 1; slice thickness: 1.5 mm; 16 slices. Further, signal decay of all four echo times 
were assessed and a R2* maps (R2* = 1/T2*) were calculated using Matlab (Mathworks, 
Natik, MA, USA) 118. Images were analyzed using the freeware Osirix (Pixmeo, Bernex, 
Switzerland). For each sample, a rectangular region of interest (ROI) based 
measurement of the R2* was performed. ROIs were placed over the whole container of 
each iron concentration. Image analysis was carried out using the freeware Osirix 
(Pixmeo, Bernex, Switzerland). For each sample a rectangular region of interest (ROI) 
based measurement of the R2* was performed. ROIs were placed over the whole 
container of each iron concentration. Artifacts, which typically appear in the boundary of 
the containers, were excluded.  
2.7 STATISTICAL ANALYSIS 
Presented graphs were created using GraphPad Prism 5 software (GraphPad Software, 
San Diego, Calif), except all experiments on CD133+ cells where SigmaPlot 11.0 software 
was applied (Systat Software, Inc., San Jose, CA, USA). To perform statistical analysis, 
SigmaPlot 11.0 software was used. All the data are presented as mean ± SEM (n is 
specified for each experiment). For normally distributed variables significant differences 
between groups were defined applying Student’s t-test (2 groups) or 1-way ANOVA 
(multiple groups), for non-normally – by Mann-Whitney test (2 groups) and ANOVA on 
ranks (multiple groups, Student Newman Keuls post-hoc test). A p-value of p < 0.05 was 
considered as denoting statistical significance and marked with an asterisk (increase) or 
“#” (decrease) in figures (*p˂0.05, **p˂0.01, ***p˂0.001; #p˂0.05, ##p˂0.01, ###p˂0.001).
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3 RESULTS 
3.1 STANDARDIZATION OF VECTOR PRODUCTION AND ITS EXTENDED 
CHARACTERIZATION  
Standardized production of the delivery vectors in the laboratory is an important step 
towards meeting GLP guidelines, which is a prerequisite for a clinical translation. 
Therefore, in this work, a number of efforts were dedicated to establishing well 
described protocols and detailed characterization of vector components. 
First, the magnetic properties of the nanoparticle component, MNPs, were defined as 
they were not addressed previously by our group94,97 (Figure 6A). According to the 
obtained magnetization curve, MNP demonstrate typical superparamagnetic behaviour.  
Saturation magnetization was 86 Am2/kg Fe, usual for magnetite MNP. The Langevin 
model with log-normal distribution of MNP moments was used to extract a median 
magnetic moment of 940(+/- 90) µB (Bohr Magneton) of a single MNP at a distribution 
width of s=1.7. This corresponds to a mean particle size of about 4.3(3) nm. The latter 
was confirmed via TEM images. In addition, the morphology of filtered nanoparticles 
was defined: MNPs are formed by multiple round-shaped cores embedded in a single 
matrix (Figure 6B). 
Figure 6. Characterization of magnetic nanoparticles (MNPs). 
The magnetization curve obtained for MNPs characterizes them as a typical superparamagnetic material 
with a mean particle size of 4.3(3) nm. The demonstrated saturation magnetization of approximately 
about 86 Am2/kg Fe is standard for magnetite material. (B) TEM micrographs revealing core 
characteristics and morphology of MNPs. 
Magnetic properties of MNPs were analysed by Dr. F. Wiekhorst131; TEM images of filtered MNPs were 
obtained by Dr. M. Frank in the Electron Microscopy Center, University of Rostock, Germany. 
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The two parts of the introduced PEI/MNP vector are brought together by the strong 
interaction between biotin attached to PEI and streptavidin in the MNP coating. 
Whereas MNPs are available commercially and only require filtration to exclude bigger 
toxic aggregates94, PEI has to be biotinylated in the laboratory. This procedure must be 
well defined and repeatable. Therefore, existing protocol was updated taking into 
account recent changes in availability of reagents on the market; in addition, the 
chemical and biological characterization of the final product were extended and its 
similarity to the PEI/MNP complexes previously used in our group was defined. 
Figure 7. Selection of optimal degree of biotinylation for PEI. (A & B) Cos7 were transfected with 
pDNA/PEI or pDNA/PEI/MNP complexes where either PEI70x or PEI20x was included, which differ in the 
degree of biotinylation. For both of these, various complex formulations were applied: DNA amount 1 
µg/cm²; nitrogen/phosphate ratio of 2.5, 5 or 10 and 0.5 or 1 µg/ml of MNP iron. Transfection efficiency 
(A) was evaluated 24h after by luciferase reporter gene assay: RLU calculated per mg of total cell protein 
is depicted. Viability of cells (B) was evaluated using MTT assay and is reflected in the % of viable cells on 
the plot. Cell viability (B) was evaluated by MTT assay. Next, the influence of pH on the activity of PEI70x 
(C) and PEI20x (D) was assessed in the luciferase reporter gene assay. All results are representative of 
three independent experiments, each involved eight replicates (n = 8). The values are shown as mean ± 
SEM.  
* (A) Statistically significant difference in transfection efficiency between PEI20x and PEI70x as compared 
for each complex formulation; (B) Significant increase in Luciferase expression caused by the presence of 
MNPs as defined for each NP ratio and pH value (*p˂0.05, **p˂0.01, ***p˂0.001). 
MTT assay: 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; RLU: Relative light unit. 
During the biotinylation 2 different ratios of biotin to PEI were tested in accordance with 
the manufacturer’s instructions: 70-fold excess of biotinylating reagent and 20-fold – 
“70x” and “20xPEI”, respectively. After the reaction and following purification, the 
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concentration of primary amino groups in obtained solutions was 32.61± 3.205668 mM 
for 70x PEI; 34.76± 2.599481 for 20x vs 41.6 ± 1.122394 mM for the initial 
unbiotinylated PEI (mean ± SEM, n=3). Next, resulting products were characterised by 
the degree of biotinylation, which for 70x PEI was 2.36 ± 0.016997 molecules of Biotin 
per 1 molecule of PEI and for 20x - 1.35 ± 0.018346 (mean ± SEM, n=3). 
 
Furthermore, we have tested the obtained PEI 70x and 20x in the fibroblast-like cell line, 
cos7, a common cellular model for transfection previously used by our group94. 
Figure 8. Testing different iron concentrations to form PEI/MNP with optimally biotinylated PEI. 
Transfection complexes were obtained using different amount of components:  DNA 1 µg/cm²; NP ratio of 
2.5, 5 or 10 complemented by 0.5 or 1 µg/ml of MNP iron. The efficiency of transfection in cos7 (A) was 
evaluated after 24h of incubation using luciferase reporter gene assay. Bars represent RLU calculated per 
mg of total cell protein. Viability of cells (B) was evaluated using MTT assay. The plot reflects the % of 
viable cells in total cell population. All results are representative of three independent experiments, 
whereas in each experiment eight replicates were included (n = 8). The values are shown as mean ± SEM. 
*Significant difference in transfection efficiency between pDNA/PEI complexes vs pDNA/PEI/MNP 
defined within each NP ratio (*p˂0.05). n.s. no significant difference. 
MTT assay: 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; RLU: Relative light unit. 
As a result, PEI 70x was almost 100 fold less efficient in transfection than PEI 20x, with 
and without MNPs (Figure 7 A) with cell viability remaining unaffected for both cases 
(Figure 7 B). An increase in pH of the reaction mixture from physiological 6-7 to 8-9 – in 
order to possibly influence protonation and transfection activity - did not enhance the 
efficiency of PEI 70x, whereas addition of MNPs improved transfection efficiency for 
certain complex formulations (Figure 7 C & D). However, the resulting level of protein 
expression remained significantly lower than PEI 20x. Thus, PEI 20x – with 1.35 
molecules of Biotin per 1 molecule of PEI – was preferred for further investigations 
(named “PEI” below). 
During the following transfection tests with Luc pDNA, different amounts of MNPs were 
added and the level of target protein expression was measured along with cell viability. 
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Figure 9. Transfection of cos7 with EGFP using optimized magnetic polyplexes. Transfection 
efficiency and cell viability were assessed 24h (A-C) and 48h (D-F) after delivery of EGFP-encoding 
plasmid by PEI or PEI/MNP using flow cytometry. Resulting average number of EGFP+ cells relative to the 
whole cell population was plotted (A, D) as mean ± SEM (n = 3). On the graphs illustrating cell viability 
after transfection (B & E), bars represent the ratio between the average number of viable cells and the 
whole cell population (n=3; error bars: SEM). Representative fluorescence microscopy images depict 
EGFP-expressing cos7 24h (C) and 48h (F) post-transfection. Scale bars = 10 µm. 
*Significant difference in transfection efficiency between pDNA/PEI and pDNA/PEI/MNP complexes as 
compared within different NP ratios (*p˂0.05). n.s. no significant difference. 
# Significant negative change in cell viability vs untransfected control (#p˂0.05).  
Resulting numbers were comparable to the previously published data94, thereby 
confirming the similarity of the obtained biotinylated PEI product. In particular, 
presence of MNPs significantly increased the transfection efficiency up to 100-fold for 
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the following complex compositions: NP ratio 2.5 complemented by 1, 2 & 3 µg/ml of 
MNPs and NP ratio 5 with 2 & 3 µg/ml MNPs (Figure 8 A) with cell survival remaining 
high (Figure 8B).  
At the same time, the use of Luc as a test plasmid is limited as measured relative light 
units (RLU) depend on the portion of transfected cells in the whole population as well as 
the number of protein produced per transfected cell35. We have, therefore, extended the 
biological characterisation of PEI/MNP complexes by using EGFP plasmid and flow 
cytometry analysis to estimate the correct percentage of transfected cells (Figure 9).  
The values obtained for EGFP/PEI – up to ~40% of cells were transfected – 
corresponded with values previously reported in the literature for bPEI 25kDa119. In 
general, the obtained results correlated with those of Luc transfection: the presence of 
certain amounts of MNPs significantly enhanced transfection efficiency up to ~50-55% 
24h after transfection (Figure 9 A, C). Follow–up monitoring of transfected cells at the 
time-point 48h showed that the overall transfection efficiency increased, reaching ~60-
70% of EGFP-positive cells for certain complex compositions (Figure 9 D, F). In all 
described experiments cell survival remained level with untreated cells except the 
highest MNP concentrations at 48 h post-transfection: NP 5 MNP 3 & 4, NP 10 MNP 4 
(Figure 9 B, E). 
To conclude, we observed strong evidence that the proposed strategy - including 
parameters previously published by our group94,97 and newly reported assays and 
characteristics - is sufficient to maintain a standardized production of biotinylated PEI 
and resulting PEI/MNP transfection complexes. 
3.2 SELECTION OF OPTIMAL TARGETING STRATEGY 
Human umbilical vein endothelial cells (HUVEC) are recognized as one of the most 
appropriate and commonly used cell types to study angiogenesis in vitro: human 
primary cells which are relatively easy to isolate (compared to e.g.  bone-marrow 
derived HSCs) performing all key functional assays related to angiogenesis. In addition, 
being difficult to transfect and susceptible to toxic influence, they are very well suited to 
test new therapeutic agents120–122. Therefore, the investigation for PEI/MNP magnetic 
vector was initiated using HUVEC as a model.  
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First, we defined optimal transfection conditions for both, plasmid and microRNA. Next, 
two targeting approaches were assessed in vitro: direct vector guidance and magnetic 
targeting of transfected cells. As a result, an optimal strategy was selected for further 
detailed investigation (schematically illustrated in Figure 10). 
 
 
 
 
 
 
 
Figure 10. Schematic 
representation of 
experiments carried 
out with HUVEC. 
HUVECs were 
transfected with both, 
miR and pDNA,  
First, we have carried 
out transfection 
optimization in HUVEC 
(I) with both, miR and 
pDNA. Defined optimal 
conditions were 
further used for the 
selection of optimal 
targeting strategy (II). 
The direct 
NA/PEI/MNP vector 
targeting (left panel) 
was compared to cell 
targeting after their 
magnetic engineering 
with PEI/MNP (right 
panel).  More 
promising setup from 
these – cell-based – 
was investigated in 
detail (III), including 
intercellular 
communication of 
transfected cells and 
their possibility to be 
monitored using 
magnetic resonance 
imaging. 
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3.2.1 ENDOTHELIAL CELLS CAN BE SAFELY AND EFFICIENTLY MODIFIED USING 
NA/PEI/MNP 
The identity of cells isolated from the umbilical cords was defined by the expression of 
the endothelial cell marker CD31 (platelet endothelial cell adhesion molecule, PECAM-
1)123 and an in vitro functional angiogenesis assay,  tube formation32 (Figure 11 A & B).  
Preliminary transfection optimization was carried out using polyplexes NA/PEI in order 
to define the optimal formulation for further experiments including MNP. The chosen 
setup revealed that under certain conditions extremely efficient miR uptake and 
unaffected cell survival were ensured. In particular, complexes built by 2.5 pmol/cm2 
miR and NP25 were taken up by 99% of HUVEC 24h after transfection (Figure 12A) and 
their viability did not differ from untreated cells (Figure 12B) as measured by flow 
cytometry.  
Figure 11. Characterization of HUVEC after isolation.  
Isolated HUVECs were analyzed in terms of specific surface marker CD31 (PECAM-1) expression (A). 
Representative image was obtained as a result of immunofluorescent staining (green) and nuclei staining 
with DAPI (blue). Functional activity of cells was evaluated in a standard tube-formation assay 
(differential interference contrast image (B)). 
Microscopy confirmed these observations and the fact that cell morphology remained 
normal. Several tested complex formulations led to similar results. However, when the 
total amount of added PEI was taken into account and pilot experiments with MNPs 
were conducted, the above mentioned miR/PEI composition was selected for following 
trials.  
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Figure 12. Optimization of transfection in HUVECs using tagged miR and biotinylated PEI. For miR, 
delivery efficiency (A) and cell viability (B) were evaluated 24h after transfection using Cy™3 labeled 
nucleic acid. Cells were treated with different amounts of miR (0.5, 1, 2.5 and 5 pmol/cm²) and NP ratios 
(from 2.5 to 210) and subsequently analyzed using flow cytometry. The average number of Cy3+ viable 
cells (A) or viable cells (B), relative to the whole cell population, was plotted (error bars: SEM, n=6). 
* Indicates a significantly enhanced Cy3-miR uptake as compared between marked groups. 
# Significant difference (decrease) in cell survival was determined in comparison with untreated cells 
serving as negative controls. * and # indicates p ˂ 0,05.  
Finding an optimal complex formulation for pDNA delivery turned out to be a more 
complicated issue. The highest level of transfection efficiency (~50-52%) was achieved 
Figure 13. Optimization of transfection in HUVECs using pDNA/PEI complexes. Evaluation of pDNA 
delivery with PEI was carried out 24h (A, B) and 48h (C, D) after transfection in terms of protein 
expression (A, C) and cell survival (B, D). Cells were treated with polyplexes containing various amounts 
of EGFP-encoding pDNA (0.25 or 0.5 µg/cm²) and PEI (NP from 5 to 25) and analyzed by flow cytometry. 
Bars represent the average percent of EGFP-positive viable cells (A, C) or viable cells (B, D) in the whole 
cell population (error bars: SEM, n=3).  
* Significantly enhanced expression of EGFP between indicated complex formulations. 
# Significant difference (decrease) in cell survival was determined in comparison with untreated cells 
serving as negative controls. * and # indicates p ˂ 0,05. 
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for 0.25 µg/cm2 of pDNA and NP ratio 20, 0.5 µg/cm2 of pDNA and NP 10 (Figure 13A). 
These conditions were also characterized by an acceptable decrease of cell viability by 
10% compared to untransfected cells (Figure 13B). However, when cells were treated 
with respective complex formulations and examined 48h thereafter, a dramatic decline 
in cell survival down to ~60 and ~38% was discovered (Figure 13 C&D). This result was 
not compatible with the ultimate goal of developing a vector for clinical use. Therefore, 
balanced vector compositions of 0.25 µg/cm2 NP15 and 0.5 µg/cm2 NP 7.5 were chosen, 
which were characterized by moderate efficiency (average 35 and 46% EGFP-positive 
cells, respectively), and excellent HUVEC tolerance 24 and 48h after transfection. 
The presence of magnetic nanoparticles in the vector changed the transfection pattern 
significantly (Figures 14, 15).  In case of miR delivery (Figure 14A), its uptake level 
declined by 5 to 10% at 20 & 25 µg/ml of MNPs (µg of iron per ml of prepared NA/PEI).  
Figure 14. Optimization of HUVEC transfection with miR/PEI/MNP complexes. The efficiency of miR 
uptake and cell viability after transfection were assessed using different complex compositions: 2.5 
pmol/cm² of Cy3-miR, NP ratios 15, 20 or 25 complemented with 2.5 to 25 µg/ml MNPs. Bars are 
depicting the ratio between the average number of either Cy3-positive viable (A) or viable cells (B) and 
the whole cell population (n=6; error bars: SEM).  (C) Representative image illustrates the active uptake of 
Cy3-miR (red) by every cell (treated by 2.5 pmol/cm² of Cy3-miR, NP ratio 25 with 5 µg/ml MNPs), which 
were fixed 24h after transfection with their nuclei counterstained with DAPI (blue). Scale bar = 20 µm.  
*Significant changes in the EGFP expression due to MNPs added as compared within different NP ratios 
(*p˂0.05, **p˂0.01, ***p˂0.001).  
This observation can be explained by interference of excessive MNP amounts with the 
PEI activity during transfection124,125. Since the targeting potential directly depends on 
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the magnetic component and the miR uptake was decreased only by 5 & 10% we 
decided to carry out all further targeting experiments with miR using the full range of 
tested MNP amounts: 2.5 pmol/cm2 NP ratio 25 and MNP 5, 10, 15, 20 & 25 µg/ml. 
In contrast, the amount of EGFP-expressing cells was not changing significantly as a 
result of pDNA transfection with MNP-containing vector (Figure 15A). The decrease in 
efficiency of 7 & 12% caused by nanoparticles was observed only with two formulations: 
0.5 µg/cm2 NP 7.5 MNP 3 & 4, respectively. However, in all experiments involving 0.5 
µg/cm2 pDNA and NP 7.5, the presence of MNP in delivery complexes resulted in greatly 
declined cell survival 24h and 48h after transfection (Figure 15B). At low iron 
concentrations of 0.5 µg/ml 48h after transfection, 65% of cells remained viable, while 
1-4 µg/ml iron caused substantial cell death up to 42-68%. At the same time, the 
influence of MNP on cell viability was much lower in case of 0.25 µg/cm2 NP 15 
composition: this decrease was statistically significant, but it did not exceed 10% at all 
tested iron concentrations. Due to these findings, the formulations 0.25 µg/cm2 pDNA 
NP ratio 15 with MNP 0.5, 1, 2, 3 & 4 µg/ml were selected for further studies involving 
pDNA. 
Figure 15. Optimization of HUVEC transfection with pDNA/PEI/MNP. Plasmid transfection was 
evaluated 24h and 48h after cell treatment with 0.25 or 0.5 µg/cm² of EGFP-encoding pDNA, complexed 
by PEI at NP ratios 15 or 7.5 and complemented with 0.5 to 4 µg/ml of MNP iron. As a result, the rate of 
EGFP-expressing cells within whole population (A) was measured by flow cytometry along with the rate 
of living cells (B) (values are presented as mean ± SEM, n=6).  (C) Representative fluorescence microscopy 
image (EGFP - green, nuclei stained with DAPI - blue) depicts EGFP-expressing HUVECs 24-h post-
transfection (0.25 µg/cm² of pEGFP, NP ratio 15 and 1 µg/ml MNPs). Scale bar = 50 µm. 
*Significant changes in the EGFP between EGFP/PEI/MNP vs EGFP/PEI  within different NP ratios 
(*p˂0.05, **p˂0.01, ***p˂0.001). 
# Significantly decreased cell viability vs untreated cells (#p˂0.05, ##p˂0.01, ###p˂0.001). 
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It can be assumed that the difference in cell behavior after miR or pDNA transfection 
with PEI/MNP complexes is based on the total amount of PEI contained within the 
complex. For all cases plotted in Figures 12-15, the necessary amount of PEI for miR 
delivery was significantly lower than was required for pDNA delivery. Therefore, the 
toxicity of miR/PEI was substantially lower at baseline. Thus, for targeted delivery 
considerably higher amounts of iron (2.5-25 µg/ml) could be added to miR/PEI without 
causing cell damage, whereas only relatively low MNP concentrations of 0.5-4 µg/ml 
were tolerated by cells in case of pDNA/PEI transfection. At the same time, these iron 
levels of 15-25 µg/ml started to influence the delivery efficiency due to their excess 
versus PEI.  
3.2.2 MAGNETIC TARGETING OF PEI/MNP VECTOR IS LIMITED 
Next, the direct vector targeting approach was tested for selected optimal transfection 
conditions. The main purpose behind guided and localized delivery of therapeutics is to 
avoid off-target effects and reduce the dosage. Therefore, we carried out testing of 
possible transfection localization in parallel with attempts to gradually reduce the 
necessary amount of transfection complexes down to 50% from initial values (Figures 
16 & 17).  
For pDNA/PEI/MNP targeting evaluation, at first the most promising formulations were 
defined by LSM (0.25 µg/cm2 pDNA NP 15 combined with MNP2). For this complex 
composition, after transfection with pDNA and magnet application the EGFP expression 
was localized to a certain degree, which increased at lower EGFP/PEI/MNP dosages of 
50-80 % (Figure 16).  At the same time, the lower the complex dosage was, the lower 
dropped the levels of transfection efficiency. For the dosages of 80 & 90% this shift was 
not very dramatic and the amount of EGFP-positive cells remained at 26-27% (Figure 16 
B & C). Notable, these values are comparable with the results obtained during the 
transfection optimization steps by flow cytometry, which was employed to validate the 
cell counting from microscope images (Figure 16 C). With lower amounts of complexes 
added, the transfection efficiency reached 18, 16 & 9% minimums for 70, 60 and 50% 
dosages, respectively. 
Similarly, in case of guided Cy3-miR uptake, at the lowest dosage (50% from initial) a 
substantial amount of cells was Cy3-positive in the off-magnet area (Figure 17 A-C), 
except for at high MNP concentrations, where transfection efficiency was insufficient 
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(below 30%) even above the magnet (Figure 17D). No difference in fluorescence 
intensity of transfected cells was observed over the magnet and without the magnet 
(Figure 17E). 
Figure 16. Magnetic guidance of DNA/PEI/MNP transfection in HUVEC. Pre-selected complex 
formulation (0.25 µg/cm² of EGFP-pDNA, NP ratio 15 & 2 µg/ml of MNP) was applied on HUVEC in 
different dosages from original: from 50 to 100%. Immediately after transfection the magnet was 
applied locally under the culture well and cells were incubated in this manner for 24h. Obtained samples 
were fixed, stained with DAPI and analyzed for possible magnetic guidance of EGFP expression due to 
PEI/MNP vector targeting. Representative images illustrate obtained results (A): EGFP channel is green, 
DAPI – blue. Scale bar = 200 µm. Presented plots were created out of such images: they depict calculated 
ratio between the area with and without magnet application in terms of Nr of EGFP+ cells (B) and 
transfection efficiency (C). Values are presented as mean ± SEM (n=3). Results, previously obtained by 
flow cytometry and indicated as “FACS 100%” on the plot, were used to validate the counting method 
applied to define transfection efficiency.  
*Significant difference between areas with and without magnet are defined for every dosage by comparing 
respective values pairwise (**p˂0.01, ***p˂0.001). 
These findings indicate that direct vector targeting was significant, but never complete 
and a certain number of off-target transfected cells was always observed. Acceptable 
targeting selectivity can be achieved for the pDNA/PEI/MNP vector only by reducing the 
dosage dramatically and, therefore, compromising transfection efficiency. 
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Figure 17. Magnetic guidance of miR/PEI/MNP uptake by HUVEC. Localized by a magnetic force 
uptake of Cy3-labelled miR was examined 24h post-transfection by confocal laser scanning microscopy. 
Representative images (A-C) were obtained for cells treated with 50% of the original complex amount 
(2.5 pmol/cm² Cy3-miR, NP ratio 25 & 5 µg/ml of MNP). Different acquisition and processing settings 
were applied in cases A & B vs C: in the latter, the laser power was 5 times higher and resulting z-stacks 
were compressed to detect significantly weaker Cy3 signal in the cytoplasm. Scale bars: 20 µm. To 
compare the areas with and without a magnet, cell from these regions were selectively collected and 
analyzed separately using flow cytometry in terms of uptake efficiency (D) and mean fluorescence 
intensity of Cy3+ cells (E). Bars represent the rate of Cy3+ cells in the total cell population (D) and 
fluorescence intensities of these cells (E) in the areas over and without a magnet (n=4, error bars: SEM). 
* Significantly higher level of Cy3-positive cells mag+ versus mag- as defined for each complex formulation 
after pairwise comparison (**p˂0.01, ***p˂0.001). 
3.2.3 MAGNETICALLY ENGINEERED CELLS REPRESENT AN OPTIMAL TARGETING 
APPROACH 
Another targeting opportunity offered by PEI/MNP vector is the generation of 
magnetically responsive NA-modified cells as tools for their subsequent targeting, which 
we investigated further.  
For this purpose, HUVEC were treated with various complex formulations defined 
previously as optimal (5 pmol/cm2 miR NP ratio 25 complemented by 2.5-25 µg/ml of 
MNP or 0.25 µg/cm2 pDNA NP ratio 15 combined with 0.5-4 2.5 µg/ml MNP), incubated 
for 24h, collected and seeded again with the magnet attached locally under the culture 
well-plate. Resulting cell growth in the areas with and without applied magnet was 
recorded and is illustrated by Figure 18. Magnetically guided cell migration was 
observed for both, miR- (Figure 18A) and pDNA- (Figure 18B) modified cells, except for 
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Figure 18. Magnetic targeting of NA/PEI/MNP-HUVECs in static conditions. Representative images of 
cell targeting (A, B) depict the growth of HUVECs, which were collected 24h after transfection, seeded 
with the magnet applied locally under the well-plate and analyzed 24h thereafter. NA/PEI/MNP 
formulations used for transfection were the following: 2.5 pmol/cm² miR, NP 25 & 25 µg/ml MNP (A) and 
2.5 µg/cm² pDNA NP 15 & 4 µg/ml MNP (B). Scale bars: 100 µm. Quantitative analysis of targeting for 
transfected cells was also carried out 24h after their treatment with various magnetopolyplex 
compositions: 2.5 pmol/cm² miR, NP 25 with 5 - 25 µg/ml MNP and 2.5 µg/cm² pDNA NP 15 with 1- 4 
µg/ml MNP. To separate transfected cells into magnetically positive (mag+) and negative (mag-) fractions, 
MACS columns were applied. Subsequently, cells numbers in both fractions were recorded (C, E) and their 
viability was assessed via Trypan blue exclusion assay (D, F). Bars represent either percentage of 
magnetically-responsive cells or rate of living cells in the whole cell population, respectively (n=3; error 
bars: SEM).  
* Significant differences in the amount of magnetically responsive cells for different MNP concentrations 
(*p˂0.05, **p˂0.01, ***p˂0.001). 
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the low iron concentrations of 2.5 µg/ml of MNP used for miR delivery and 0.5, 1 & 2 
µg/ml applied for plasmid.  
To quantify the amount of magnetically responsive (mag+) and non-responsive (mag-) 
cells, these fractions were separated using MACS© columns. Moreover, this allowed to 
carry out independent analyses of mag+ and mag- cell fractions and to identify a 
possible toxic influence of static magnetic field on MNP-loaded cells. Subsequent cell 
counting revealed that on average 70-83% of miR/PEI/MNP-modified cells were 
responding to the magnetic field (Figure 18C). In case of pDNA transfection, similarly 
high values of 66-71% mag+ cells were achieved only with the highest iron 
concentrations of 3 & 4 µg/ml. With all other MNP amounts in pDNA/PEI/MNP, the 
number of cells remaining in the column varied from 11 to 55% (Figure 18E). 
Viability evaluation using Trypan blue exclusion assay of both, mag+ and mag- fractions, 
showed no significant cell death (Figure 18D & F), except for the magnetically non-
responsive miR-modified cells.  Interestingly, their survival was 10 to 20% lower as 
compared to untreated control (Figure 18D), whereas the survival of magnetically 
responsive cells did not differ from untransfected HUVECs. This observation 
corresponds with the previously published observation that MNP can improve vector 
safety94. 
Next, a more challenging set-up was used for cell targeting evaluation – simulation of 
dynamic conditions in vitro. Here, miR-modified cells were examined as containing 
higher amounts of iron vs pDNA. For this purpose, HUVEC treated with 2.5 pmol/cm2 
miR NP 25 with MNP 5 & 25 µg/ml were collected 24h after transfection and transferred 
into the wells of a well-plate attached to a shaker rotating at 150 RPM.  
After 12h, the guidance of these cells by a magnet placed locally on the side of each well 
was studied. As illustrated in Figure 19, the majority of magnetically modified HUVEC 
were growing in the area of magnet application and the lowest cell density was recorded 
in the non-magnetic area. At the same time, a conspicuous difference between static and 
dynamic set-up was observed: in the latter case, liquid flow was concentrating some 
cells in the middle of the well. However, their amount was still significantly lower than 
near the magnet, thereby confirming that even active movement of the liquid is not 
interfering with efficient cell targeting. 
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Figure 19. Magnetic targeting of HUVEC modified with miR in simulated dynamic conditions in 
vitro. Cells were transfected with optimized complex formulations (2.5 pmol/cm² of Cy3-tagged miR, NP 
25 complemented with MNPs 5 (A) & 25 (B)), collected after 24h of incubation, seeded in the wells of a 
plate attached to a rotating shaker, whereas on the sides of wells a magnet was applied locally. Resulting 
cell growth was recorded on PFA fixed and stained with DAPI cells 12h thereafter. Scale bars: 50 µm.  
3.2.4 DEFINING IRON LOADING OF CELLS SUFFICIENT FOR THEIR MAGNETIC 
GUIDANCE 
Further, in order to identify the amount of MNP loading of cells sufficient for their 
magnetic targeting, magnetic particle spectroscopy measurements were carried out. 
These revealed that 0.16 pg of iron per cell is enough for massive migration of cells to 
the area of local magnet application (Table 2). This required level of MNPs in cells was 
reached when the following compositions of transfection complexes were used: 0.25 
µg/cm2 pDNA NP 15 with MNP 3 & 4 µg/ml and 2.5 pmol/cm2 miR NP 25 with MNP 5, 
15, & 25 µg/ml. For all formulations which did not ensure efficient cell guidance the 
intracellular iron concentration was below the detection limit.  
To summarize, the detailed investigation of both targeting approaches – direct vector 
guidance and magnetic modification of cells for their further targeting – clearly 
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demonstrated substantial advantages of the latter. Therefore, the further investigation 
was focused on magnetic cell engineering. 
Table 2. Intracellular iron content of transfected cells measured by MPS. 
The MPS examination of transfected cells was carried out by F. Wiekhorst131. 
3.3 DETAILED EXAMINATION OF MAGNETICALLY ENGINEERED ENDOTHELIAL 
CELLS 
3.3.1 TIME DEPENDENT ANALYSIS OF MAGNETICALLY RESPONSIVE AND NON-
RESPONSIVE TRANSFECTED HUVEC 
In this study, the vector NA/PEI/MNP is proposed for magnetic cell engineering prior to 
transplantation. Therefore, monitoring of cell characteristics is of great importance, 
including their behavior after the exposure to a strong magnetic field.  
The examination of transfected HUVECs was carried out after the separation of mag+ 
and mag- fractions with a MACS column (Figures 20 & 21). In particular, cells were 
analyzed by flow cytometry either immediately after magnetic separation (0h) or after 
culturing them for 24h, which was equal to 24, 48 and 96 hours after transfection, 
respectively. 
The viability assessment showed that cell survival remained very high during the entire 
time of observation, up to 96h after transfection. For both, miR and pDNA, it did not 
differ significantly from untransfected controls, independently of the iron concentration 
(Figure 20D & F; 21B, D & F). The only notable exception was observed directly after 
Delivered NA, 
NA/PEI composition 
MNP content in NA/PEI/MNP, 
µg/ml of NA/PEI 
Intracellular iron, pg/cell 
(Mean ± SEM, n=3) 
 
 
miR, 
2.5 pmol/cm2 NP ratio 25 
0 0.02 ± 0.002 
2.5 0.11 ± 0.033 
5 0.37 ± 0.079 
15 0.62 ± 0.204 
25 0.7 ± 0.150 
 
 
pDNA, 
0.25 µg/cm2 NP ratio 15 
 
0 
 
0.05 ± 0.023 
0.5 0.03 ± 0.009 
1 0.03 ± 0.012 
2 0.05 ± 0.026 
3 0.16 ± 0.038 
4 0.34 ± 0.147 
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isolation during the analysis of magnetically non-responsive cells transfected with 
miR/PEI/MNP (Figure 21B). Their survival was significantly decreased as reported 
above. 
Figure 20. Long-term characterization of magnetically responsive and non-responsive 
miR/PEI/MNP-HUVEC. HUVEC were transfected at optimal conditions with Cy3-miR/PEI/MNP (2.5 
pmol/cm² of miR, NP ratio 25 & 5-25 µg/ml of MNP), incubated for 24h and collected. In order to 
differentiate between magnetically-responsive (mag+) and non-responsive (mag-) cells within total 
volume of transfected HUVEC, they were applied on MACS separation columns. Resulting mag+ and mag- 
fractions were split in 3 parts: for immediate analysis with flow cytometry (A, B) or for seeding and 
further analysis, after 24h (C, D) or 48h (E, F) in culture. Both, amount of Cy3-positive cells (A, C, E) and 
viability (B, D, F) were assessed and are presented on the plots as ratio between the average amount of 
viable Cy3-positive cells (A, C, E) or viable cells (B, D, F) and total cell number (n=3; error bars: SEM).  
* Significant increase in the amount of Cy3-positive cells in mag+ vs mag- defined for each complex 
formulation (*p˂0.05, **p˂0.01, ***p˂0.001).  
# Statistically significant decrease in cell viability compared to untransfected cells (#p˂0.05, ##p˂0.01, 
###p˂0.001).  
The overall amount of Cy3-positive cells in the magnetically-responsive fraction 
declined over time with all iron concentrations used to form miR/PEI/MNP complexes 
(Figure 20A, C & E). For the MNP amount of 5 µg/ml, the Cy3-HUVEC number remained 
constant at first, after 24h of incubation (98%), but was decreased nearly by half at 72h 
time-point (96h after transfection). With growing concentration of iron, the tendency 
became more pronounced. The following decrease in the amount of Cy3-positive cells 
was observed for 10 & 15 µg/ml of MNP: from 98 and 90% in the beginning through 
88% and 82% 24h after separation down to 35% and 32% after 72h in culture. The 
amount of Cy3-positive cells at 20 & 25 MNP declined in the same manner, ie in the first 
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probe, in average, 60% of HUVEC were positive for Cy3, 40% of them were detected 24h 
after and only 10% - 72h after. 
Figure 21. Long-term characterization of magnetically responsive and non-responsive 
pDNA/PEI/MNP-HUVEC. Magnetically responsive (mag+) and non-responsive (mag-) transfected 
HUVECs were analyzed independently. For this purpose, they were transfected (2.5 µg/cm² of EGFP-
encoding pDNA, NP ratio 15 & 0.5-4 µg/ml of MNP) 3-miR/PEI/MNP (optimal 2.5 pmol/cm² of miR, NP 
ratio 25 & 5-25 µg/ml of MNP), incubated for 24h, collected and separated using MACS columns. Obtained 
mag+ and mag- fractions were analyzed by flow cytometry for viability and amount of Cy3-positive cells at 
3 time-points: directly after separation (A, B) or after 24h (C, D) and 72 (E, F) hours in culture. Bars 
represent the ratio between the average amount of viable EGFP-positive cells (A, C, E) or viable cells (B, D, 
F) and total cell number (n=3; error bars: SEM).  
*Significantly higher eGFP expression in mag+ vs mag- as defined within each complex formulation 
(*p˂0.05, **p˂0.01). 
# Statistically significant decrease in cell viability as compared to untreated HUVECs (#p˂0.05, ##p˂0.01). 
Cells treated with miR/PEI/MNP and collected in the negative fraction behaved similarly 
in terms of gradual decrease. The only difference was observed in the total numbers of 
Cy3-positive cells: they were significantly higher for magnetically-responsive cells 
compared to non-responsive cells of respective complex formulations directly after 
separation and 24h after culturing.  
The same tendency was observed during the analysis of cells transfected using 
pDNA/PEI/MNP (Figure 21A, C & E). Numbers of EGFP-positive HUVEC collected in the 
positive fraction slowly declined from 21-32% as measured immediately after isolation 
to 13-21% after 24h of incubation and down to 8-13% after 72h in culture. At all iron 
concentrations, the amount of EGFP expressing cells in the positive fraction was 
RESULTS 
 
 
57 
 
significantly higher (versus respective complex formulations in negative fraction) on 
average when recorded right after cell separation. 
Transfection with miR/PEI complexes was used as a control and resulted in a very slow 
decrease of Cy3-positive cell amount over time. Even 72h after isolation (96h after 
transfection) its rate remained at an average level of 80%. Interestingly, the level of 
EGFP expressing cells obtained as a result of pDNA/PEI transfection was declining in the 
same manner as for HUVEC modified with pDNA/PEI/MNP-containing complexes. This 
observation can be explained by the differences in these complex formulations, ie by the 
higher amount of iron added in case of miR vs pDNA and its influence on PEI 
intracellular processing.  
 
Notably, in case of pDNA delivery, safe magnetic loading of cells with iron was limited to 
a certain degree because of the higher overall amounts of PEI required for efficient 
transfection compared to miR. Due to this fact and several others, which are described in 
detail in the Discussion section, further investigation focused on miR modification of 
cells. 
3.3.2 ANTI-MIR DELIVERY WITH PEI/MNP RESULTS IN EFFICIENT KNOCKDOWN OF 
ENDOGENOUS MIR 
Previously, efficient and safe intracellular delivery of tagged Cy3-miR was demonstrated 
and intense Cy3 signal was detected in the cytoplasm (3.2.1). However, this does not 
necessarily correlate with subsequent intracellular miR release and its adequate 
functional activity, especially when endosomal escape is considered as one of the major 
barriers for non-viral miR delivery126. Moreover, even if transfection complexes are 
released from endosomes, miR can be overly tightly condensed by PEI/MNP, which 
might prevent its intracellular processing.  
In order to prove proper miR functioning after its delivery with PEI/MNP, functional 
studies were carried out based on an anti-miR directed against miR-92a which is 
expressed in HUVEC32. As a result of qRT-PCR measurement, the efficient silencing of 
miR-92a was recorded (Figure 22A). Further investigation of target gene expression 
(integrin subunit α5, ITGA5 – directly suppressed by miR-92a32) revealed that it was 
significantly upregulated as a result of efficient miR-92a knockdown (Figure 22B). 
Interestingly, whereas miR-92a expression was reduced to negligible levels, ITGA5 gene 
expression was enhanced only to a certain degree (1.5-fold). This observation can be 
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explained by the fact that gene expression is most often regulated by several miR 
simultaneously. 
Figure 22. Functionality of delivered by PEI/MNP anti-miR in HUVECs. Proper processing and 
functioning of delivered miR was assessed by qRT-PCR 48h after transfection. Anti-miR targeted against 
HUVEC’s endogenous miR-92a was delivered with PEI/MNP (2.5 pmol/cm² of miR, NP ratio 25, 5 & 25 
µg/ml of MNP). Resulting silencing was observed in terms of miR-92a suppression (A) and enhanced 
expression of its target gene (B): ITGA5 is known to be downregulated by miR-92a. 
Bars represent relative expression either of miR-92a (A) or ITGA5 (B), normalized to RNU6B or 18s 
expression, respectively (n=3, error bars: SEM). 
* Significant up-regulation of gene expression as compared to untreated HUVECs (*p˂0.05) 
# Significantly decreased expression of miR-92a vs untreated cells (###p˂0.001). 
The PCR analysis of transfected cells was carried out by Dr. C. Rimmbach131. 
3.3.3 CELLS TRANSFECTED WITH MIR/PEI/MNP MAINTAIN THEIR KEY FUNCTIONAL 
PROPERTIES 
Furthermore, extended studies of vector safety were carried out since PEI toxicity 
remains its main limitation. In particular, the functional capacities of miR/PEI/MNP-
modified cells were examined in terms of proliferation and tube formation, which are 
commonly used for HUVEC characterization32. Both assays have confirmed the negative 
influence of PEI alone, which decreased the functionality of cells dramatically: ~20-50% 
decrease in tube formation parameters (Figure 23A, B) and 60% lower proliferation rate 
compared to untreated cells (Figure 23C, D). Notably, the presence of MNPs in the vector 
restored tube formation by HUVECs and improved their proliferative capacity. 
However, in the latter case all complex formulations decreased the proliferation to a 
certain extent vs untransfected cells (~35%). 
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Figure 23. Functional capacities of miR/PEI/MNP-modified HUVECs. 
(A) Standard for endothelial cells functional assay – tube formation – was performed to evaluate safety of 
transfection using 2.5 pmol/cm² of scrambled miR, NP ratio 25, 5 & 25 µg/ml of MNPs. Modified cells were 
collected 48h post-transfection, seeded on Matrigel and incubated for 18h before evaluation.  Bars depict 
the ratio between transfected HUVEC and untreated control in % for several parameters: tube length, 
number of branches and junctions (n=3, error bars: SEM). (B) Representative images of tubes for different 
complex formulations were taken using confocal microscope in differential interference contrast. Scale 
bar = 100 nm. (C) Another key functional parameter, proliferative capacity, is presented as the ratio 
between proliferating cells in transfected samples vs untreated HUVECs (n=3, error bars: SEM). (D) To 
obtain representative images, cells were transfected as described above and stained for EdU, whereas 
nuclei were counterstained with DAPI (blue). Scale bar = 200 nm. 
* Significantly improved functional capacity of transfected HUVEC in miR/PEI/MNP vs miR/PEI (*p˂0.05). 
 
3.3.4 VECTOR INTERNALIZATION STUDIES 
Endocytosis is a fundamental determinant for the efficiency of non-viral vectors and the 
activity of the delivered cargo. Therefore, understanding of the uptake route and 
improved control over it are of crucial importance for every new vehicle which is 
introduced as a therapeutic agent. Many reports have been published on cellular entry 
and subcellular trafficking of PEI98,99. However, MNP presence in the vector might 
change its pattern dramatically100. Moreover, it could shed light on how MNPs decrease 
PEI toxicity since endosomal escape (i.e. disruption) is one of the key points in PEI-
mediated transfection and its toxicity14,127. Therefore, the investigation of PEI/MNP 
uptake mechanism was carried out. 
Using Dynasore – an inhibitor of Dynamin and, hence, of clathrin-based and caveolar 
endocytosis98 – the predominant way of vector internalization was defined as active 
uptake. By application of low dosages of Dynasore111, it was possible to avoid its toxic 
influence and to discriminate the difference between PEI and PEI/MNP (MNP 5 & 25 
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µg/ml): the activity of Dynasore in the suppression of uptake was stronger with higher 
amounts of iron in the vector composition (Figure 24B).  
In order to understand the underlying mechanisms, the colocalization between 
transfection complexes and endocytosis-related organelles was examined, i.e. between 
labelled PEI of transfection complexes and immunofluorescently stained early 
endosomes (EEA1 marker), lysosomes (LAMP1) or endoplasmic reticulum (Calnexin). 
Different time-points – 30 min, 1h and 4h – during the uptake were investigated for 
different complex formulations (2.5 pmol/cm2 miR NP 25 with MNP 5 & 25 µg/ml). In 
general, iron-containing complexes were taken up slower than miR/PEI. In addition, 
after 30 min and 1h the overall amount of vesicles for PEI/MNP vector was lower than 
that for PEI only. Massive colocalization of delivery vector with early endosomes was 
detected 30 min after transfection (Figure 24C), which later significantly decreased and 
4h after transfection only single events of colocalization could be recorded. At the same 
time, the most pronounced overlap between PEI and LAMP1 signal was observed at 1h 
and 4h time-points. On the contrary, no significant colocalization was observed with the 
endoplasmic reticulum. Taken together, the obtained data suggest that subcellular 
vector processing involves mainly acidifying pathways.   
Next, a protocol for 3-color fluorescent labelling of miR/PEI/MNP complexes previously 
developed in our group94 was employed and applied for superresolution imaging. The 
tagging procedure does not affect transfection efficiency or viability and allows to study 
the intracellular vector distribution. In case of transfected HUVECs, transfection vector 
and delivered cargo formed round structures of 50-500 nm in diameter (rarely up to 1 
µm) located in the cytoplasm (Figure 24A). The signal of PEI in these structures was 
colocalized either with the signal of MNP or with both, miR and MNP. Interestingly, the 
miR signal was colocalized with the other two only in X-Y dimension, whereas in Z they 
were laying apart. This can be explained by the fact that lateral SIM resolution is 
significantly higher than axial. 
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Figure 24. Vector internalization and intracellular localization. (A) Intracellular localization of 3-
color labelled transfection complexes was studied 24h after transfection using structured illumination 
microscopy. Nuclei were counterstained with DAPI. Scale bars: 5µm. (B) Activity of endocytosis inhibitor 
Dynasore was studied using flow cytometry. Dynasore pre-treated cells were transfected with Cy3-miR 
using PEI or PEI/MNP (2.5 pmol/cm² of miR, NP ratio 25, 5 & 25 µg/ml of MNP). The resulting uptake of 
miR was measured 4h after transfection and respective efficiency of Dynasore (%) in blocking endocytosis 
was calculated (n=4; error bars: SEM). (C) Representative images illustrate the colocalization of 
transfection complexes, miR/PEI/MNP, with early endosomes (EEA1, magenta) or lysosomes (LAMP1, 
red) at different time-points during the internalization and intracellular processing. To obtain them cells 
were fixed, stained using appropriate antibodies and DAPI and visualized using confocal miscoscopy. Scale 
bar = 5µm. 
* Significantly higher inhibiting activity of Dynasore in miR/PEI/MNP treated cells compared to miR/PEI 
transfection (***p˂0.001). 
The experimental work on organelle staining and subsequent image acquisition during co-localization 
studies was shared with Dr. H. Lemcke131. 
3.3.5 IMPACT OF TRANSFECTION ON GJIC 
NA of interest used for cell modification can be applied to improve the properties of 
transplanted cells or to influence cells in the injured organ. In the latter case, modified 
cells can serve as carrier, i.e. for miR, and bring them to the site of interest. Therefore, it 
is important to evaluate if normal intercellular communication pathways and molecular 
transfer mechanics are affected by the proposed transfection vector.  
Several mechanisms have been described to mediate the intercellular exchange of miR, 
including exosomes or GJs (reviewed in 128). The gap-junctional pathway was selected as 
GJs connect the cytoplasm of two adjacent cells, allowing for a more directed/targeted 
shuttling of miR molecules. Moreover, speed and efficiency of miR transfer are increased 
due to the lack of dilution effects caused by the intercellular space. In order to evaluate 
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GJ-intercellular communication (GJIC), FRAP technique was used since it allows for non-
invasive dynamic monitoring of cells with high temporal resolution112, whereby the 
applied 3D-setup is superior to 2D as it is more sensitive for subtle alterations of 
fluorescence intensity. 
 
Figure 25. Intercellular communication of miR/PEI/MNP-HUVEC via gap-junctions. Transfected with 
miR/PEI (A) or miR/PEI/MNP (B) HUVECs (2.5 pmol/cm² of miR, NP ratio 25 combined with 5 (A) & 25 
(B) µg/ml of MNP) were loaded with gap-junction permeable fluorescent dye (orange). Selected cells were 
bleached and recovery of their fluorescence was measured. Representative images reflect the recovery 
process (A, B) Scale bars: 20 µm. Quantitative measurements were also carried out (C) using untreated 
HUVECs and HeLa cells as controls. The extent of gap-junctional communication expressed in % of initial 
fluorescence is reflected in plotted values (n≥50 cells, error bars: SEM). 
 
In order to exclude unspecific dye transfer and exosomal molecular exchange, the FRAP 
data for HeLA cells (which do not establish GJs113) was collected. As expected, the 
amplitude of the recovery was negligible compared to that of HUVECs (Figure 25C). In 
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addition, chosen setup of the FRAP experiment, with its short recording time of 15 
minutes, allowed to include mainly fast ways of molecular exchange like GJIC, whereas 
slower exosomal transfer was not accounted129. Together these factors mean that when 
using 3D-FRAP to study molecular exchange in endothelial cells, mainly GJIC was 
assessed. As a result, in magnetically modified HUVEC the intercellular transfer of the GJ-
permeable dye calcein was recorded: the fluorescence was partly recovered in the 
bleached cells already after 15 minutes (Figure 25). Yet, the efficiency of recovery was 
slightly lower for transfected cells, with both, miR/PEI and miR/PEI/MNP, compared to 
untreated. 
This indicates that modified cells maintain their machinery to exchange molecules 
including miR. Therefore, they do have a significant potential to serve as miR vehicles in 
addition to their intrinsic therapeutic properties. 
3.3.6 DETECTION LIMITS OF MRI VISUALIZATION FOR MIR/PEI/MNP-MODIFIED 
CELLS 
Further, another possible PEI/MNP benefit was explored, offered by the presence of a 
magnetic component – non-invasive MRI tracking. For this purpose, in vitro agarose 
phantoms mimicking susceptibiity of murine tissues130 were prepared with different 
numbers of magnetically modified cells embedded inside (Figure 26A).   
First, preliminary tests were carried out with the highest cell number of 5,5 x 105, 
transfected with complexes containing 25 µg/ml of iron 24h prior to phantom 
preparation. These cells were clearly visible with MRI (Figure 26B). Notably, hypo-
intensities were detected in the samples which contained untreated cells or miR/PEI- 
modified cells and no MNPs. These negative controls, therefore, were used to set a 
baseline and exclude possible false-positive results. Relying on this, MRI detection limits 
were defined using various amounts of cells modified with different miR/PEI/MNP 
formulations: 2.5 pmol/cm2 miR NP 25 with MNP 5, 15 & 25 µg/ml (Figure 26B). As few 
as 10 000 cells could be visualized when their iron loading exceeds 0.37 pg iron/cell 
(Table 2). This is achieved by transfection with 2.5 pmol/cm2 miR NP 25 complemented 
by at least MNP 5 µg/ml. 
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Figure 26. Detection limits of 
miR/PEI/MNP-modified HUVEC in 
magnetic resonance imaging.  
(A) Agarose gel phantoms were prepared 
for in vitro MRI experiments with different 
numbers of transfected cells (2.5 pmol/cm² 
of miR, NP ratio 25 complemented by 5, 15 
& 25 µg/ml of MNP). (B) Representative 
images illustrate obtained results for 
various iron concentrations and cell 
numbers. 
The MR imaging and data acquisition of 
agarose phantoms was performed by Dr. J.-
P. Kühn131. 
 
 
 
 
 
To conclude, PEI/MNP vector is highly suitable – in terms of safety and efficiency – for 
the delivery of plasmid DNA as well as microRNA into human endothelial cells. 
Importantly, the possibility of MNP to reduce the cytotoxicity caused by the cationic 
polymer was shown. Moreover, an optimal targeting strategy for PEI/MNP was defined – 
production of magnetic miR-engineered cells which are suitable for further targeting or 
retention at the site of interest. The possibility of these cells to be efficiently guided 
magnetically and visualized non-invasively with MRI has been proven in vitro.  
3.4 APPLICATION OF THE DEVELOPED ENGINEERING APPROACH FOR A 
PRODUCTION OF MODIFIED HEMATOPOIETIC STEM CELLS 
Further, the developed strategy was transferred to a cell type with even higher 
therapeutic potential, namely, CD133+ hematopoietic stem cells. 
3.4.1 CD133+ CELLS WELL TOLERATE TRANSFECTION WITH MIR/PEI/MNP 
RESULTING IN EFFICIENT MIR UPTAKE 
The purity of cells isolated from bone marrow was defined using their specific surface 
marker expression measured by flow cytometry (Figure 5). This value varied between 
patients, however, for all experiments only samples with a purity of ≥80% CD133+ cells 
were used. In addition, functional hematopoietic capacities of these cells was analyzed in 
a standard CFU assay. 
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Transfection optimization was carried out similarly to HUVECs (3.2.1). First, different 
compositions of miR/PEI were tested (10; 20; 30 and 40 pmol of tagged Cy3-miR per 
5x104 cells combined with PEI at NP ratios 2.5, 5 or 7.5) in order to select the most 
appropriate ones for testing of MNP. 
Figure 27. Optimization of transfection in CD133+ cells using miR/PEI polyplexes. CD133+ cells were 
transfected with different amounts of Cy3-miR (10; 20; 30; and 40 pmol). These were combined with PEI 
at different NP ratios: 2.5, 5 & 7.5. Uptake efficiency of miR (A) and cytotoxicity (B) were evaluated by 
flow cytometry 18 h post-transfection. Bars represent the % of either viable Cy3+ (A) or dead (B) cells in 
total CD133+ population (mean ± SEM; n = 4). 
(A) * Significantly increased miR uptake vs lowest miR concentration 10pmol. (B) * Statistically significant 
decrease of cell viability vs untransfected control. (*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001) 
The experimental data presented in this figure was obtained as a result of equally shared contribution of 
N. Voronina, P. Müller & F. Hausburg132. 
In CD133+, starting from 20 pmol of miR high uptake rates could be reached, which 
varied from 70 to 95% depending on NP ratio and miR amount (Figure 27A). In 
particular, the higher NP ratio and miR amount was, the more efficiently complexes 
were taken up. However, a significant decrease in cell viability was observed for all 
transfected samples: on average 40% of cells were dead at all NP combinations with 10 
& 20 pmol; 45-55% at 30 pmol; 60-80% at 40 pmol (Figure 27B). At the same time, 
untreated cells also showed significantly decreased survival rate (down to ~80%) after 
18h in culture, whereas directly after isolation this value was 95%.  
Taking this into account, the actual toxicity of transfection complexes with 10 and 20 
pmol of miR did not exceed 20%, which can be considered acceptable to carry out 
further investigations. Therefore, complexes built by 20 pmol miR and PEI at NP ratios 
2.5, 5 and 7.5 were selected for the following tests with MNPs. 
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Figure 28. Optimization of transfection in CD133+ cells using miR/PEI/MNP magnetopolyplexes. 
CD133+ cells were transfected at pre-optimized conditions – 20 pmol of miR with NP ratios 2.5, 5 & 7.5 – 
complemented by different amount of iron (0, 1, 2, 3, 4 & 5 µg/ml MNP). Uptake efficiency (A) and cell 
viability (B) were assessed by flow cytometry 18 h after transfection. Bars depict the % of viable Cy3+ 
cells (A) or dead cells (B) in total CD133+ cells. Values are presented as mean ± SEM (n = 4). During the 
extended analysis of cell viability (C), CD133+ cells from more patients were transfected with pre-selected 
optimal complex formulations (20 pmol miR with NP ratio 7.5 and 0, 3 or 5 µg/ml MNPs). Untreated 
freshly isolated cells and untreated cells after 18h in culture were used for comparison. The plot depicts 
the % of viable cells in whole cell population are presented as mean ± SEM; n = 3. 
* Significantly changed miR uptake (A) or cell viability (B) compared to either uptake at 20 pmol miR NP 
2.5 & respective MNP (A) or untreated control (B). (*p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001) 
The experimental data presented in this figure was obtained as a result of equally shared contribution of 
N. Voronina, P. Müller & F. Hausburg132. 
Different amounts of iron were included in transfection complexes: 1, 2, 3, 4, and 5 µg 
MNPs per ml of ready miR/PEI. As a result, no significant difference was observed in the 
Cy3-miR uptake between PEI and PEI/MNP within certain NP ratio (Figure 28A). The 
amount of Cy3-positive cells varied from ~40 to 80 % and this value was increasing with 
higher NP ratio and miR amount. (Fig. 28B). Notably, observed result differs from the 
data obtained for HUVECs, where presence of MNPs decreased the efficiency of miR 
uptake (Figure 14A).  
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The amount of dead cells ranged between ~25 – 35% for all applied complex 
compositions and similar numbers were obtained for the untreated control (Figure 
28B). Based on these data, complexes composed by 20 pmol miR NP ratio 7.5 
complemented by 3 and 5 µg/ml MNPs were selected for further tests with respect to 
their high uptake rates and acceptable cytotoxicity vs untreated cells.   
Since the experiments on transfection optimization had shown a variability in cell 
survival from patient to patient, cell viability was examined for several more patients. 
The obtained average value differed from that in the transfection optimization setup, but 
the tendency was similar: no significant difference in viability was recorded between 
untreated and transfected cells (20 pmol miR, N/P 7.5 and 0, 3 and 5 µg/ml MNPs). 
Notably, a significant decrease in CD133+ viability in the untransfected control was 
observed during culture: from ~95% viability directly after isolation down to 77% after 
18 h in culture (Figure 28C). Such cell death most likely resulted from suboptimal 
content of culture medium – serum-supplemented DMEM – selected for the 
establishment of transfection system. Thus, obviously, the transfection setup optimal for 
targeting does not affect CD133+ cell survival itself, whereas culture conditions decrease 
cell viability.  
Next, the intracellular localization of transfection complexes (including delivered miR) 
was confirmed, z-stack imaging of transfected cells was performed using laser scanning 
confocal microscopy. Representative images (Figure 29A) of CD133+ transfected with 
20 pmol Cy3-miR NP 7.5 & MNP 3 correlate with flow cytometry data in terms of high 
uptake rates and illustrate the intracellular localization of the Cy3 signal. Moreover, the 
intracellular localization of transfection complexes was studied in greater details using a 
previously described technique for 3-colour labelling of miR/PEI/MNP94. It was adapted 
here for suspension cells and used for confocal and superresolution imaging of prepared 
cells. As a result, both, miR/PEI and miR/PEI/MNP complexes, were mainly detected in 
the cytoplasm. The signal of polyethyleneimine was always colocalized with MNP and 
miR and formed complexes were located in the perinuclear region (Figure 29B). Formed 
structures of 100-400 nm in size were located in a different focal plane than the nucleus, 
as a recording of z-stacks demonstrated. 
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Figure 29. Intracellular localization of transfection complexes in CD133+ cells. (A) CD133+ cells 
were transfected with Cy3-labeled miR (20 pmol) using different NP ratios (2.5, 5 and 7.5) and MNP 
amounts (0, 1, 2, 3, 4 and 5 µg/ml). Representative images illustrating intracellular localization of Cy3 
signal were taken 18 h post-transfection using laser scanning confocal microscopy. (B) The detailed 
localization of miR, PEI and MNP in cells was defined using structured illumination microscopy. 
Representative images were obtained 18h after transfection with 3-color labelled complexes (Cy5-miR 
(red), Atto488-PEI (green) and Atto565-MNPs (yellow)) at optimal conditions: 20 pmol miR, NP ratio 7.5, 
3 µg/ml MNPs. Nuclei were counterstained with DAPI (blue). Scale bar = 5 µm. 
The experimental data presented in this figure was obtained as a result of equally shared contribution of 
N. Voronina, P. Müller & F. Hausburg132. 
3.4.2 MAGNETICALLY MODIFIED CD133+ ARE EFFICIENTLY GUIDED IN VITRO 
Next, the targeting potential of magnetically modified cells was investigated under static 
conditions in vitro. For this purpose, transfected cells (18h) were transferred into wells 
with a magnet applied locally under the plate and incubated for 24h (illustrated by 
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 Figure 30A). Similar numbers of untransfected cells were detected in both areas, with 
and without magnet (Figure 30B). This confirms that magnetic MACS CD133 MicroBeads 
used for isolation are not sufficient for targeting of cells. On the contrary, cells 
magnetically modified with miR/PEI/MNP (20 pmol miR, NP 5 and 7.5 combined with 
MNP 3 and 5 µg/ml) were efficiently targeted.  
Figure 30. Magnetic targeting of miR/PEI/MNP-CD133+ cells in static conditions.  
Representative images of magnetically guided cell migration (A) were taken for CD133+ cells modified in 
pre-selected conditions: 20 pmol Cy3-miR, NP ratios 5 and 7.5 complemented by MNPs 3 & 5 µg/ml. For 
this purpose, cells collected 18h post-transfection were seeded with the magnet applied locally under the 
well-plate and analyzed 24h thereafter with laser scanning confocal microscopy. Scale bars = 100 µm. In 
addition, cell numbers in the areas with and without magnet application were counted (C) and correlated 
magnetic targeting ratios were calculated (B). Values are presented as mean ± SEM (n = 3).  
* Significant magnetic targeting as compare to untransfected cells (*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001).  
The experimental data presented in this figure was obtained as a result of equally shared contribution of 
N. Voronina, P. Müller & F. Hausburg132. 
In particular, in untransfected samples the ratio between magnetically guided and non-
guided cells was 1 ± 0.12 (Mean ± SEM). For transfected cells this value varied: 1.6 ± 
0.09; 1.9 ± 0.02; 2.6 ± 0.17 and 2.2 ± 0.08 for complexes formed at NP 5 with MNP 3 & 5 
µg/ml and for complexes with NP 7.5 with 3 & 5 µg/ml MNPs, respectively (Figure 30C). 
These numbers - ~70% of modified cells are targeted – obtained for CD133+ cells (20 
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pmol miR, NP ratio 7.5 and 3 or 5 µg/ml MNP) are corresponding to the targeting 
efficiency demonstrated for HUVECs.  
Next, for this optimal targeting complex formulation the amount of intracellular iron in 
CD133+ was defined by MPS. It reached 0.155 ± 0.0419 pg iron per cell, which also 
corresponded with data obtained for HUVECs. 
Importantly, in case of CD133+ where magnetic MicroBeads were used for cell isolation, 
the MPS technique allowed to distinguish between these MicroBeads and internalized 
MNPs to avoid false positive signals. This discrimination was possible due to the fact that 
miR/PEI/MNP-cells were characterized by A5/A3 values in the range 20.5 ± 3.1 %, 
whereas A5/A3 values in the range 27 to 30 % were attributed exclusively to CD133 
MicroBeads used for cell isolation. 
3.4.3 TRANSFECTION WITH MIR/PEI/MNP HAS NO NEGATIVE INFLUENCE ON 
CD133+ SURFACE MARKER EXPRESSION AND DIFFERENTIATION 
Since the proposed transfection method is intended for cell modification prior to their 
transplantation, maintenance of intrinsic therapeutic cell properties is crucial. 
Therefore, the retention of specific surface markers and maintenance of hematopoietic 
differentiation potential by CD133+ was evaluated using flow cytometry.  
As a result, 18h after cell transfection at conditions optimal for targeting (20 pmol miR, 
NP 7.5 complemented by 0, 3, and 5 µg/ml MNPs), no significant changes in the 
expression of surface markers were observed (Figure 31A). In particular, for CD133+ it 
remained 89-92% for all vector compositions vs 87% for untreated cells. Interestingly, 
CD133+ expression did not change over time: as the examination of the untreated cells 
showed, it was 93% at 0h and remained at 87% after 18h. Thus, in case of CD133+ 
culturing for 18h negatively influenced only cell survival (3.4.1), but not stem cell 
marker expression. 
Furthermore, the multipotency of miR/PEI/MNP-modified CD133+ cells was examined 
in terms of hematopoietic differentiation capacity by application of CFU assays.  No 
significant difference between transfected (20 pmol NP 7.5 and MNP 0, 3, or 5 µl/ml) 
and untreated cells was observed in the numbers of formed CFU-granulocyte, erythroid, 
macrophage, megakaryocyte (CFU-GEMM), CFU-granulocyte, macrophage (CFU-GM), 
burst-forming unit-erythroid (BFU-E), and CFU-erythroid (CFU-E) (Figure 31B & C). In 
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addition, no morphological abnormalities were detected during visual examination of 
the CFUs. 
 
Figure 31. Surface marker pattern and differentiation capacity of CD133+ after transfection. The 
safety of transfection in terms of cell functional activity was defined by surface marker expression and 
hematopoietic differentiation potential. Optimized miR/PEI  (20 pmol miR, NP ratio 7.5) and 
miR/PEI/MNP (20 pmol miR, NP ratio 7.5; 3 and 5 µg/ml MNPs) were applied during transfection with 
following 18h of incubation. (A) Surface marker expression was examined by flow cytometry; untreated 
CD133+ cells were used for comparison. Values are presented as mean ± SEM (n = 3). (B) Hematopoietic 
differentiation potential of transfected cells was assessed in colony-forming unit (CFU) assay (14d 
incubation). Resulting numbers of CFU-erythroid (CFU-E), Burst-forming unit-erythroid (BFU-E), CFU-
granulocyte, erythroid, macrophage, megakaryocyte (CFU-GEMM) and CFU-granulocyte, macrophage 
(CFU-GM) were counted and compared to respective numbers obtained for untreated cells. (C) 
Representative images reflect the appearance of the colonies. Values are presented as mean ± SEM (n=3). 
n.s. no significant difference.  
The experimental data presented in this figure was obtained as a result of equally shared contribution of 
N. Voronina, P. Müller & F. Hausburg132. 
3.4.4 PEI/MNP VECTOR IS EFFICIENT IN SUPPORTIVE CYTOKINE-SUPPLEMENTED 
MEDIUM OPTIMAL FOR CD133+ CELLS 
The establishment of transfection and targeting was carried out in DMEM culture 
medium, simple and easily controlled. In this case, 18 h of incubation were sufficient for 
miR/PEI/MNP delivery but cell viability was strongly affected (~25 % dead cells). In 
order to improve culture conditions, StemSpanTM supplemented with StemSpan CC100 
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was tested as highly suitable for hematopoietic stem cells. This medium is more complex 
in terms of its molecular content, however, this factor did not prevent efficient 
transfection with PEI and PEI/MNP. In particular, after the transfection with 20 pmol 
miR, NP 7.5 combined with 3 and 5 µg/ml MNPs uptake efficiencies in StemSpan were of 
87 ± 2 % and 82 ± 5 %, respectively, whereas in DMEM corresponding values were 79 ± 
9% and 80 ± 8 % (Figures 32A, 28A).  
Figure 32: miR uptake, cell viability and surface marker expression of transfected CD133+ in 
supportive cytokine-supplemented culture medium. Formulations optimized for transfection and 
targeting (20 pmol miR; NP ratio 7.5; 0, 3 and 5 µg/ml MNPs) were added to CD133+ cells cultured in 
StemSpanTM H3000 supplemented with StemSpanTM CC100. Cy3-miR uptake efficiency (A) and cell 
viability (B) were measured 18- and 24h post-transfection by flow cytometry, along with the expression 
of CD45, CD34 and CD133+ (C). Untransfected cells (freshly isolated and cultured) were used for 
comparison. Values are presented as mean ± SEM; n = 2. 
The experimental data presented in this figure was obtained as a result of equally shared contribution of 
N. Voronina, P. Müller & F. Hausburg132. 
Importantly, in StemSpanTM transfected and untransfected CD133+ cells retained their 
viability after 18 and 24 h in culture: cell survival did not differ from freshly isolated 
cells (Figure 32B). In addition, no changes in stem cell surface marker expression were 
observed after an incubation of 18 h and 24 h vs 0h (Figure 32C). 
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These results clearly demonstrate that efficient transfection of CD133+ cells with 
PEI/MNP can be performed under optimized cell culture conditions with no resulting 
negative influence on cell survival and surface marker expression. 
 
To conclude, for CD133+ hematopoietic stem cells, the key findings demonstrated for 
endothelial cells were confirmed in terms of vector efficiency, safety and targeting 
potential of modified cells. 
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3.5 SUMMARY 
First, this work provides evidence that a vector previously designed in our group based 
on PEI/MNP is suitable for such susceptible and difficult to transfect cells types as 
endothelial cells and hematopoietic stem cells.  
In endothelial cells, the uptake of non-functional tagged miR of ~98% was achieved, the 
delivery of functional anti-miR was followed by almost complete silencing of respective 
target miR and pDNA transfection resulted in ~40-55% of gene expression. At these 
optimal transfection conditions cell viability and functionality remained unaffected. 
Importantly, MNPs were demonstrated to dramatically reduce the known toxicity of PEI. 
In this study, no mechanistic influence of MNPs on the transfection process which could 
lead to this positive impact was observed. 
In CD133+ hematopoietic stem cells, 80% of miR uptake level was reached with cell 
survival unaffected and intrinsic differentiation potential fully maintained. Notably, cell 
culture conditions required optimization even for such a short time of post-transfection 
incubation as 18h. 
 
Next, magnetic cell engineering for their further guidance was proven to be a superior 
targeting approach for a PEI/MNP vector compared to direct vector targeting. In 
particular, direct guidance of NA/PEI/MNP on cells was restricted – presumably by PEI 
action during transfection. This is possibly explaining why previous in vivo studies of our 
group had limited success. In contrast, over 70% of miR-modified cells, both HUVECs 
and CD133+, responded to the influence of a static magnetic field. For HUVECs, this was 
additionally confirmed in dynamic conditions simulated in vitro. Modified cells were 
proven to maintain their intrinsic functional properties. Moreover, the capability of 
miR/PEI/MNP-modified cells to realize GJ-associated intercellular communication was 
proven for HUVECs. 
 
Furthermore, for miRNA/PEI/MNP-modified cells loaded with 0.37 pg iron/cell, the MRI 
detection limit is not less than 104 cells as experiments on HUVECs demonstrated.
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4 DISCUSSION 
To date, conventional surgical and pharmaceutical treatment of CVDs is limited and they 
remain a major cause of mortality worldwide (1.1.2). In order to solve this problem, 
alternative therapeutic strategies are being actively developed, whereby cell therapy, 
gene therapy and their combination are the most promising approaches (1.1.3). Genetic 
cell engineering is a complex answer to currently existing drawbacks in both fields. 
There are various methods that enable delivery of genetic material, however, the 
development of adequate vectors for its delivery of genetic material remains one of the 
major engineering challenges. 
In our group, a non-viral PEI/MNP vector was designed as a potential tool for gene 
therapy of CVD, either by direct vector application or by vector-assisted genetic 
engineering of cell therapeutics. In addition to the delivery of genetic material, the 
proposed NA/PEI/MNP construct has a considerable potential for magnetic guidance 
and non-invasive MRI monitoring post-application due to its superparamagnetic 
nanoparticle based part (MNP)86,95,133. 
First, these potential benefits were examined in endothelial cells – HUVECs (parts 4.1-
4.3). These cells were selected as a test model since they are relatively easy to isolate 
and represent a well described, widely accepted in vitro model of angiogenesis32, which 
is in turn one of the key targets in CVD treatment16,44. Extensive optimization of 
transfection conditions, selection of the most appropriate magnetic targeting strategy 
and its detailed characterization were performed in vitro (4.1-4.3). Further, the 
optimized concept and protocols were translated into a more clinically relevant cell type 
– bone-marrow derived CD133+ hematopoietic stem cells134–138 (4.4). 
4.1 PEI/MNP EFFICIENTLY DELIVERS FUNCTIONAL MIR AND DNA TO 
ENDOTHELIAL CELLS AND ENSURES THEIR LOADING WITH IRON 
Transfection optimization experiments have demonstrated that a PEI/MNP vector can 
be applied for the efficient delivery of both, miR and pDNA, into HUVEC (3.2.1, Figures 
12-15). HUVECs are known as cells difficult to transfect and susceptible for toxic 
influence.  In particular, the levels of EGFP expression resulting from pDNA delivery are 
reported to range from 12-20 to 33-50% on average 120–122,139. Thus, protein expression 
levels of ~35-46% obtained safely with EGFP/PEI/MNP are among the highest reported 
in the literature. The level of Cy3-miR uptake over 95% reached in HUVECs using 
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PEI/MNP is typically obtained by PEI-based delivery vectors and Lipofectamine™ 
(commonly used cationic lipid-based transfection reagent)140.  
Interestingly, the selected optimal concentrations of plasmid and miR – 0.25 µg/cm2 and 
2.5pmol/cm2, respectively (Figures 12, 13) – differ dramatically from those previously 
reported for PEI/MNP. In particular, 1-3  µg/cm2 for pDNA94 and 5pmol/ cm2 for miR97 
were defined as optimal in earlier work of our group for hMSCs and obtained in the 
course of this study for cos7 fibroblasts. At the same time, the here defined optimal NP 
ratios (25 for miR and 7.5-15 for pDNA) correspond with previously published numbers 
of NP 20-40 for miR and 10-20 for DNA97,141. This observation illustrates the known fact 
about the dependence of transfection efficiency and toxicity on the respective cell 
type142. 
Importantly, such low required amounts of miR resulted in overall low amounts of PEI 
necessary for its delivery. Therefore, the baseline toxicity of miR/PEI was low before 
adding MNPs, which allowed avoiding synergistic toxicity between PEI and MNPs using 
high iron oxide loading. In particular, up to 25 µg/ml MNPs could be introduced without 
affecting cell survival (Figure 14), whereas previously in our group MNP concentrations 
up to maximum 6 µg/ml were applied94,97. The situation was different for pDNA: PEI 
amounts required for efficient gene expression were on average much higher, which is 
easily explained by the size and charge density of DNA molecule vs miR141. In this case, 
the amounts of iron oxide nanoparticles introduced without cell damage did not exceed 
4 µg/ml (Figure 15).  
Interestingly, the increase in the amount of iron in NA/PEI/MNP – potentially beneficial 
for targeting and MRI detection – was negatively influencing transfection efficiency (~5-
10% of miR uptake and ~7-12% of EGFP expression; Figures 14A, 15A). This can be 
explained by the extensively demonstrated fact that the presence of free PEI is necessary 
for efficient transfection when using complex delivery vectors on its basis125,143. 
Moreover, the importance of the polymer end-group structure has been proven124. 
These are required for efficient NA condensation, internalization of transfection 
complexes and, for pDNA, its delivery to the nucleus125. In case of high iron 
concentrations in PEI/MNP, excessive nanoparticles could bind all PEI diminishing  its 
activity125. 
In this project, this hypothesis was confirmed directly by tests with the same amount of 
miR and lower amounts of PEI, at NP ratios 15 & 20. The resulting decrease of miR 
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uptake was more intensive with a higher iron to PEI ratio and the amount of Cy3-
positive HUVEC gradually declined to averages of 90, 70, 60 and 25% (Figure 14A). 
Indirectly, it was supported by the examination of uptake mechanism of miR/PEI and 
miR/PEI/MNP with endocytosis inhibitors and colocalization studies with endosomes at 
different time points post-transfection (3.3.4). In particular, the internalization of the 
delivery vector was slower in case of MNP-containing complexes and the number of 
formed vesicles was lower, too. In addition, the low dosages of endocytosis inhibitor 
Dynasore were much more efficient in preventing miR/PEI/MNP uptake compared to 
miR/PEI (Figure 24B). This observation is easily explained when the decreased uptake 
efficiency of particle-containing complexes is taken into account. 
 
The highly efficient uptake of Cy3-tagged non-functional miR applied during 
optimization, does not necessarily guarantee proper miR processing and function144.  In 
case of PEI, with its tight electrostatic condensation of NA, the release from endosomes 
and further biological processing is a critical step in delivery (1.4.2). Previous 
investigation of miR/PEI/MNP by our group demonstrated that once the transfection is 
optimized with Cy3-miR – these conditions are successful with functional miR97. In 
addition, the intracellular localization of tagged miR in HUVECs has been proven by z-
stacks of confocal LSM (Figure 14C). However, in this project, the resulting functional 
capacity of delivered miR was tested, too. In particular, a functional miR endogenously 
expressed in HUVEC – miR-92a32 – was selected and anti-miR against it was delivered 
using PEI and PEI/MNP. As a result, almost complete knock-down of target miR-92a 
(Figure 22A) proved the efficient release of the anti-miR from transfection complexes. 
Moreover, while the highest tested MNP amounts negatively influenced the Cy3-miR 
cellular uptake, the transfection efficiency of delivered anti-92a did not differ from PEI 
only. Interestingly, the examined effect of anti-92a on its target gene ITGA5 was very 
pronounced, yet limited to a certain degree (Figure 22B). This might be explained by 
multiple miR involved in the regulation of the same gene simultaneously21. In addition, 
in the reported setup HUVECs were treated in normal conditions, whereas a disease can 
alter gene expression patterns significantly and miR activity can change dramatically, 
too21. 
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To summarize, during the optimization a transfection setup suitable for HUVECs was 
selected: it allowed to retain cell viability unaffected up to 48 h, while pDNA and miR 
were successfully delivered and simultaneous cell loading with iron was achieved. 
4.2 SELECTION OF OPTIMAL TARGETING APPROACH – MIR/PEI/MNP-
MODIFIED CELLS 
4.2.1 MAGNETICALLY ENGINEERED CELLS REPRESENT A SUPERIOR TARGETING 
APPROACH COMPARED TO DIRECT PEI/MNP TARGETING  
When successful, localized delivery of therapeutics will ensure target organ selectivity, 
maximal avoidance of off-target activity and, as a result, reduction of their dosage. This 
has a great potential in solving such problems of gene therapeutics as insufficient 
accumulation at the site of interest and off-target toxicity (1.2.2, 1.2.4). This is 
particularly important for the delivery to highly perfused organs like heart. 
The observed outcome of the direct NA/PEI/MNP magnetic guidance on seeded cells 
clearly demonstrated that targeting was notable, but never complete (3.2.2; Figures 16, 
17). When the applied dosages of transfection complexes were reduced by half (in % 
from initial amount used in transfection optimization), the rate of vector targeting was 
higher. However, it was accompanied by inefficient transfection, below 30% of uptake 
for Cy3-miR and 9-18% of eGFP-positive cells for pDNA. Here, the necessity of free PEI 
for efficient transfection (4.1.)100,125 explains the limitations of PEI/MNP vector magnetic 
targeting, which was also observed in a previous in vivo proof-of principle study of our 
group96. In particular, free PEI ensuring efficient transfection is not controlled by a 
magnetic field and can bring NA to off-target cells. Therefore, acceptable targeting 
conditions can be obtained by application of suboptimal transfection conditions and 
thereby compromising the efficiency. Another negative factor which must be taken into 
account in the direct vector targeting approach is a lack of control over the amount of 
iron loaded into cells. 
 
Magnetic engineering of cell therapeutics for their further magnetically controlled 
guidance is another targeting approach, which was investigated (3.2.3). Successful 
application of this strategy would allow to overcome such difficulties of cell therapy as 
low retention and poor engraftment in the injured area (1.3.2)49–51 by providing 
magnetically guided cell products for transplantation. Moreover, simultaneous 
DISCUSSION 
 
 
79 
 
introduction of genetic material could promote cell properties and thus increase 
functional benefits (1.3.3)62. 
For both, with miR and pDNA, ~0.11-0.16 pg of iron loading per cell was sufficient to 
obtain magnetic responsiveness and cell guidance in vitro (3.2.4, Figure 18, Table 2). 
This iron content was achieved and exceeded with MNP amounts of 3-25 µg/ml without 
affecting cell viability. Notably, in case of magnetic cell engineering, the necessity of free 
PEI does not put limitations on targeting as the magnetic field is applied after successful 
transfection. Moreover, magnetically responsive cells can be sorted: MACS separation, 
applied in the current study, has not compromised the viability of NA/PEI/MNP-cells 
(Figures 17, 19, 20). Interestingly, in case of miR/PEI/MNP modification magnetically 
sorted cells were more viable than non-responsive cells. This can be explained by lower 
toxicity of PEI/MNP transfection complexes compared to PEI alone (magnetically non-
responsive), which corresponds with previously obtained data for hMSCs94. 
 
To summarize, for PEI/MNP vector, the option with magnetic cell engineering is 
preferable compared to direct vector targeting. 
4.2.2 MIR DELIVERY USING PEI/MNP IS BENEFICIAL AND OPTIMAL VS DNA 
In this study, safe and efficient delivery of pDNA and miR to endothelial cells has been 
achieved with PEI/MNP. However, the maximally achievable iron loading of cells under 
conditions free from cytotoxic effects – beneficial for magnetic targeting and further MRI 
detection – was significantly higher using miR. In addition, miR-based therapeutics 
possess significant benefits per se compared to DNA (reviewed in 145). In particular, 
plasmid DNA transfection requires its delivery to the nucleus by overcoming the nuclear 
membrane, limiting thereby its wide application in non-proliferating cell types145. 
Moreover, low transfection efficiencies are restricting pDNA application for stem and 
precursor cells in a clinical setup: cell modification is usually performed directly prior 
transplantation and sorting of positive cells may compromise the procedure146. In 
addition, use of pDNA-based therapeutics is associated with the risk of insertional 
mutagenesis, including abnormal cell functioning and latent oncogenesis146. 
Furthermore, since miR recognition involves only partial complementarity, a single miR 
can influence expression of multiple targets147. Thus, properly selected miR for delivery 
can regulate complex disease-associated networks of gene expression28,148,149. 
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As a result, further investigation was focused on the miR/PEI/MNP-modified cells. 
 
Long-term observation of miR/PEI/MNP-transfected cells (3.3.1; Figure 20A, C & E) has 
demonstrated that the level of Cy3-positive cells was dramatically reduced by the end of 
the observation period (96 h). This fact characterizes the proposed system as 
predictable and controlled. Regulation of such events as angiogenesis in CVDs requires 
transient genetic modification. However, the protein expression and miR presence might 
not last long enough to ensure a time-frame sufficient for therapeutic angiogenesis, 
which is usually described as several weeks150,151. Although vector safety clearly 
supports the possibility of repeated administration, the selected cell-based strategy does 
not. Thus, for future pre-clinical studies the application of therapeutic miR aimed to 
improve the properties of transplanted cells should be considered, rather than focusing 
on pro-angiogenic miRs or genes. In particular, survival and engraftment of transplanted 
cells (e.g. miR-133a, miR-126, miR-34a, combination of 3 miRNAs, namely miR-21, miR-
24, and miR-221) or their homing to target sites (miR-150, miR-146, miR-15a/16)152,153 
could be modified. As a recent report on the clinical trial CELLWAVE indicated, an 
increase in cell homing to the target area (in this case caused by shock wave) can 
enhance the outcome of cell therapy154. Moreover, the functionality of transplanted cells 
can be improved, e.g. by application of protective miR-214 or by enhancing their 
differentiation (e.g. miR-1, miR-499)153. This approach is supported by the C-CURE 
clinical trial, where priming of hMSCs was performed in order to obtain cardiopoietic 
lineage-specified cells155. This study did not involve genetic engineering of these cells, 
however it has proven the safety of such a modification and its feasibility, which resulted 
in initiation of similar trials CHART-1 and CHART-24. Moreover, attempts could be made 
to correct the negative effect of aging on the regenerative capacity of transplanted cells, 
which was demonstrated in several recent trials41,47,48 (e.g. miR-10a*, miR-21153, and 
miR-34a28). In addition, internalized miRs could be employed to influence endogenous 
cells in the injured tissues156 (1.2.3). 
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4.3 DETAILED CHARACTERIZATION OF MIR/PEI/MNP-MODIFIED CELLS 
4.3.1 MNP PRESENCE RESTORE FUNCTIONAL CAPACITY OF HUVEC INITIALLY 
COMPROMISED BY PEI 
Polyethyleneimine (PEI) and its derivatives are commonly used for virus-free delivery of 
nucleic acids (NA) due to their high efficiency and flexibility for modifications71,157. In 
addition, PEI is often incorporated into different types of hybrid nanoparticles as a NA 
binding and endosome escape agent147. To date, PEI has been included in clinical trials 
testing local gene therapy of various cancers (phases 1 and 2) and multiple successful 
multi-purpose in vivo trials have been published71,157. Nevertheless, safety concerns 
keep the PEI-based vectors from being widely integrated in clinical trials and 
practice71,147,157. Therefore, multiple approaches have been proposed to reduce its 
toxicity which are mainly intending either to increase biocompatibility or to exclude 
possible off-target effects by specific guidance71,100,157,158. 
Previously, the decrease of PEI toxicity by the MNPs (in terms of cell survival) was 
reported by our group for hMSCs94. In HUVECs, this positive influence has not been 
observed in such viability assays as Trypan blue exclusion or LIVE/DEAD® staining with 
following flow cytometry (Figures 14, 15, 18). The only exception was the higher 
viability of miR/PEI/MNP-modified Mag+ cells versus Mag- cells shown 24h after 
transfection and directly after their magnetic separation (Figure 18D). This can be 
explained by the fact that during the optimization step only such compositions of 
NA/PEI and NA/PEI/MNP were pre-selected which did not affect cell viability (3.2.1).  
In order to address possible PEI toxicity and MNP influence in greater detail, functional 
studies have been carried out. Tube formation and proliferation are among the most 
commonly accepted and illustrative assays used to study HUVECs in vitro32. While 
extremely high toxicity of miR/PEI was observed in both tests (~60% proliferation 
inhibition and ~20-50% decrease in tube formation parameters vs untreated), the 
presence of MNPs improved the vector properties dramatically (3.3.3; Figure 22). In 
particular, in the presence of iron, the tube formation capacity of cells was fully restored 
and proliferation activity was improved (up to ~35% proliferation inhibition).  
The mechanism of this improvement is unclear. It has been previously hypothesized by 
our group94 and others125 that MNPs prevent PEI from aggressive interaction with 
nuclear DNA, which has been reported as one of the cytotoxic mechanisms127,147. This 
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hypothesis was partially confirmed by laser confocal125 and structured illumination 
microscopy (SIM) imaging94. In particular, the lower degree of PEI co-localization with 
nucleus was demonstrated in the presence of MNPs compared to PEI only. However, 
even SIM superresolution technique does not allow to detect single molecules of PEI, 
which might be still detectable in the nucleus by other methods159.  
In this study, another mechanism was investigated – possible influence of MNPs on 
endocytosis since endosomal/lysosomal disruption is a proposed point in PEI toxicity, 
too127. As studies of vector colocalization with early endosomes, lysosomes and 
endoplasmic reticulum have demonstrated, PEI/MNP vector follows the same acidifying 
pathway within cells as PEI does and there is no shift to transport via endoplasmic 
reticulum (avoiding lysosomes) (3.3.4). 
Notably, in the particular case of HUVECs the significant improvement of tube formation 
might occur due to transient production of ROS which is a known property of iron oxide 
nanoparticles160. A strong correlation exists between the levels of ROS and angiogenic 
growth factors161. Moreover, simultaneous increase in ROS, VEGF and FGF has been 
reported for endothelial progenitor cells as a result of their loading with 
superparamagnetic iron oxide nanoparticles162. Similar processes could occur in 
HUVECs163 after transfection with PEI/MNPs influencing thereby functional activity of 
cells. 
 
The majority of MNP-associated toxicity is dose-dependent and related to ROS formation 
and cytoskeleton 160. Specific investigation of these two possible side-effects was not 
conducted, however, indirect evidence strongly suggests the safety of applied amounts 
of MNPs. First, the production of ROS-related to iron oxide particles is transient and 
peaks 24 h post-treatment – a suitable time point to study possible resulting toxicity 
(apoptosis) is 72 h160,164. During this study, the HUVECs survival was monitored up to 96 
h and no decrease in cell viability was observed. Second, the toxic cytoskeletal damage in 
HUVECs results in their inability to form tubes165. Here, the functional activity of MNP-
treated HUVECs on the Matrigel® was very active and did not differ from untreated cells 
(Figure 23A & B). 
 
To conclude, it is remarkable that decrease of PEI toxicity, one of the biggest concerns on 
its way to clinical trials, was achieved by the introduction of low levels of iron oxide, 
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biocompatible and routinely used as a contrast reagent in human subjects160,166. 
Moreover, in the current project, no MNP-related toxicity has been observed within the 
range of selected optimal conditions. 
4.3.2 APPLICATION OF STATIC MAGNETIC FIELD IS SAFE FOR MIR/PEI/MNP-
MODIFIED CELLS 
Characterization of MNPs magnetic properties has demonstrated that the average size of 
a single iron oxide core within nanoparticles is 4.3(3) nm and this data corresponded 
with TEM images (Figure 6). Thus, MNPs have demonstrated typical superparamagnetic 
behaviour, beneficial for biomedical purposes: such small core size results in no 
remnant magnetization remaining in the absence of an external magnetic field, whereas 
the magnetic susceptibility for such materials is comparable to that of ferromagnetic 
bulk material133,160. At the same time, superparamagnetic nanoparticles are magnetized 
in the presence of static magnetic field (SMF). Therefore, it is reasonable to examine the 
behavior and cytotoxicity of MNP-containing agent in combination with SMF since its 
application is implied and can possibly cause additional unidentified adverse effects167. 
The recent work of Bae et al. has demonstrated that SMF (field strength 0.4 T for 1 h) 
can enhance the acute toxicity of MNPs (liver-selective MRI contrast agent) in 
hepatocytes due to resulting formation of bigger aggregates167. At the same time, Shaw 
et al. demonstrated that damaging effect of combination of SMF and iron oxide 
nanoparticles on DNA integrity and membrane potential can be reversible and cell-type 
dependent168. In particular, cancer cells were much more susceptible to genotoxicity 
than “normal” peripheral blood mononuclear cells. This was attributed by the authors to 
certain flexibility of “normal” cells in terms of depolarization168. To date, very few 
studies have been carried on the topic160.  
Thus, in the current study, the properties of magnetically-modified cells (transfected 
without a magnetic field influence) were studied after the application of SMF in the 
magnetic cell separation columns MACS© (field strength 0.4-1T, gradient up to 104 
T/m)107. This allowed quantifying the amount of magnetically-responsive cells, to 
characterize them separately from magnetically non-responsive cells and to define the 
influence of strong SMF on MNP-loaded cells (3.3.1; Figures 18D & F; 20B, D & F; 21B, D 
& F). The examination of NA/PEI/MNP-HUVECs` properties up to 72 h after magnetic 
separation (96 h post-transfection) demonstrated no negative influence on cell viability 
of either magnetic field itself (untransfected cells control) or its combination with MNPs. 
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Importantly, the reported toxicity of SMF in previous works was dose dependent167 and 
in case of miR/PEI/MNP with highest obtained intracellular MNP loading, no toxicity 
was observed.  Moreover, during the targeting of modified cells (Figures 18, 19) a 
magnet was applied for at least 12 h. Even after such lasting exposure to a strong SMF 
(1.3 T), no adverse effects on cell survival or morphology were observed. 
 
The obtained results indicate that intracellular iron loading achieved with 
miR/PEI/MNP is safe even in the presence of a SMF. 
4.3.3 TARGETING PERSPECTIVES OF MIR/PEI/MNP-CELLS IN VIVO 
The proposed in vitro approach with magnetic targeting of transfected cells is clearly 
sophisticated in terms of successful future in vivo application. To date, multiple studies 
have reported successful in vivo magnetic guidance of magnetized stem and progenitor 
cells for the purposes of regenerative medicine162,169–174, including CVD 
treatment169,170,173,175. In those studies, where iron oxide nanoparticles were 
internalized and the amount of iron loading was identified, it varied between ~4 and 30 
pg/cell162,169–171. These numbers significantly exceed the values ~0.16-0.7 pg/cell, which 
were sufficient for in vitro targeting of NA/PEI/MNP-HUVECs in static conditions.  
Such low iron amounts are beneficial in terms of safety and functional capacity of 
modified cells. For example, a commonly known mechanism of iron oxide nanoparticle-
associated toxicity – production of reactive oxygen species (ROS) – is known to be 
directly associated with the amount of internalized nanoparticles160. In addition, several 
studies have demonstrated that high intracellular levels of iron oxide nanoparticles can 
lead to dose-dependent cytoskeletal disorganization and damage165,176.  
However, too low MNP loading might be not sufficient for magnetic targeting in a 
turbulent environment with blood flow. In order to come closer to the challenging in 
vivo situation, dynamic conditions were simulated in vitro (3.2.3) by placing culture 
plates with targetable miR/PEI/MNP-HUVECs suspension on the rotating shaker114. 
While this experiment clearly cannot cover all the interactions within a living organism, 
it leads to better understanding of targeting potential and in vivo usability of PEI/MNP-
modified cells. As a result, the highly efficient cell targeting was demonstrated and even 
active shaking of the culture medium did not interfere with cell movement towards the 
magnet (Figure 19). 
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Notably, the majority of mentioned in vivo studies169,171 (including the most successful 
ones with significant magnetic cell targeting followed by beneficial therapeutic 
effect170,173,174,177,178) practiced cell retention strategy after local administration over the 
cell guidance after i.v. injection. In one study, where successful cell targeting and 
positive therapeutic outcome were achieved after i.v. administration, magnetic and 
antibody-based targeting were combined179. At the same time, in the clinical trials of 
gene therapy for CVD – which is an ultimate aim for PEI/MNP – local injections are well 
established and the most preferred type of intervention4,16. Taken together, the above 
mentioned factors indicate that PEI/MNP-modified cells will be well suited for magnet 
based retention at the site of injection in vivo. 
4.3.4 MODIFIED CELLS MAINTAIN GJIC CRITICAL IN CELL ENGINEERING 
The therapeutic effects of SKMs transplanted to patients with CVD were seriously 
compromised by their arrhythmogenic potential. This was mainly accounted to SKM’s 
lack of Cx43 leading to inability of GJ-mediated intercellular communication and 
resulting inability of electromechanical integration after transplantation1,38,180. 
Moreover, some studies have shown that transplantation of cells overexpressing of Cx43 
significantly decreases the risk of ventricular arrhythmias after MI180.  
Furthermore, modified cell therapeutics can serve as a vehicle for therapeutic miR and 
bring it to the injured tissues – having thereby gene regulatory effects in the recipient 
cells27. In this case, their capacity to exchange miR with surrounding tissues defines 
their success as a carrier. Therefore, it is of great importance to investigate the influence 
of delivery vectors to intercellular communication capacities of modified cells. 
In case of miR/PEI/MNP-modified HUVECs, cells were capable to establish GJ, although 
in a slightly decreased rate as compared with untreated HUVECs (3.3.5; Figure 25). This 
indicates that potentially, when modified cells are transplanted, they can maintain 
intercellular communication, miR transfer and integration. 
4.3.5 MIR/PEI/MNP-TRANSFECTED CELLS CAN BE SUFFICIENTLY VISUALIZED USING 
MRI 
In case of magnetic nanoparticle-based vectors, therapy can be associated with 
imaging81,133.  
To date, 2 major non-invasive visualization strategies are proposed for iron oxide-
containing vectors: MRI and tracking and a novel sensitive imaging modality magnetic 
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particle imaging (MPI)81,95. HUVECs transfected with miR/PEI/MNP were tested in vitro 
for their potential in non-invasive monitoring by MRI. As a result, 104 cells with iron 
loading 0.37 pg/cell (embedded in in vitro agarose phantoms) were detectable using 7.1 
Tesla animal MRI system. This result corresponds with detection limits reported by 
other groups for such levels of intracellular iron181. Detected cell numbers are not 
among the lowest described: from single-cells to hundreds were visualized using various 
MRI configurations90,182,183. However, in these cases the intracellular iron amounts were 
also incomparably higher, 5-60 pg/cell. Such loading is often applied in cancer research, 
but not compatible with the transfection approach proposed in this study (discussed in 
4.2.2). At the same time, the amount of cells used for transplantation in patients with 
CVD typically reaches several millions and billions4. Therefore, detection limits defined 
for miR/PEI/MNP-HUVECs could be sufficient to evaluate cell retention and targeting 
efficiency after cell transplantation. 
4.3.6 THERAPEUTIC VALUE OF MODIFIED HUVEC 
The perspective of HUVECs transplantation in CVD treatment is very questionable and 
they mainly serve as a model to study angiogenesis and endothelial cell development184. 
At the same time, in vivo HUVECs were investigated as an alternative cell source for 
cardiac regeneration since they are easily isolated, have strong proliferative activity, and 
do not possess ethical issues184. When transplanted to rats after MI, HUVECs caused 
significant functional improvement in terms of neovascularization, LVEF and 
ventricular remodeling184,185. Importantly, such mechanism as endothelial-to-
mesenchymal transition has been proven to contribute to heart development and 
regeneration186. Thus, efforts which are made to develop HUVECs cell banks are 
justified187, especially since the allogenic transplantation has been proven safe in clinical 
trials for hMSCs1,4. 
In addition, magnetically modified endothelial cells (BAEC) were proposed as a guided 
coating for steel stents as an alternative solution for the lack of reendothelization after 
stent angioplasty188. Interestingly, the targeting of cells towards the stent is ensured by 
the application of a uniform magnetic field and by using 304-grade stainless steel as a 
material for the stent (more magnetically responsive than commonly applied medical-
grade 316L). In this situation, the short-range, high-gradient magnetic fields are 
produced by the magnetizable wires of a stent and, therefore, the regional magnetic 
force on magnetically engineered endothelial cells is maximized188.  
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More importantly, in co-culture HUVECs were proven to positively affect the 
differentiation and proliferation rates of other cell types184. Furthermore, they 
participate in the regulation of the activity of hematopoietic stem and progenitor 
cells189,190. In addition, when used as a feeder for HSC, HUVECs provide a marker for cell 
sorting of target HSCs cells after co-culture (by not expressing CD34 and CD45)191. Thus, 
they are successfully applied in platforms for HSC culture and expansion192,193, which is 
crucial in HSC-based therapies194. Genetic engineering of HUVECs could facilitate their 
properties. To summarize, having a readily established tool for safe and efficient genetic 
modification of endothelial cells and their simultaneous magnetization could provide a 
great benefit for all applications mentioned above. 
4.4 APPLICATION OF THE DEVELOPED STRATEGY TO HIGHLY CLINICALLY 
RELEVANT CD133+ HEMATOPOIETIC STEM CELLS 
4.4.1 PEI/MNP IS SUITABLE FOR MIR DELIVERY TO CD133+ AND THEIR 
MAGNETIZATION 
Using HUVEC as a model, the PEI/MNP vector has been proven efficient for transient 
transfection and magnetic engineering of proliferating cells. Next, it would be of great 
importance to investigate the suitability of PEI/MNP for non-proliferating cells with 
higher clinical relevance. In this project, bone-marrow derived CD133+ (highly 
conserved transmembrane antigen prominin-1195) hematopoietic stem and progenitor 
cells were investigated. 
Apart from safety of transplantation proven in multiple clinical trials44,196, CD133+ bear 
significant regenerative potential in cardiovascular field135. These cells were proven to 
participate in angiogenesis and stimulate healing due to endothelial differentiation, 
activation of Wnt-signalling and paracrine mechanisms134,197,198. In addition, they have 
also been described to differentiate into haematopoietic197 and myogenic lineages199 
(interestingly, the myogenic potential of muscle-derived CD133+ was reportedly higher 
than for myoblasts200). Moreover, as compared to cells isolated on CD34 expression 
(also actively applied in clinical trials, 1.3.1), the CD133 marker is correlated with a 
higher content of long-term culture initiating cells and increased proliferative 
capacity in vitro201. Based on these properties, more than 30 clinical trials have been 
initiated based on application of CD133+ stem cells for the treatment of various 
degenerative diseases (clinicaltrials.gov). Among these, the increase in LVEF of ~6-7% 
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was demonstrated for the patients with chronic ischemic heart disease after 
intramyocardial CD133+ cell injection202; ~3-4% of LVEF improvement and ~5-6% of 
decrease in myocardial perfusion were reported after intracoronary cell administration 
for patients with MI203. 
Hence, CD133+ hematopoietic stem cells are among the strongest cell type candidates 
for CVD regeneration (1.3.3). At the same time, they share such major difficulties of 
cellular therapeutics as inconsistent therapeutic outcomes and limited efficacy, partly 
explained by rapid washout from damaged myocardium and initial cell death post-
transplantation (1.3.2)22,44,204. Therefore, production of miR-modified magnetically 
guided CD133+ would be beneficial since it could custom-improve their properties and 
ensure retention after transplantation. 
 
Despite the fact, that HSC are extremely difficult to transfect and electroporation is the 
methods of choice for their modification among non-viral delivery techniques144,205, 
PEI/MNP has successfully delivered Cy3-tagged miR into cells (~80%) with no 
significant cytotoxic effects as compared to untreated cells (3.4.1; Figure 28). Moreover, 
the introduction of miR/PEI/MNP has not affected stem cell marker expression and the 
hematopoietic differentiation capacity of CD133+ cells, indicating thereby preservation 
of their intrinsic properties (3.4.3, Figure 31). 
 
Interestingly, it has been reported recently that PEI was unable to sufficiently deliver 
labelled miR into CD133+ cells and transfection complexes were mainly accumulated on 
the cell surface144. However, in our case both, LSM and superresolution SIM confirmed 
that delivery vector and miR were located inside the cells (Figures 29). This dramatic 
difference can be explained by the difference in the PEI used: in the published study low 
molecular weight branched PEI (2 kDa) has been applied144, whereas PEI/MNP vector is 
built on branched 25 kDa PEI. The molecular weight and structure (branching) of PEI 
are major factors defining PEI efficiency in transfection (1.4.2) 72. This is mostly 
explained by the respective growth of the net positive charge and the presence of 
primary, secondary, and tertiary amines in the branched PEI (vs primary and secondary 
in the linear)72,206. Together, these factors ensure better complexation and condensation 
properties and higher pH-buffering capacities of the branched PEIs with higher 
molecular weight. Partly, the choice of low molecular weight PEI is justified because 
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with the increasing molecular weight and efficiency, the toxicity increases, too72,206. At 
the same time, in the PEI/MNP vector, MNPs are successfully introduced in order to 
reduce toxicity and it is not compromising high efficiency of branched 25kDa PEI (3.2.3). 
4.4.2 TARGETING POTENTIAL OF MIR/PEI/MNP-CD133+ IN VITRO IN STATIC 
CONDITIONS 
Modified CD133+ were guided in static conditions in vitro by the locally applied magnet 
(~70% of cells, which corresponds to HUVECs) whereas MACS CD133 MicroBeads alone 
were not sufficient for magnetic targeting of cells (3.4.2; Figure 30). This observation 
contradicts the studies of Ochis’ group, where CD133+ cells isolated from peripheral 
blood were successfully retained by a magnet either in the injured spine or skeletal 
muscle due to the presence of magnetic isolation beads174,207. Several points could lead 
to the difference in results: 1) in the reported papers the characteristics of beads are not 
specified and could differ from MACS CD133 MicroBeads; 2) distances used in the 
experiments could lead to different resulting magnetic field gradients – both, spine and 
muscle injuries were located on the surface; 3) in the setup applied here the migration of 
CD133+ was required, while in 174,207 mainly cell capture was involved; 4) a much more 
advanced setup of the magnet was applied by Fujioka et al. and Ohkawa et al. with 
higher field strength and the peak of the magnetic gradient adjusted to the target 
site174,207. This means that the presence of MACS CD133 MicroBeads remaining on the 
cell surface is beneficial and that a proper setup of the magnet can lead to the improved 
targeting.  
4.4.3 OPTIMAL CULTURE CONDITIONS ENSURE HIGH CD133+ SURVIVAL WITHOUT 
AFFECTING TRANSFECTION EFFICIENCY OF MIR/PEI/MNP 
Notably, culture conditions applied to establish the PEI/MNP transfection were 
dramatically decreasing CD133+ cell viability (by ~25 % after 18 h cultivation time vs 
freshly isolated cells). 
Multiple independent studies have demonstrated that the fate of HSC in terms of self-
renewal, differentiation and apoptosis is greatly affected by such extrinsic components 
as growth factors/interleukins and serum included in culture medium33,208. To date, to 
define optimal culture and expansion protocols, multiple cytokines and their cocktails 
have been studied including SCF, Tpo, Flt-3L, IL-11, IL-3, IL-6 and GM-CSF208. As a result, 
a combination of SCF, Flt-3L and IL-11 has been defined as efficiently supporting HSC 
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survival, proliferation and maintenance in vitro33 and, thus, included in basic 
supplement in respective types of medium such as StemSpanTM CC100 supplement.  
Since electroporation is a commonly applied transfection tool for HSCs, which is not 
affected by culture medium, very few information is available on suitability of complex 
supporting medium for transfection with chemical agents209. Therefore, for the 
optimization and establishment of PEI/MNP transfection, simple and controllable DMEM 
medium was applied. As a result, the suitability of delivery vector was demonstrated for 
miR delivery to CD133+ cells and their magnetic targeting. However, such culture 
conditions were proven to be suboptimal already after 18 h incubation time necessary 
for miR/PEI/MNP uptake (70-75% viable cells in both, treated and untreated samples). 
Thus, transfection with optimal complex formulations was carried out in StemSpanTM 
H3000 (xeno- and serum-free) supplemented with Stem SpanTM CC100, more suitable 
for HSCs. Under these conditions, transfection efficiency remained as high as in DMEM 
(80-90% Cy3-miR positive cells) with preserved expression of stem cell markers, 
whereas cell viability was comparable to freshly isolated CD133+ cells (Figure 32).  
 
To conclude, the established PEI/MNP vector was proven to be suitable for safe 
transfection of CD133+ hematopoietic stem cells in optimal culture condition. This 
resulted in the production of miR-modified magnetically targetable CD133+ cells with 
retained stem cell marker expression and hematopoietic differentiation capacity, 
suitable for further pre-clinical evaluation. 
4.5 PERSPECTIVES 
Such detailed and extensive in vitro research as was carried within this project 
maximizes the chances of the proposed concept in preclinical trials. Several factors 
should be considered during future investigation of magnetically guided miR/PEI/MNP 
cells.  
Vector development. Current state of standardized vector production and 
characterization obtained during this study is satisfying for laboratory and in vivo tests. 
However, any level of clinical testing requires GLP standards of the applied procedures. 
Therefore, attempts should be made to produce PEI/MNP according to GLP guidelines. 
Studies on modified CD133+ cell product. Further optimization in terms of CD133+ 
cell expansion prior to transfection is of great importance33.  The progress in HSC 
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research would be greatly facilitated when such problems as lack of donor material and 
low cell numbers after isolation can be solved.  
After selection of suitable therapeutic miRs for delivery, functional assays with modified 
CD133+ are needed. It has been clearly demonstrated in the previous work of our 
group97 and in this study, that once Cy3-miR is internalized at optimal conditions its 
functional efficiency is also observed in the following gene expression analyses. This 
indicates that the obtained intracellular miR delivery into CD133+ will also result in an 
efficient cell transfection. However, the precise details about the functional outcome of 
delivered miR are necessary for CD133+, too. In addition, the same functional tests with 
therapeutic miR should be performed in ischemic conditions in vitro to predict the 
response of modified cells in vivo.  
The possible intracellular toxicity of miR/PEI/MNP modification has to be studied in 
greater detail. Notably, the recent study of Jin et al. has demonstrated a new aspect of 
miR mimics application: their transient supraphysiological increase in cells caused non-
specific alterations in gene expression210. Moreover, it is known that the amounts of 
RNAi pathway components are limited126. Therefore, it would be interesting to 
understand to which degree exogenous miR might compete with endogenous for the 
intracellular processing machinery and whether this mechanism could cause 
cytotoxicity. Moreover, the potentially beneficial multi-targeting of miRs can cause 
unpredictable effects. Thus, the effects of selected therapeutic molecules must be 
studied in detail. 
In vivo targeting experiments. The setup and configuration of magnets should be most 
carefully considered since this is a crucial criterion of the targeting success. 
Interestingly, the absolute majority of successful pre-clinical targeting studies was 
performed in small animals (mainly mice162,171 and rats169,170,173,175). From a technical 
perspective, the adaptation of these approaches to bigger animals is challenging. The 
main reason is the rapid decay of the magnetic field gradients which occurs with 
increasing distance from the magnet and results in the limited interventional depth of 
permanent magnets211. However, improved engineering setups have been developed to 
solve this question, including custom-made electromagnets, the use of an arrangement 
of permanent magnets, the implantation of a magnetizable material, or the design of 
special gradient coils for conventional MRI scanners211. Moreover, advanced strategies 
for noninvasive targeting of magnetized therapeutics are being actively investigated – 
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application of MR and MRI equipment is among them212. In particular, MRI has been 
successfully applied in vivo to image-guide gene therapy213, to ensure delivery in difficult 
to access anatomic sites214,215 and to directly target therapeutics216. In addition, the use 
of simulation models is highly suitable in the cardiovascular field since the variation in 
basic conditions (e.g. flow and vascular access to damaged myocardium) is relatively 
low, which potentially allows successful estimation of magnetic targeting efficiency211. 
In vivo MR imaging. The possibility of HUVEC detection has been demonstrated using in 
vitro phantoms mimicking susceptibility of murine tissues. This setup is conclusive as 
proof-of-principle, however, further dynamic in vivo studies are required. In addition, 
the iron oxide loading of CD133 is several times lower compared to analyzed HUVECs 
and the detection limits for their MR imaging should be defined. 
In vivo toxicity studies. Next, the fate of PEI/MNP in vivo in terms of degradation and 
exocytosis has not been studied and should be subject to examination. It is unlikely that 
introduced MNPs would have adverse effects164 since the applied MNP loading is very 
low (~0.155-0.7 pg per cell) and did not have any negative influence on modified 
endothelial and hematopoietic stem cells in vitro. In general, moderate amounts of iron 
oxide nanoparticles are proven to be non-toxic: they remain detectable in serum more 
than 3 weeks (the concentration starts to decrease after 1 week), accumulate mostly in 
liver and spleen and lead to transient non-pathological increase in ALT, AST and AKP217.  
As published studies suggest, nanoparticles would likely be rapidly cleared by the 
reticuloendothelial system147,218. On the other hand, PEI has a very low biocompatibility 
and its possible accumulation in different organs, interaction with serum proteins and 
circulation half-life should be closely monitored206. Here, established 3-colour labeling of 
transfection complexes could be tested and applied to obtain histological information of 
vector distribution133. Importantly, the absence of immune stimulation which might be 
produced by PEI needs to be determined by appropriate tests in vivo. 
Intracellular processing investigation. The intracellular trafficking of PEI/MNP vector 
has been described partly in previous works of our group94 as well as in the current 
report. However, these studies lack resolution, whereas such microscopic techniques as 
PALM and STED allow much higher resolution and single-molecule detection159. Their 
application is challenging and requires the development of complex protocols219, but 
will bring the mechanistic descriptions of PEI/MNP transfection to a different level. For 
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example, the understanding of the degree and dynamics of remaining PEI binding to 
nucleus will define possible means to protect from its toxicity. 
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